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Abstract
The introduction in 2002 of the first drug-eluting stents (DES) revolutionized interventional
cardiology and their use led to a dramatic reduction in the rates of in-stent restenosis (ISR)
and the need for subsequent revascularization procedures as compared with bare metalstents
and balloon angioplasty. Stents provide mechanical support to maintain an open lumen of the
damaged vessel and enable local drug delivery to the area of vascular injury, thereby avert-
ing the needto deliver the high doses of drug required if they were to be delivered systemi-
cally. Howeverthe long term residency of the polymeric coating formulations currently used
and the fact that most of the anti-restenotic agents remain in the polymer has raised some
concerns regarding late stent thrombosis, delayed arterial healing (which may be an unin-
tended effect of the anti-restenotic agents used on the stents) and hypersensitivity reactions
to the polymers.
Biodegradable polymers with shorter residency times may help reduce the long term unde-
sirable effects and facilitate the release of active agents over a more controlled and desirable
profile. In this study the degradation and paclitaxel elution profile of two biodegradable
polymers, a tyrosine containing polyarylate termed TyRx P22-10 and poly(p,-lactide-co-
glycolide) (PLGA)coated onto coronary stents was determined in an acellular in vivo model
using gel permeation chromatography (GPC), massloss, scanning electron (SEM) andlight
microscopy (LM)asthe analyticaltools.
The presence of paclitaxel had no significant effect on the degradation rate of TyRx and
50:50 PLGA. TyRx degraded rapidly over a period of 120 days from an original molecular
weight (MWt) of approximately 59,000 to around 9,000. By 150 days the MWtofthe poly-
mer had degraded to around 5,000 after which degradation proceeded more slowly. Degrada-
tion of PLGA wasfaster than TyRx and was dependant on the GA:LA (glycolide:lactide)
ratio with higher GA content leading to faster degradation rates. PLGA coatings degraded to
a MWtof around 12,000 in 30, 45 and 90 days in 50:50, 75:25 and 85:15 PLGArespectively
after which the rate of degradation decreased markedly. At a critical MWt (approximately
5,000 and 12,000 for TyRx and PLGArespectively) the polymer chains becomesoluble in
the aqueous media and polymererosion occurs, leading to bulk mass loss from the polymer
matrix. As polymer massloss progressed visual deterioration in the stent coatings became
evident with the creation of pits and pores creating a more porousstructure within the stent
coating eventually leading to the exposure of the bare metal ofthe stent as the bulk of the
polymer coating eroded. Complete solubilisation of the TyRx coating had not occurred by
the end of the study period and was in excess of 280 days. Complete solubilisation of 50:50
and 75:25 PLGA had occurred by 45 and 105 days respectively, while traces of the 85:15
PLGAcoating couldstill be detected after 120 days
The elution of the paclitaxel waslinked to the degradation state of the polymer and occurred
over two distinct phases: a diffusion controlled stage (lag phase) in which the drug slowly
diffused out of the polymer matrix, this coincided with hydrolytic degradation of the poly-
mer and was followed by an erosion controlled stage of more rapid release associated with
massloss of the polymer and the appearance of a more porous structure of the stent coating
which wasvisible using SEM. Theonset of polymererosion was slow in the TyRx coatings
due to the low watersolubility of the degraded monomersresulting in a lag phase of around
250 days before there wasany significant amountof paclitaxel release. The onset of polymer
erosion wasfaster in the PLGA coatings resulting in a shorter lag phase in paclitaxel elution.
Paclitaxel release was fastest from a 200ug 50:50 PLGA coating with a minimal lag phase.
The paclitaxel elution profile was similar for all the 400g PLGA coatings but occurred over
different time scales dependant on the GA content of the polymer. Elution of paclitaxel was
fastest in the 50:50 PLGAcoating and slowest in the 85:15 PLGAcoating. There wasa lag
phase in paclitaxel release of 15, 30 and 60 daysin the 50:50, 75:25 and 85:15 PLGArespec-
tively and complete elution of the drug had occurred by 45, 75 and 120 daysin the 50:50,
75:25 and 85:15 PLGA coatingsrespectively.
The drug release profile of PLGA devices has been modified by blending PLGA with low
molecular weight, hydrophilic, water soluble copolymers or blending different PLGA co-
polymers. The degradation and drug release profile of PLGA wasfurther studied in vitro by
blending a hydrophilic low molecular weight pluronic or 50:50 PLGA into 85:15 PLGA
films coated onto PTFEdiscs. In this study blending hydrophilic pluronics had no effect on
the degradation rate or release ofpaclitaxel from 50:50 and 85:15 PLGAfilms. But the onset
of polymererosion and the duration of the lag phase in paclitaxel release from 85:15 PLGA
films was reducedby blending 50:50 PLGAintothefilms. Blending 50:50 PLGA with a low
molecular weight of around 6,000 resulted in increased rates of mass loss and further reduc-
tions in the length of the lag phase in paclitaxel release and could be considered a viable
method to modify 85:15 PLGAfor use as a coronary stent coating.
Clearly there is significant potential to develop endovascular stents to augment the physical
physiological role of these devices to prevent ISR using coatings which either providesig-
nificant benefits directly by promoting the natural healing of the endothelium and/or indi-
rectly by delivering molecules that can control the surrounding tissues in which they are
dwelling.
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Introduction
1.1 Introduction and purposeof the study.
Coronary stents are small expandable wire mesh devices shaped in a tube that are
used to unblock diseased arteries in the heart and peripheral vessels [1, 2]. Stenting is
now the most common form of interventional treatment for symptomatic coronary
artery disease [1]. But the effectiveness of the procedure may be compromised due to
cellular in-growth (in-stent restenosis -ISR) into the lumenofthe vessel through and
around the stent struts causing re-occlusion of the artery following the injury caused
by placement of the stent [1, 3]. Drug-eluting stents (DES), in which an anti-
restenotic agent or drug is released from a polymeric coating on the stent, provides a
mechanism ofsite specific drug delivery to the site of injury [4] and have been dem-
onstrated to have significant advantages as compared to bare metal stents (BMS) in
reducing ISR andloss of luminal capacity [5-7]. However, recent reports of late stent
thrombosis (LST) and delayed arterial healing in patients receiving DES hasraised
concerns aboutthe safety of DES and the non-degradable polymer coatings that are
currently used and the fact that most of the anti-restenotic agents remain sequestered
in the durable polymer coating in somestents [8-14].
The dosage andthe release kinetics of the drugs needs to be optimized to avoid the
potential risks associated with DES [15]. The action of the drugs used in DES not
only inhibit neointimaproliferation but also delay the process of re-endothelialisation
and arterial healing of the stented section which maybe a cause oflate stent throm-
bosis (LST) [16]. The optimal dose and elution profile for paclitaxel DES has notyet
been identified but it would be such that sufficient drug is delivered to prevent pro-
liferation of smooth muscle cells but without affecting the re-endotheliazation proc-
ess [16].
Drug delivery from coronary stents has become an important area of research for sci-
entists, cardiologists and industry to address the issues with currently available DES
[16, 17]. Biocompatible, biodegradable polymers have a number of advantages for
drug delivery from medical devices [18] and complete and uneventful degradation of
biodegradable polymers with few toxic effects from their degradation products and
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which facilitate controlled delivery of the drug may present a way to improve the
performance of DES. Complete dissolution of the polymer may help reduce any hy-
persensitivity effects associated with the polymer coating and avoid any possible
long term consequences dueto disruption and deterioration to the integrity of durable
polymer coatings, while complete elution of the contained drug may reduce any con-
cerns regarding the long term impact that may be associated with its long term pres-
ence in the stent [12, 19].
In this research project the degradation and paclitaxel elution properties of two bio-
compatible, biodegradable polymers, namely a tyrosine derived polyarylates called
TyRx™ and poly(p,-lactide-co-glycolide) (PLGA) was determined to assess their
potential as polymer coatings for paclitaxel DES. Adequate drug release properties as
well as blood and tissue biocompatibility are amongst the requirements of a polymer
coating for DES [20]. Tyrosine polyarylates have been shown to have good biocom-
patibility [21] and show a diffusion controlled release mechanism of low molecular
weight drugs [22] and have been used for the release of water soluble peptides [23]
and anticoagulants [24] cited by [25]. PLGAare aliphatic biodegradable polymers
that have been used in a numberofapplications for sustained drug-release [26] and
have excellent biocompatibility and are considered safe [27] cited by [28] and [29,
30] cited by [26]. Due to their biocompatibility, biodegradability and drug delivery
properties, TyRx and PLGA were considered as suitable candidates to test the hy-
pothesis that controlled drug delivery and complete polymer dissolution can be
achieved using coronary stents coated with biodegradable polymers.
1.2 Coronary stents: development, advantages andlimitations.
1.2.1 Developmentof drug-eluting stents
The term ‘stent’ was originally used by Charles R Stent to describe a curved device
which wasused as a scaffold for oral skin grafts [2]. Stents have also been described
as devices or mouldsthat are used to hold a skin graft in place or to provide support
for tubular structures that are being anastomosed (Dorlands Medical Dictionary cited
by [2]). While coronary stents are probably the best known and most common form
of this device there are many other applications of such devices and they have been
2
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used in other natural body conduits, such as central and peripheral arteries and veins,
bile ducts, oesophagus, colon, trachea or large bronchi,ureters, and urethra [2].
In late 1970 Andreas Gruentzig and A. Senning described a catheter based method
for treatment of obstructive coronary atherosclerosis which they termed percutaneous
transluminal coronary angioplasty (PCTA) [31] cited by [32]. Problems with such
procedures occurred due to vascular recoil of the artery and in particular blockage of
the vessel due to proliferation of smooth muscle cells (restenosis) and accumulation
of intercellular matrix [20]. In 1987 Sigwart et a/ [33] used bare metal stents in the
arteries of patients who had coronary or coronary—bypass graft surgery and were
having complications due to restenosis or abrupt closure [32]. The bare metal stents
(BMS)weresuperior in giving mechanical support to the damaged vessel, acting as a
scaffold to keep the vessel open and reduced the incidence of vessel recoil [4]. The
rate of restenosis was reduced with the introduction of BMS as comparedto balloon
angioplasty (PCI) [20, 33] and two randomisedtrials demonstrated that use of bare
metal stents reduced the incidence of restenosis as compared to balloon angioplasty
(32-42% for balloon angioplasty as compared with 22-32% for BMS [34, 35] cited
by [32] ). But ISR was a major problem in 20-30% of BMSdevices leading to dra-
matic loss of luminal capacity [20].
1.2.2 Restenosis and in-stent restenosis (ISR).
Restenosis has been a major problem associated with vascular procedures such as
balloon angioplasty and stenting [36]. Restenosisis the arterial healing response after
injury to the vessel wall during transluminal coronary revascularization andresults in
loss of lumen diameter of the repaired vessel [36]. Injury occurs during balloon an-
gioplasty as the balloon is inflated (sometimes several times) to compress the plaque
and so unblock the artery. Similarly, injury occurs during stenting. Prior to use, the
stent is in its collapsed form attached onto the outside of a balloon catheter. Place-
mentof the stent involves inserting the catheter into an artery usually via the wrist or
groin, which is then advanced tothe site of the diseased artery [3]. Once in place at
the site of vessel occlusion the balloon is inflated, expanding the stent which com-
presses the plaque thereby opening up the artery. The balloonis then deflated and the
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catheter withdrawnleavingthe stent in- situ acting as a scaffold and support to main-
tain an open lumenoftheartery [3].
Stretching of the vessel caused by the high pressures exerted whenthe balloon is in-
flated during placement of the stent causes mechanical injury causing rupture of the
elastic lamina, intimal and/or medial tears, endothelial denudation and crushing of
the occluding plaque [37-40]. Following this traumathere is a maladaptive response
by the coronary artery leading to a sequence of events consisting of thrombosis, in-
flammation, cellular proliferation, and extracellular matrix production whichresult in
a loss of lumen capacity post-operatively over approximately 6 months [41, 42]. Loss
of lumen diameter following balloon angioplasty consists of three phases: early loss
dueto elastic recoil, late loss due to negative remodelling and neointimal hyperplasia
[36, 42]. Endovascular stents act as a mechanical scaffold and virtually eliminate
vessel recoil and reduce lumen loss due to remodelling [42, 43]. There are however
differences between the inflammatory response associated with balloon angioplasty
and that induced by the injury caused during stent implantation [44] and the presence
of the stent may amplify the proliferative componentof restenosis [36, 42].
ISR is solely caused by neointimal hyperplasia. Mechanical injury caused by stent
placementand the foreign body responseto the presenceofthe stent, incite acute and
chronic inflammation in the vessel wall [45]. The processes leading to ISR have been
described previously [36-40, 44, 45].
Within minutes of the injury to the endothelium ofthe vessel, platelet rich thrombus
deposition beginsat the site of injury andthis is rapidly and simultaneously followed
by activation and aggregation of platelets which along with fibrin, formsclots at the
site of injury on and around the stent struts [38, 40]. Thrombus formation occurs
within 1-3 days after stenting injury but platelet deposition and thrombus formation
maypersist for 2-4 weeks after stent placement [45]. Activated platelets express ad-
hesion molecules such as P-selectin and glycoprotein (GP) Iba which attach to circu-
lating leukocytes via platelet receptors such as P-selectin glycoprotein ligand. The
loosely attached leukocytes then begin to migrate along the injured surface, facili-
tated by a gradient of chemoattractant cytokines called chemokines which are re-
leased by the smooth muscle cells (SMC) and resident macrophages. Cytokines
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stimulate the leukocytes to become moretightly bound to the platelets via leukocyte
integrin adhesion molecules, such as Mac-1, by attaching directly to platelet recep-
tors such as GP Iba andvia cross linking with fibrinogen to the GP IIb/IIa receptors
[38, 39].
Prior to injury the SMCare quiescent, but mechanical injury and the subsequentre-
lease of growth factors induce a change from a contractile to a synthetic phenotype
[36, 39] and a phase ofcellular proliferation commences. Following activation of
platelets and thrombus formation, vasoactive agents and mitogens such as thrombin,
thromboxane A2 andplatelet derived growth factor (PDGF) are released from SMC,
platelets and inflammatorycells. [46, 47] cited by [37]. This inducesthe proliferation
and migration of SMC’s from the media andinto the neointima, resulting in a neoin-
tima consisting of SMC’s, extracellular matrix and macrophages. Formation of this
neointima occurs over several weeks after injury, but over longer periods of time
there is increased production of extracellular matrix with fewer cellular elements [38,
39]. Thrombin induces proliferation in SMC andthe secretion of platelet derived
growth factor (PDGF) andfibroblast growth factor (FGF). Thrombin mayleadto in-
timal hyperplasia via induction of PDGF and FGFproduction by SMC.Accordingly,
thrombin-dependent VSMCproliferation and migration may contribute to restenosis
after stent deployment [45]. Serotonin is another growth factor released during plate-
let activation and thrombus formation. Clot bound thrombin maypotentiate the mito-
genic effect of serotonin and thereby prolong the period of VSMCproliferation [45].
Inflammatory cells have subsequently been found to havea critical role in ISR and
the presence of the stent induces a more prolonged and intense inflammatory re-
sponse [38]. Acute inflammation occurs within 24 hours of stent placement. Infiltra-
tion of the vessel wall by neutrophils is followed by adhesion and infiltration of
monocytes. Farb et al [46] found that the severity of the inflammatory response was
associated with the contact between the stent struts and the vessel wall, with in-
creased numbers of acute inflammatory cells produced when the stent struts were
adjacent to the injured mediaor lipid core as opposed to the struts pressing on the
fibrous plaque.Infiltration of chronic inflammatory cells e.g. leukocytes, histiocytes
and giant cells occurs around the stent struts and produce cytokines such asinter-
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leukin-1 and tumour necrosis factor (TNF) which further stimulate the proliferation
and migration of VSMC[45].
1.2.3. Drug-eluting stents (DES).
DESweredesigned to provide the mechanical support offered by the BMSbut with
the capacity to deliver anti-restenotic drugs from a polymer coating (drug delivery
system) to combat some of the problems associated with BMSbypreventing ISR
[20]. DES essentially consist of the stent platform, the drug or active agent and a
coating (normally a polymer) which controls the release of the active agent [12].
Proliferation and migration of Vascular Smooth Muscle Cells (VSMC) and extracel-
lular matrix deposition can be significantly reduced by passivating the metal surfaces
of the stent using polymer coatings [48] and adding slowly released anti-restenotic
drugs to the polymercoatings can further reduce in-stent restenosis [36]. Delivery of
the anti-restenotic agent via the DES facilitates drug release at the site of vessel in-
jury at concentrations sufficient to prevent cell proliferation and migration but not at
high enough concentrations to cause toxicity in surrounding tissues and organs [48]
thereby avoiding the use of high concentrations of the drugs (which mayhavecyto-
toxic effects) that would be required were they administered systemically [20].
Drug-eluting stents (DES), have been demonstrated to have significant advantages as
compared to Bare Metal Stents (BMS) in reducing neointimal hyperplasia, ISR and
loss of luminal capacity [5-7] and the reduction in ISR seen with the use of DES as
compared to BMShasin turn reduced the need for subsequent revascularization pro-
cedures [49, 50]. Over 1.5 million patients worldwide are now treated using metallic
coronary stents per year. Polymercoated stents containing drugs suchaspaclitaxel or
sirolimus are increasingly used in preference to bare metal stents (BMS) [11] and
about 85% of the percutaneous coronary interventions (PCI) in the US are now done
using drug eluting stents (DES) [8, 11, 13]. In the USA in 2006 the market for coro-
nary stents was worth some $5 billion and DES accounted for about 90% of the
revenue [7].
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1.2.4 Efficacy of DES
Both the Cypher and the Taxus DEShave been shownto significantly reduce rates of
ISR and angiographic events as compared with BMS[51]. Eisenberg and Konnyu [6]
reviewed randomised controlled trials comparing paclitaxel or sirolimus(or its de-
rivatives) DES’s to BMS and DES’sto other DES’s published in the PubMed data-
base and found a definite therapeutic advantage associated with sirolimus and poly-
meric paclitaxel coated stents in comparison to BMS. A number of combinations of
agents, polymerand stent platforms have been developed for clinical use [20, 52] but
only two DES have been shownto have both a beneficial effect and a suitable safety
profile in large-scale randomisedclinical trials, namely the Cypher™stent consist-
ing of a durable polymer coating and the drug sirolimus (rapamycin) and the
Taxus™ paclitaxel eluting stent which is coated with a non-biodegradable durable
polymer [52]. The Taxus™ Express”stent is coated with a styrene isobutylenesty-
rene triblock copolymer (SIBS) called Translute™ and contains 1 ug/mm?paclitaxel
[53] which is equivalent to 108ug on a 16mm Express Stent [12]. Two formulations
of the Expressstent have been usedin clinical practice (and Taxus IV-VI clinical tri-
als): a slow release formulation (SR) and a medium (MR) release formulation. The
SR and MRstents contain 8.8% w/w and 25% w/w paclitaxel respectively but with
the same dose density of 1pg/mm? paclitaxel [4]. The NIRx™ — paclitaxel/SIBS-
coated coronary stent (Boston Scientific, USA) wasused in the TaxusI to II] trials in
SR and MRformulations (1.0 g/mm”loaded drug/stent surface area; total dose 85
pg per stent) [52, 54].
Thesafety and efficacy of the Taxus DES wasevaluated in randomised double blind
multicenter investigations comparing 6 studies (Taxus I-VI) in comparison with
BMS(nb except for Taxus III which was an open-label investigation) and the results
have been reviewed elsewhere [4, 6, 52, 54]. The safety of the Taxus DES was dem-
onstrated in the TaxusI trial which compared MACE(major adverse cardiac events)
rates between the Taxus (SR formulation) stent and BMS and found that at 12
months the MACE rate was 3% and 10% in the DES and BMSgroupsrespectively
with no patients requiring target lesion revascularization (TLR) in the Taxus arm of
the trial. The Taxus II study demonstrated lower rates of target vessel revascularisa-
tion and restenosis in patients receiving either SR or MR formulations of paclitaxel
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as compared with controls (patients receiving BMS). At 12 months the MACErate
was 10.9%, 9.9% and 21.7% for the SR, MR formulations and BMSrespectively
with TLR of 4.7%, 3.8% and 14.4% respectively. Additionally there was nosignifi-
cant difference between the SR and MR formulations in efficacy or safety in this
trial. The Taxus II study involved patients with standard risk, de novo coronaryle-
sions. The Taxus IV trial, which was larger than TaxusII, was designed to evaluate
the Taxus SRstent in a broad spectrum of patients and lesion subsets to more closely
reflect ‘real life’ situations than had been used in previoustrials. Patients enrolled in
previoustrials had had focal lesions in larger vessels, but in Taxus IV the patients
had either symptomatic artery disease, objective evidence of ischemia and the target
lesions weresolitary de novo lesions 10-28mm in length occurring in vessels with a
diameter of 2.5-3.75mm. This trial confirmed the results from previous trials and
demonstrated lower rates of restenosis, TLR and MACEfor the Taxus SR stent as
compared with BMSwith the benefit being maintained at two years. In Taxus V and
VI the Taxus SR and MRstent formulation were evaluated in higher risk patient
populations, defined as those requiring 2.25 — 4.00mm stents or vessels with longer
lesions requiring overlapping stents. In these trials, the TLR rate was significantly
lower in the Taxus SR and MR groups as compared with the BMScontrol group at 9
months. Furthermore there were less MACEevents, lower rates of restenosis in pa-
tients receiving the Taxus stents as compared with BMSand there wasno significant
difference in rates of death, myocardial infarction and stent thrombosis (which was
low in all groups).
There have been seven randomisedcontrolled trials designed to evaluate the efficacy
and safety of the sirolimus DES (Cypherstent) [6]. The early trials demonstrated the
safety and efficacy of sirolimus DES in reducing TLR,significantly reducing rates of
restenosis with similar rates of death and myocardial infarction as patients receiving
BMSin a population of lowerrisk patients. The improvementsin restenosis rates and
TLR wereseen in trials involving more complex lesions and in patients with diabe-
tes. The random controlled trials have consistently demonstrated the sirolimus DES
capacity to reduce or prevent ISR andto significantly reduce the need for subsequent
TLR procedures for up to one year, while having a safety profile comparable to that
of BMS[6].
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1.2.5 Late stent thrombosis and delayed endothelial healing
 
Despite the success of stenting some concerns remain and recent reports concerning
late events including increased stent thrombosis, myocardial infarction and death
have called into question the long term safety of DES and may be a consequence of
delayed arterial healing associated with DES [7, 13, 49, 50]. The most likely causes
for this affect appear to be either the presence of the durable polymer causing an in-
flammatory response, and/or an unintended effect of the anti-restenotic agents used
in DES[7, 15, 49, 55]. Although there are no reported toxic side-effects related to the
use of paclitaxel after 6 or 12 months, concern has been raised about the long-term
biological effect of the non-erodable polymer used on the Taxusstent as well as the
persistence of significant quantities of drug still present in the polymer at 30 days;
92.5% for the slow release formulation or 78.1% for the moderate release [12] and
only 10% and 25% respectively of the paclitaxel is released in the slow-release and
moderate-release formulations of the polymer [54, 56].
Thepossibility that late complications leading to excess stent thrombosis in DES was
raised in 2003-2004 [54], an infrequent but nevertheless catastrophic complication
that may be manifest as myocardial infarction (MI) or sudden death [57]. McFadden
et al [11] reported 4 cases (2 paclitaxel and 2 sirolimus DES) of stent thrombosis
(ST) occurring 2-15 months after stenting and these cases were considered unusual
since late ST was rare with BMS[58]. The term ‘late ST’ generally refers to ST oc-
curring at least 1 month following implantation, whereas events occurring more than
12 months following implantation are referred to as ‘very late ST’ [59]. Subacute ST
(1 to 30 days after implantation) rates have been found to be <1.0% using BMS[58]
and randomisedtrials using large datasets have shown similar rates of ST occurring
up to 30 daysafter stenting between BMSand DES(for review see [57, 58]).
Studies using data from registries, randomised trials and meta-analyses which have
investigated the relative risk of stent thrombosis from BMS and DESovervarying
follow-up periods have yielded conflicting results [57]. Follow-up of up to one year
from randomisedtrials did not show anysignificant increased risk of late thrombosis
due to DES as compared with BMS in which patients were also taking combined
therapy of clopidrogel and aspirin to prevent clotting [60] cited by [9] and [61]. Mo-
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reno et al [61] found no difference in stent thrombosis betweeneither paclitaxel and
sirolimus DES or between DES and BMSprovided that appropriate anti-platelet
therapy is applied. But the authors found that stent length increased the rate of stent
thrombosis and longer stents were of the DES type. Mauri et a/ [62] found nosig-
nificant difference for Sirolimus DES compared with BMS. Spaulding et a/ [63]
found no significant difference in death rate, stent thrombosis or myocardial infarc-
tion between Sirolimus and Paclitaxel DES as compared with BMSbutin patients
with diabetes a significant advantage was foundin patients receiving BMS.
But incidences of late stent thrombosis have been reported [11, 64, 65]. Stone et al
[50] found that after 1 year stent thrombosis in patients receiving either Sirolimus
DESor Paclitaxel DES was significantly higher as compared to patients receiving
BMSbut that over four years follow up there was no significant difference in the
cumulative rates of death or myocardial infarction between DES and BMS.Pooled
analysis of the RAVEL, SIRIUS, C-SIRIUS, and E-SIRIUStrials showed that be-
tween | and 4 years after implantation there were five cases of late thrombosis with
sirolimus DESas opposed to no cases in the BMS group. While pooled data from
the Taxus II, IV, V and VI revealed eight cases of late thrombosis from the DES
group as opposed to one case from the BMSgroup [66] cited by [67], although the
survival free time from stent thrombosisat three years wasnot significantly different
for the DES versus the BMS[59].
The BASKET-LATEtrial, in which patients receiving either a DES or BMSand had
stopped anti-platelet therapy 6 months after stenting, showed that the incidence of
late cardiac death or non-fatal myocardial infarction was greater for DES compared
with BMS (4.9% and 1.3% respectively). Given that the DESstill showed an advan-
tage in reducing ISR,late clinical events, possibly related to late stent thrombosis,
were cited as likely causes for the effect [68]. Bavry et al [69] performed a meta-
analyses on 14 contemporaryclinical trials comparing paclitaxel and sirolimus DES
with BMSandfound 5 events per 1000 of late stent thrombosis in patients receiving
DESwith 2.8 events in the BMS group. Based on the type of DES there was 3.5 and
4.9 events per 1000 patients for sirolimus DES and BMSrespectively and 6.3 and1.1
events per 1000 patients for paclitaxel DES and BMSrespectively. Daemanet al
[67] found early and late stent thrombosis occurred with both types of DES, butlate
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stent thrombosis was moreprevalent in patients receiving the paclitaxel DES. Data
from the Large Multicenter Registry-Stent Group using ‘real world patient popula-
tions’ showed no significant difference in death, myocardial infarction and target
vessel revascularization between sirolimus and paclitaxel DES at 9 months [70]. Us-
ing this data Simonton ef a/ [70] concluded that clinical restenosis and major ad-
verse cardiac events are infrequent and similar for patients receiving either sirolimus
or paclitaxel DES. Stettler et a/ [71] reviewed controlled trials from databases such
as Medline, EmBase, CENTRALandother published studies up to March 2007 us-
ing data from patients with symptomsor signs of myocardial ischemia due to coro-
nary artery disease and compared Taxus and Cypher DES and BMS.They concluded
that DES and BMSareassociated with similar rates of cardiac mortality. Sirolimus
DESwasassociated with a lower rate of myocardial infarction as compared with pa-
clitaxel DES or BMS. There waslittle evidence of an overall increase in ST using
DES as compared with BMSbutpaclitaxel DES was associated with an increase in
LST as compared with sirolimus DES and BMS. Both types of DES showed a
marked reduction in target revascularisation rates as compared with BMS.
While there is no significant evidence to suggest that there is greater risk of ST from
DES as compared with BMS [58], the incidence of very late stent thrombosis
(through years 1 to 4 post implantation) appears to be around 0.2-0.6% higher for
DESas compared with BMS[57-59, 67, 69]. Whether this risk continues after year 4
is as yet unknown [59].
The cause oflate stent thrombosisis likely to be multifactorial [58, 72-74] involving:
e the stent deployment procedure (sub optimal stent deployment and problems
with blood flow throughthestent).
e stent design (e.g. strut thickness)
e the patient (discontinuing antiplatelet therapy, resistance to antiplatelet treat-
ment, intrinsic thrombogenicity, type of lesions).
e polymer coating (causing hypersensitivity, inflammation and being throm-
bogenic).
e anti-restenotic drugs causing delayed healing and possibly increasing the risk
of late stent apposition.
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In terms of the polymer and the action of the anti-restenotic drugs the DES can affect
LSTin three main ways
e hypersensitivity to the stent coating
e thrombogenicity caused bythe action of the anti-restenotic drugs
e the effect of the anti-restenotic drugs on endothelial healing
1.2.5.1 Polymer coat hypersensitivity effects
An inflammatory response to stent coatings and drug releasing polymers has been
shown in animal models and the biomedical polymers currently used on stents incite
inflammation to a variable degree that is proportional to the mass of polymer on the
coating [75]. The durable polymers currently used on the Taxus and Cypherstents
have been associated with chronic eosinophilic infiltration of the arterial wall indicat-
ing hypersensitivity reactions in animal studies [76] and in a small numberof cases
involving humans[74]. Hypersensitivity to metals such as molybdenum, chromium
and nickel have been reported but the reaction is different to that associated with
DESand the effect has led to restenosis rather thrombosis. Cases of hypersensitivity
associated with BMSresulted in infiltration of macrophages, T-lymphocytes with
few B-lymphocytes andis not associated with an eosinophil rich infiltrate [13].
In pigs, hypersensitivity reactions start to occur about 28 days after Cypher stent
placement, with a gradual increase in the presence of granulatomousreactions, with
eosinophilic infiltrate over the following 5 months. Since the hypersensitivity reac-
tion peaks following complete elution of sirolimus from the Cypherstent, the effect
is likely related to the polymer coating on the stent [74]. Given that sirolimus has
been shown to suppress eosinophil infiltration in an animal model of bronchial hy-
persensitivity [13] it may be that granulation is retarded initially due to the presence
of the sirolimus in the stent. Biodegradable and non-biodegradable polymers when
coated onto stents have been shown to induce inflammatory reactions in porcine
coronary artery [77] but this study has been criticised as no BMScontrol stents were
used, the stent samples were notsterilized and the degradation of the polymer was
not characterized [7].
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Virmaniet a/ [13] reported a case of severe localized hypersensitivity reaction in re-
sponse to the polymercoating resulting in myocardial infarction in a patient who had
received a Cypher stent. CD45-positive lymphocytes, macrophages, plasmacells and
eosinophils were found to have infiltrated into the intima, media and the adventia of
the arterial wall at the stented zone. Thick layers of fibrin thrombus were found sepa-
rating the stent struts from the underlying plaque and there wasa focal giant cell re-
action surrounding fragments of the polymer coating which had become detached
from the stent struts. Virmanief a/ [14] attributed that the presence of a nonreabsorb-
able polymeralone mayhave inducedthe chronic inflammation leading to the persis-
tent fibrin deposition, varying degrees of inflammation and delayed endothelial heal-
ing in patients at 12 months after receiving a stent containing a paclitaxel derivative
with a polyacrylate sleeve. But giant cells, which are usually seen in reactions to
polymers, were not observedin this study.
In 2003 the Food and Drug Administration (FDA) reported a numberof cases of hy-
persensitivity reactions in humansafter stent placement but later concluded these
were due to concomitantly prescribed medications such as clopidogrel [55]. Ne-
becker et al [55] looked events from FDA's adverse-device-event database, the pub-
lished literature, and from the Research on Adverse Drug/Device Events And Re-
ports (RADAR)project. Out of 5,783 reports identified for the DES in the FDA da-
tabase there were 262 hypersensitivity events. Although hypersensitivity to clopido-
grel therapy has been reported, only 2 of these cases were caused by clopidogrel and
10 cases were probably caused by the DES. Outofall the sources examined 17 cases
of hypersensitivity to the DES were confirmed, with 14 cases being reported for Cy-
pher stent and 3 for the Taxus stent. The Cypher and Taxus DESare coated with dif-
ferent carrier polymers but whether this accounts for the differences in the hypersen-
sitivity between the DES is uncertain. Translute™ (used in the Taxus paclitaxel
DES) is a triblock copolymer, poly(styrene-b-isobutylene-b-styrene) [4] while the
sirolimus containing Cypher stent is coated with a permanent polymer composed of
polyethylene-co-vinyl acetate and poly-n-butyl methacrylate [53]. Given that LST
due to polymerinduced inflammation has only been proven in a minority ofcases,it
maybethat this effect is restricted to those patients who posses a proinflammatory
phenotype [74].
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1.2.5.2 Prothrombiceffect of the drugs
The drugs loaded onto a DES may themselvesexert a prothrombogeniceffect. At the
concentrations found in the arterial cell wall after stent deployment both paclitaxel
and sirolimuscan increasetissue factor expression. This may contribute to creating a
prothrombotic environment[74] since tissue factor expressionis a principal activator
of the coagulation cascade that activates factors IX and X [78]. Sirolimus binds to
FK-binding protein 12 which inhibits the mammalian target of sirolimus (mTOR).
mTORis a downstream target of the phosphatidylinositol-3-kinase pathway which in
turn has an inhibitory effect on the regulation of tissue factor in endothelial cells and
monocytes. As a result of the inhibition of mTORthere is an increase in thrombin-
and tumournecrosis factor (TNF)-a@ induced endothelial tissue factor expression and
activity [74]. Paclitaxel can enhancetissue factor expression andactivity in endothe-
lial cells by activating c-Jun NH>-terminal kinase which is a mediator of endothelial
and monocytic tissue factor induction [79, 80]. Additionally, plasminogen activator
inhibitor type 1 which is a potent inhibitor of fibrinolysis and a mediator of acute
thrombosisis selectively enhanced by paclitaxel and sirolimus[73].
1.2.5.3 Delayed healing
Both paclitaxel and sirolimus are delivered directly into the arterial wall from the
stents and dueto their lipophilic properties they are readily absorbed and retained by
the cells of the vessel [74] where due to their anti-proliferative properties SMC pro-
liferation and migration is inhibited thereby preventing formation of a neointima
[79]. But due to the non-specific targeting of anti-restenotic agents such as paclitaxel
and sirolimus, the intended anti-restenotic activity of the drugs may have the unin-
tended effect of delaying arterial healing and the process of re-endothelialisation [15,
74, 76]. A coverage of endothelial cells over stent struts and the injured arterial wall
is essential for the maintenance of long-term luminal patency as these cells provide
essential structural functions [73] and an intact endothelium separates thrombogenic
elements in the artery wall, any underlying plaques and the stent struts from the
blood stream and secretes antithrombotic and vasodilatory substances [57] such as
histamine . The delay in arterial healing with persistent fibrin deposition, inflamma-
tion, impaired re-endothelialisation and exposed stent struts are factors which can
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increase the likelihood of late stent thrombosis [76] and extends the window during
whichstents are prone to thrombosis [81].
Following denudation due to stent placement, re-endothelialisation of the damaged
artery wall and stent struts occurs by endothelial cell proliferation and migration
from intact areas of arterial segments into the adjacent damaged areas of the stented
segment in BMS[73, 74]. Jn-vitro studies have shownthat paclitaxel and sirolimus
suppress endothelial cells and consequently impair the normal healing process of the
injured arterial wall [74, 76, 82]. Bone marrow-derived endothelial progenitor cells
may also be involved in re-endothelialisation. Sirolimus has been shown to inhibit
proliferation, migration and differentiation of human endothelial progenitor cells in-
vitro [74, 76] while paclitaxel has been shownto inhibit endothelial cells at nanomo-
lar concentrations [76]. Thus the anti-restenotic drugs on the Taxus and Cypher
stents may further impede endothelialisation by affecting the number, homing and
differentiation of endothelial progenitorcells [74, 76, 80].
Joner et al [73] compared re-endothelialisation in a number of DES and BMSin a
rabbit iliac artery model. They found significantly reduced endothelial coverage over
stent struts in paclitaxel and sirolimus DES as compared with BMSat 14 days (but
not at 28 days). Furthermore platelet-endothelial adhesion molecule (PECAM)-1 at
cell-to-cell contacts points and thrombomodulin (TM) was reduced in the DES as
compared with a BMS. PECAM-1, an endothelial antigen, is critical for endothelial
homeostasis and is a transmembrane glycoprotein found in areas ofcell-to-cell con-
tact between neighbouring endothelial cells. During periods of cell growth and mi-
gration, junctions between cells are poor and PECAM-1 expression is reduced. Endo-
thelial regrowth as assessed by PECAM-1 expression was reduced in DES as com-
pared with BMSat 14 and 28 daysindicating inhibition of endothelial cell migration
and proliferation, endothelial injury and perhaps evidence of increased rate ofcell
turnover. Increased vascular endothelial growth factor (VEGF) levels are associated
with regenerating endothelial cells and levels peak early after arterial injury and then
diminish as healing progresses. Joneret a/ [73] found highest levels ofVEGF in DES
as compared with BMSat 14 and 28 days which wasassociated with poor endothe-
lial healing.
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TM is a regulator of platelets and coagulation and loss of TM function can cause
thrombosis in the arterial and venouscirculatory system [83] cited by [73]. Joner et
al [73] found reduced expression of TM in DES as compared with BMS (whichin
turn had reduced TM as compared with non-stented segments at 14 and 28 days, in-
dicating a change in endothelial homeostasis to a more prothrombotic state in DES.
This change becomes important as the combination of a dysfunctional endothelium
combined with increased vessel wall thrombogenicity due to poor endothelial cover-
age of the injured artery wall and thestent struts mayincreasethe possibility of LST.
Other studies using animal models have shown incomplete healing, poorer rates of
endothelialisation and fibrin deposition for DES as compared with BMS[10, 84].
Paclitaxel DES whenplaced in rabbit iliac arteries were associated with delayed in-
timal healing with increased local arterial inflammation and fibrin deposition as
compared with BMSfor up to 180 days by Drachmanet a/ [84] using a poly(lactide-
co->'-caprolactone) copolymer coated stent containing 200ug paclitaxel. Farb et al
[10] using a similar model but using stents containing lower doses of paclitaxel (up
to 40ug per stent) contained in a chondroitin sulphate/gelatine coating also found de-
layed arterial healing and local arterial inflammation at 28 days but this effect had
disappeared by 90 days. In this study chondroitin sulphate/gelatine coated stents
without paclitaxel had lowerincidence of intimal haemorrhage and reduced inflam-
mation as compared with the DES,and so the effect was probably due to the action
of paclitaxel.
While the process ofarterial repair following stent placement occurs at a faster rate
in pigs and rabbits than in humansafter stent placement the sequence of biological
events during the healing process are very similar [73, 76]. In patients receiving
BMSendothelialisation is either complete or near complete at 3 to 4 months [81].
Joner et al [82] found that in human patients both Cypher and Taxus DESstents had
significantly higher fibrin scores and decreased endothelial healing as compared with
BMSfor a similar duration of implantation. The study also revealed higher fibrin
scores and decreased endothelialisation from DES in which late thrombosis had oc-
curred as compared with patent DES. Poor endothelial junction formation with mi-
crothrombi of focal platelet aggregation was seen at 16 monthsin a patient that had
received a sirolimus DES [74]. Delayed arterial healing has been blamed for endo-
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thelial dysfunction [85] and poorer vasodilation [86] in patients receiving Sirolimus
DES. Virmani et a/ [14] in 12 month follow-up studies found evidence of persistent
fibrin deposition with varying degrees of inflammation in patients receiving a pacli-
taxel derivative in a DES, pathological changes that represent delayed healing which
are usually observed up to only 3 months in humancoronaryarteries with stainless
steel balloon-expandable stents. Awata et a/ [87] used angioscopy to compare endo-
thelial repair in patients receiving either BMSorsirolimus DES. The study showed
that while there was complete neointimal coverage in patients receiving BMSby3 to
6 months, coverage was poorerin patients receiving DES upto 2 years after implan-
tation and the low grade coverage of the stent struts left the underlying plaques ex-
posed to thrombogenic elementsin the blood stream.
1.3 Elution of antirestenotic drugs from polymerstent coatings
1.3.1 Polymersas stent coatings and drug release vehicles
A numberof polymers are knownto havethe potential to act as a drug delivery coat-
ing for coronary stents (for review see [88]). The polymer coating on DESacts both
as a carrier vehicle and as a meansto control the release of the anti-restenotic agent
[17].
The polymeric coating needsto fulfil a numberofcriteria [17, 89] including;
e have good vascular compatibility and have no adverse reactions above those
seen with a BMS
e beable to maintain good mechanicalintegrity during handling, clinical
deployment and whilein situ
e beable to withstand processing, sterilization and storage
e have suitable drug release properties
e compatibility with the anti-restenotic drug
Polymer coatings are tested for biocompatibility, but polymer delamination and
fragments of polymerthat have flaked from the stent coating have been found to in-
cite foreign body hypersensitivity reactions [13, 37, 55] (see section 1.5). Further-
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more, mechanical integrity of the polymer while in situ is important since release of
delaminated polymer fragments havethe potential to form microemboli which could
be large enoughto causearterial blockage and myocardial infarction [37].
Release of the drug is controlled either by chemical or physical mechanisms [16].
Chemical mechanismsofdrug release involve grafting the active drug to the polymer
carrier via covalent bonds which are then cleaved by chemical or enzymatic action
thereby releasing the active drug [88].
Physical meansof controlling drug release include:
e diffusion of drug molecules through a polymer matrix or layer
e dissolution or degradation of the polymer matrix controlling release rate
e osmotic pressure
e ion exchange (for ionised drugs)
Diffusion-controlled drug release and dissolution/degradation-controlled drug release
are the most common forms of drug release mechanisms from currently available
DES[16].
Permanent or non-erodible polymers are utilised for diffusion control release and
these polymerstend to be waterinsoluble. In this system the drug is dispersed within
the polymer coating and the rate at which the drug is released is dependent on the
rate at which it can diffuse through the polymer coating. Within the polymer some of
the drug particles will be solubilised and dissolve into and saturate the polymer ma-
trix. These molecules can then diffuse through the polymerinto the surrounding me-
dium. Assaturation of the polymeris lost more ofthe particulate fraction of the drug
can solubilise and dissolve into the polymer matrix and diffuse though the polymer
into the release media. As the drug is released pores may beleft in the polymer ma-
trix which can fill with the aqueous media from the exteriorfacilitating further drug
release through the pores [88]. Drug molecules closest to the polymer surface and
exterior elute the fastest while the molecules further within in the body of the poly-
mer matrix have further to travel to the external environment and henceare released
the slowest [16, 37].
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The current Taxus stent is an example of diffusion controlled release. The stent is
coated with a permanent polymer (poly(styrene-b-isobutylene-b-styrene) (SIBS)
triblock copolymer) called Translute™. By varying the ratio of drug to carrier poly-
mer different rates of drug release are achieved. The three formulations that are
available have the same amount ofpaclitaxel but differ in the amount of polymer
coating, with drug-polymerratios of 35:65, 25:75 and 8.8:91.2 respectively for the
fast, medium andslow release formulations [16, 89]. The solubility of paclitaxel is
typically 2-5% in hydrocarbon-based polymers [7]. This concentration is exceeded in
all the Taxus formulations and the paclitaxel molecules exists as discrete and dis-
persed particles within the polymer matrix [89]. The elution profile of paclitaxel
from SIBS polymeris in the form of an initial burst phase during the first two days
after implantation due to the dissolution of paclitaxel available in particulate form at
the surface of the polymer followed by a longerlasting phase of slower sustained re-
lease [89].
In the Cypherstent poly(ethylene-co-vinyl acetate) (PEVA) and poly(n-butyl methy-
lacrylate) (PMBA) are mixed with a ratio of 67% polymer to 33% drug (sirolimus)
and this is added to the stent surface. A topcoat of PMBA (with no added drug) is
then added whichacts as a rate controlling membrane. During storage, drug diffuses
into the topcoat and uponstent placementthis faction of drug is rapidly released giv-
ing an early ‘burst’ of drug release. The PBMA topcoat minimizes the early burst
phase and then controls the kinetics of further drug release as drug molecules haveto
diffuse from the basecoat of PEVA and PBMA,through the topcoat of PBMAacross
a diffusion gradient to the external environment(in this case the artery wall) [16].
Other examples of diffusion controlled release include the reservoir system (e.g. the
Conorstent) in which wells and reservoirs are formed on the stent, filled with the
drug and covered with a thin polymer membrane which controls drug release via dif-
fusion. Rate of drug release is controlled by the concentration gradient between the
polymer matrix and the outsideof the barrier coating [88].
Biodegradable polymers are examples of dissolution/degradation-controlled systems
and release of the drug from the polymer matrix is via diffusion through the polymer
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coating and the rate at which this occurs will depend upon the extent of degradation
and dissolution of the polymer[88, 90].
The factors governing the elution of drugs from biodegradable polymers has been
described by Siepmann and Gopferich [90]. For polymers, biodegradation consists of
a numberofstages. Initially the polymer becomes hydrated as the aqueous medium
enters the polymer bulk, drug dissolution occurs (the extent of which is dependent
upon the hydrophilicity/hydrophobicity of the drug) and the drug will begin to dif-
fuse through the polymer matrix. The molecular weight of a polymer and the length
of the polymer chains affect the diffusion of the drug through the polymer as small
chainsoffer less resistance to diffusion than do longer chains. Therate of diffusion of
the drug at this initial stage is usually slower as the molecular weight of the polymer
is higher and the polymerchains longer. There then follows a period of polymer deg-
radation (either via hydrolysis and/or enzymatic reactions) reducing the molecular
weight of the polymer chains thereby facilitating faster drug diffusion [90]. Polymer
erosion is the process of mass loss from the polymer bulk and occurs when the mo-
lecular weight of the polymer chains decrease andat a critical molecular weight the
resulting oligomers can solubilise and diffuse out of the polymer matrix. As erosion
proceedsthere is a decrease in polymerstrength and integrity and creation of a more
porousstructure in the polymer bulk [91, 92]. Polymererosion increases drug release
by carrying along drug molecules with the eroded product and additionally, erosion
increases the diffusional space by expanding the pore volumein the polymer matrix
thereby accelerating drug release by diffusion [93].
Degradable polymers undergoeither surface erosion or bulk erosion and the method
by which erosion occurs is dependanton factors such as the rate polymer degradation
and the rate at which the aqueous media infuses into the polymer bulk [28, 90]. Sur-
face erosion occurs whenthe degradation rate of the polymeris faster than waterin-
fusion into the polymer bulk resulting in hydrolysis occurring mainly on the outer-
most surface of the polymer bulk. But, if the rate at which the aqueous media infuses
into the polymer is greater than the rate at which the polymer degrades the polymer
will undergo bulk erosion. In bulk eroding polymers the entire polymer system rap-
idly becomes hydrated and degradation occurs throughout the polymer mass[28, 90,
91]. Polymers based onvery reactive functional groups tend to degrade fast and are
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morelikely to be surface eroding polymers, whereas slower degrading polymers tend
to be bulk eroding [90]
A numberoffactors affect the rate of polymer degradation. The speed of hydrolysis
is controlled by the type of bonds present in the polymer, the polymerstructure and
environmental factors [91]. Structural factors affecting the speed of hydrolysis in-
clude composition (which determines the hydrophilicity of the matrix), crystallinity,
glass transition temperature (7,), molecular weight and the type of bonds present in
the polymer [18, 88, 94]. Environmental factors include pH and the temperature of
the release medium [91].
Hydrolytic degradation of a polymer depends on the access of water to the biode-
gradable bonds in the polymer chains. The hydrophilicity (or hydrophobicity) of a
polymeris determined by its composition and is a measure of how readily it is wetted
by water [94]. The rate at which water penetrates the polymer matrix affects the deg-
radation rate with hydrophilic polymers tending to degrade faster than hydrophobic
polymers [88, 91, 94]. For example, studies have shownthat increasing the glycolic
acid content of poly(lactide-co-glycolide) copolymers of similar molecular weight
increases the hydrophilicity of the polymer and consequently the degradation rate of
the polymer [95].
The degree of crystallinity of a polymer has implications for both the degradation
rate of the polymer and its mechanical properties. Crystallinity of a polymerrefers to
the degree of structural order within the matrix. Chemically similar chains or chain
regions tend to form polymercrystals and the ability of polymer chainsto crystallise
is dependent on the degree of regularity of their chemical structure [94]. Increasing
crystallinity tends to increase the mechanical strength of the polymer but decreases
the rate of degradation [88, 94]. Polymer chains within crystalline regionsare tightly
and regularly ordered whereas the amorphous regions are characterised by lower
chain density with greater degree of randomness and free motion of the chains [94].
The higher free volume and greater chain mobility of the amorphousregions of the
polymerallows easier access of water (and other agents such as enzymes and free
radicals) to hydrolytically vulnerable linkages in the polymer chains resulting in
faster degradation as compared with crystalline regions [94].
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The glass transition temperature (7,) is the temperature at which the polymerexhibits
a transition between two solid phases [94]. Below the 7,, the polymers are in the
glassy state, the chains are much less mobile and the free volume available for diffu-
sion of small molecules like water and drugs within the polymeric matrix is signifi-
cantly decreased. Above the 7,, polymers are in the rubberystate and this is associ-
ated with high mobility of the polymer chains whichfacilitates easier drug diffusion
through the polymer [94, 96]. The 7, of the polymer changes during degradation and
consequently the elution of the drug can be orders of magnitude lower in the glassy
state as compared with the rubberystate.
Environmental factors such as temperature and pH can have a dramatic effect on the
degradation rate of a polymer [18, 94]. A number of studies have shownthat in-
creased temperature can increase degradation rate and drug elution rates of polymers.
Hakkarainen et al [97] showedthat degradation and mass loss was faster at 60°C
than at 37°C in poly(lactide-co-glycolide) (PLGA) and poly(,-lactide) (PLLA)
polymers. Elevated polymer degradation and drug release with increasing tempera-
ture has also been reported in studies by Aso et al [98] and Zolnik et a/ [99]. For
clinical applications of biomaterials, temperature is of relevance with respect to the
T, of the polymer since polymers with 7, less than 37°C will degrade faster and re-
lease their drug load faster than polymers with higher 7,9.
Both strongly alkaline and acidic media can accelerate polymer degradation. Studies
have shown accelerated degradation of PLLA and PLGAinsolutions with pH 5 and
pH>9 [18]. For most clinical applications the degradation at pH 7.4 is most relevant
and is the pH usedfor in vitro testing of DES. Howeveractivated macrophages can
create an environment of pH 5 around implanted materials and accelerated degrada-
tion has been observed in some PLGA implants at pH 5 at the later stages of degra-
dation [94]. This may have implications for degradation of polymer coatings on DES
during the inflammatory response following stent placementin the artery.
In summary,the rate of polymer degradation and drug elution depends on different
properties [88]:
e the higher the crystallinity of the polymer the slower the degradation and drug
releaserate.
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e The type of degradable bondspresent in the polymer backboneaffects the degra-
dation rate. For example in PLGA copolymersthe glycolic acid units are more
susceptible to hydrolysis than the lactic acid units. Faster degrading polymers
havefaster drug releaserates.
e Hydrophilic polymers degrade faster than hydrophobic polymers
e Polymers with high molecular weight have slower degradation and drug release
rates than low molecular weight polymers
1.3.2 Elution and anti-restenotic action of Paclitaxel
Paclitaxel is a natural diterpenoid and can be extracted from the bark of the Pacific
Yew, from species including Taxus brevifola and Taxus media [4, 52]. Paclitaxel
worksby binding to beta-tubulin thereby stabilising the microtubules and inhibiting
the depolymerization of tubulin. Given that microtubules are found in both the cyto-
plasm and nuclei of cells this action has a numberof effects on cellular processes
such as cell division and migration, activation, maintenance of cytoskeletal frame-
work and intracellular and transmembrane protein transport [4, 52]. Stabilizing the
microtubules blocksthe cells ability to break down the mitotic spindle during mitosis
therefore inhibiting cell division [19, 39]. At high concentrations paclitaxel is cyto-
toxic and arrests the cell cycle in the G2/M phase and promotes apoptosis. At low
concentrations paclitaxel arrests the cell cycle in the Go/G; and G,/G» premitotic
phase and there is no apparent cytotoxicity, necrosis or apoptosis induction [52].
Due to its high lypophylicity paclitaxel is rapidly taken up by cells and due to the
alterations induced in the cytoskeleton its effects are long lasting [100].
Rapamycin inhibits SMC during G1 (growth phase) of the cell cycle thereby prevent-
ing production of RNA and protein synthesis. Cells are therefore prevented from en-
tering S phase andreplicating. Rapamycin targets (TOR) protein kinase element in
the downstream signalling pathway controlling mRNAtranslation and cell growth
[19, 39].
For DESto be effective the active drug must be released by the polymer coating and
then enter the media of the arterial wall to its active sites on the SMC where it must
be retained at concentrations that can inhibit SMC proliferation and migration [101,
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102]. The artery itself comprises three main layers; and innermost layer consisting of
a single layer of endothelial cells bounded bya layer of sub-endothelial connective
tissue. The middle layer which is mainly composed of SMC concentrically arranged
around the lumen is termed the tunica media. The tunica adventitia is the outermost
layer and is mainly composed of longitudinally arranged fibroelastic connectivetis-
sue. Bandsofelastic fibres are located in the outermostpart of the intima and media
forming the internal and external elastic laminae [103].
Tissue concentration, distribution and clearance of a drug delivered from stent to
the arterial wall are mainly dependant on transport forces such as diffusion and con-
vection, and the physicochemical properties of the drug such as its molecular weight,
charge and hydrophobicity. Within the arterial wall drug transport and distribution
will be further modulated due to the structure of the artery and effects such as protein
binding of the drug and facilitation of movement of the drug via carrier molecules
[103].
A pathway of drug transport and clearance from DES was proposed by Yang and
Burt [103] and is shown in Figure 1.1. The drug is released from the polymercoating
and partitions into intima or the media ofthe artery and is then transported via pas-
sive diffusion and convection through and within the artery tissue. Drug molecules
released into the intima will partition into the internal elastic lamina and then into the
media. The drug migrates via diffusion through the media to the external elastic lam-
ina wherethe drug partitions into the external elastic lamina and then into the adven-
tia. Drug can be cleared from the artery via release through the endothelium and into
the blood stream or via adventitial clearance through the vasa vasorum, via lymphatic
drainage or through loss into connectivetissues [103].
The structure of the artery, consisting of layers of smooth muscle cells between
sheets of elastin affects drug distribution and transport as the drug mayinteract with
elements within the ultrastructure [104]. Soluble, hydrophilic drugs readily penetrate
and diffuse acrosstissues. Insoluble hydrophobic drugs interact with soluble proteins
in the circulatory system and with both fixed and soluble proteins within the artery
interstitium [105].
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Figure 1.1 Proposed pathway of drug transport and clearance from drug-eluting
stents across and within the artery. Taken from Yang and Burt [103]
1. The drug dissolves in the polymer matrix and diffuses through the matrixto be re-
leased
2. Drugpartitions from the polymer matrix into the intima or the media
Drug diffuses down a concentration gradient through the intima or the media
4. Physiologic transmural hydrostatic pressure gradient results in convective transport
of drug through the vessel wall tissues
5. Drug binding and interactions with proteins in the vessel wall.
6. Drug partitions from the intimainto the internal elastic lamina, or drug partitions
from the media to the external elastic lamina
7. The drug partitions from the elastic lamina into the media or the adventitia
The drug diffuses through the adventitia
9. Adventitial clearance through the vasa vasorum, lymphatic drainage, loss into con-
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nective tissues
10. Drug release into the blood stream or washout from superficial intimaltissues.
Paclitaxel is hydrophobic and insoluble in water but highly soluble in organic sol-
vents and diffuses more slowly through the blood vessel wall than hydrophilic mole-
cules such as dextran or heparin [105, 106] resulting in high arterial retention [101,
104]. Paclitaxel is highly lipophilic and is rapidly taken up by cells as it readily
passes through the cell membrane [107]. It combines readily to arterial tissues and
binds to fixed tissue elements within the tissue interstitium and also associates with
or partitions into hydrophobicstructures such as lipid and cellular membranes[105].
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In addition to non-specific binding to cellular proteins, paclitaxel also binds specifi-
cally to its protein target, polymerized microtubules which possibly explains the un-
even distribution of paclitaxel within the artery wall with most of the paclitaxel re-
maining in the subintimal space and partitioned significantly in the adventitia with
higher concentrations of paclitaxel remaining beneath the stent struts long after re-
lease [106]. Paclitaxel binds strongly to albumin and albumin can penetrate the arte-
rial wall, especially so when the endothelium is denudated e.g. after stent placement
[104].
The interaction of paclitaxel with tissue elements within the artery wall impedes the
transport of paclitaxel downits diffusion gradient across the artery as there is compe-
tition between forward diffusion of soluble drug and the repeated binding and release
of the drug to and from arterial elements resulting in a lower diffusivity and leading
to high retention of the drug within the artery [105]. Hence paclitaxel is delivered
into the arterial wall, where it is retained for a period of time andis thus able to exert
its anti-restenotic effect.
1.4 Paclitaxel releaseprofiles — effect on in-stent restenosis and delayed arterial
healing.
The dosage and elution profile of anti-restenotic agents needs to be sufficient to pre-
vent restenosis but not at concentrations that would impairarterial healing and per-
haps giverise to late cardiac events [15, 16].
In order for the drug to be efficacious the anti-restenotic agent needs to be released
over a minimum period oftime. Proliferation of SMC may begin one dayafter stent
deployment and maypersist for up to 2 weeks [108] cited by [16] while the genes
potentially responsible for proliferation of the SMC are activated for up to 21 days
[108] cited by [12]. Consequently delivery of anti-restenotic agents may need to be
delivered for at least 3 weeksto prevent proliferation and migration of SMC [16] and
possibly for 2-3 monthsafter implantation [7].
For paclitaxel DES differing release profiles have a profound effect on efficacy and
indices of injury including fibrin deposition. In the PICEStrial on human patients a
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Conor stent in which small wells were loaded with varying concentrations ofpacli-
taxel and then covered with PLGA wasstudied. Release of a 10ug dose of paclitaxel
within 10 days showed nosignificant reduction in neointimal hyperplasia as com-
pared to a BMSwhile the same dose delivered over 30 days showed a 69% reduction
in volumeobstruction as compared to BMS [12]. From this study 30ug/30day and
10ug/30day stent loads were found to be effective at reducing ISR and in the EU-
ROSTARtrial the 10ug/30 day load with abluminal unidirectional release of the
drug was foundto result in lower levels of late lumen loss in humansubjects [109].
But in the CoStar trial in which a Conorstent with abluminal unidirectional release
of a 10/30 day load was compared with a Taxusstent, the 102/30 day load was
found to be inferior to the Taxus stent at reducing ISR and wasno better at reducing
ISR than BMS[109]. The reasons for the poorer performance in the CoStartrial as
compared with PICES and EUROSTARtrials are unclear but may be due to a more
complex patient population in the CoStar trial in which a higher density of clinical
events would be expected as compared with the study populations in the previous
trials [109].
Kamath et a/ [4] using a porcine artery model found more adverse affects from
higher doses of paclitaxel in a fast release formulation and that these effects dimin-
ished in a dose-dependant manner as the dose was reduced. A 1 ug/mm? (paclitaxel/
mm stent area) dose was found to have more vascular compatibility when released in
a slow (SR) and medium (MR)rate release formulation than in the fast release for-
mulation. In the TAXUSII study both the SR and MR formulations were equally ef-
ficacious at reducing ISR and major adverse cardiac events (MACE) at 12 months
follow up as compared to BMSdespite there being differences in the amountofpa-
clitaxel eluted from the stents. Over the first ten days there is an 8 fold increase in the
amount of paclitaxel delivered from the MR formulation as compared with the SR
formulation [56, 89]. The total amount of drug loaded onto the SR and MR TAXUS
stent is the same (108ug/16mmstent) [12, 89] with the release profile controlled by
the ratio of drug to polymer (8.8% and 25% for SR and MRrespectively). But ap-
proximately 92.5% and 78.1% of the paclitaxel in the SR and MR formulations re-
spectively is retained on the stent after 30 days [12] which suggests that approxi-
mately 8.5 and 23.6ug of paclitaxel are delivered from the stent over the first 30
days. A substantial portion of the drug in both SR and MRrelease formulations re-
27
Chapter 1
mains within the stent for a considerable length of time [7, 56] with perhaps up to
90% and 75% respectively of the paclitaxel remaining at 6 months[7, 52].
From this it would appear that restenosis can be prevented using relatively small
doses of paclitaxel (10-20ug total drug) released over a minimum of 10 days and
probably over 30 days. But it is unclear what contribution, if any, the paclitaxel re-
maining onthestent has on future ISR.
If there is a maximum period and dosage after which further paclitaxel release does
not affect ISR then further elution of the drug may be counter productive by delaying
arterial healing and re-endothelialisation of the vessel. /n vitro studies have shown
that paclitaxel inhibits migration and proliferation of smooth muscle cells at 10 to
100 fold lower concentrations than those required to inhibit endothelial cells prolif-
eration [110] and developing a release system capable of delivering sufficient pacli-
taxel to prevent ISR whilst not delaying endothelial healing would appear as a desir-
able and achievable goal. The optimal drug release profile for DESis yet to be estab-
lished and may bedifferent for different drugs, stent platforms and agents [7].
1.5 Preclinical methods of evaluating DES.
New DESformulations require vigorous testing prior to approval by the Food and
Drug Administration and equivalent bodies [111]. Drug release, polymer degrada-
tion, biocompatibility and mechanical properties of the DES need to be evaluated
prior to the stent being further tested in clinical trials [112, 113] and selection of suit-
able models to asses these parametersare crucial.
Typically, novel DESare tested in vitro to define the degradation and drug elution
profile of the polymer coating prior to further testing of the formulation in vivo. In
vitro polymer degradation and drug elution should be examined at body temperature
under infinite sink conditions and with agitation to prevent boundary layer effects
[113]. Often in vitro testing involves incubating the stent (expanded and un-
expanded) at 37°C in a physiological release media on a shaker or stirrer at 60-
120rpm. The incubation media that has been used in in vitro models includes phos-
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phate buffered saline, isotonic sodium chloride, porcine plasma and maycontain ad-
ditives such as surfactants and cosolvents [114].
Tissue chamber models, in which chambers containing polymeric materials are im-
planted subcutaneously in animals such as rats, mice and farm animals, have been
used to determine the biocompatibility of polymers, the inflammatory response to
implanted materials and the pharmacokinetics of a range of anti-inflammatory drugs
[115-117].
The rat subcutaneous implant model is an established small animal model used to
determine the impact of the in vivo environment on drug elution, molecular weight
change and massloss of biodegradable polymers (S Zhong pers comm. [115, 118]).
In this modelthe test article or polymer is contained within polymethyl methacrylate
(PMMA) chambers, which are sealed with a semi-permeable membrane and then
implanted subcutaneously into the back of male Wistar rats. The procedure causes
minimal stress to the animals and is therefore ethically acceptable [117]. The filter
allows cellular exudate to diffuse into the chamber but excludes cellular elements.
The modelis seen as a reliable method to test the properties of the polymerprior to
further testing in animal artery models (Boston Scientific in litt).
The model has a number of advantages over in vitro models including:
e Thetest article is exposed to complete interstitial exudates fluid environment
enabling degradation of the polymer in an in vivo physiological medium at
body temperature and pH
e The semi-permeable membranefacilitates diffusion of eluted drug and poly-
mer degradation products to diffuse out of the chamber and degradation and
drug elution is subjected to in vivo clearance kinetics
e Drugelution rates are not affected by boundary layer effects due to natural
agitation of the chamber exudate caused by the animals movements
e The modelis sufficiently discriminatory to detect weaknesses in implant con-
figuration (changesin physical coating characteristics over time)
e The model is pathophysiologically relevant with respect to observations re-
lated to inflammation and neo-vascularization
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e The model results in uniform and repeatable in vivo conditions based on in-
bred animalstrains
e The test article is exposed to hydrolases and oxidoreductases secreted by
macrophages and fibroblasts. This is of relevance for polymers which are
susceptible to enzymatic cleavage.
The device is retrievable for physical and chemical analysis. This is true also for in
vitro models. But analysis of degradation and coating integrity is difficult in stents
retrieved from animalarteries due to the presence of adhered tissue which needs to
be removedprior to visual assessment by scanning electron microscopyandlight mi-
croscopy. Additionally, the adhered tissue can give rise to peaks in chromatogramsin
studies using gel permeation chromatography which can impair assessment of the
degradation rate of the polymer coating. Removal of the adhered tissue either physi-
cally or chemically (e.g. by use of enzymes) may damagethe stent coating and give a
false assessment of the degradation, drug elution and visual appearance ofthe stent
coating.
In common with in vitro models, the tissue chamber model does notreplicate all
conditions of the vascular implant site and does not take into account the effect of
factors such as flow dynamics, shear stress, continuous pulsatile effects and strut en-
capsulation by SMC.
Stent formulations with a satisfactory performancein theinitial preclinical trials are
further tested using animal models. A consensus statement which set out recommen-
dations for best scientific practice in preclinical studies of DES recommended using
the porcine coronary artery model and the rabbitiliac artery model to determine the
safety and efficacy of DES [113].
1.6 Overview of the study.
In chapters 2 and 3 ofthis thesis the degradation and paclitaxel elution profile of two
biodegradable polymers, namely TyRx and PLGA,are examinedto assesstheir suit-
ability as coatings for DES. Further studies to modulate polymer degradation and pa-
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clitaxel elution by mixing different blends of PLGA andincorporating hydrophilic
copolymers into PLGA polymers are covered in chapter 4.
Molecular weight change is a measure of the reduction in size of the polymer chains
within the matrix and serves as a measure of polymer degradation [119] and was de-
termined using gel permeation chromatography (GPC). As a result of polymer deg-
radation polymererosion occurs and this was measured by calculating the change in
mass of the stents as degradation proceeded. Paclitaxel elution was monitored by
measuring the amount of drug remaining on the stent after implantation using GPC.
Degradation and erosion of the polymer can weakenthe structure of the polymer ma-
trix and cause fragments of the polymer to break away from the coating (delamina-
tion) and the visual deterioration of the stent coating was determined using light mi-
croscopy and scanning electron microscopy.
In chapters 2 and 3 polymer degradation and drug elution is determined using an in
vivo rat tissue chamber model. All of the animal procedures were conducted under
homeoffice regulations with the appropriate licence in place. In chapter 4 the degra-
dation and drug release properties of PLGA were modified by blending low molecu-
lar weight hydrophilic pluronics and PLGA copolymers with different lac-
tide:glycolide (LA:GA) content and differing molecular weights. This study wasper-
formed in vitro using polymer coated Teflon (PTFE) discs incubated in PBS, pH 7.4
at 37°C.
In chapter 5 the data obtained is discussed in relation to the polymer degradation and
drug elution profiles of paclitaxel DES and with clinical studies and assessed for its
suitability for coronary DES.
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The Degradation and Drug Elution Profile of TyRx,
a Tyrosine-Containing Polyarylate
2.1 Introduction.
Tyrosine-derived polyarylates are a group of thermally stable polymers with a range
of mechanical properties from soft elastomeric materials such as poly(DTO sebacate)
to tougher, strong materials such as poly(DTEsuccinate) [1]. The polymers were de-
signed as part of a library of structurally related polymers and a good structure to
property relationship has been established [2-3] cited by [1]. The desaminotyrosyl
tyrosine ester (DTR) usually comprises about 80-90% of the polymer massandis the
key componentfor defining properties (by its solubility) such as vascular compatibil-
ity and degradation profile. Polyarylates are not cytotoxic and cells attach and prolif-
erate on their surface depending on the polymers hydrophobicity. Degradation ofty-
rosine-derived polymers has been shownto produceless acidic degradants than poly
(lactic-co-glycolic acid) and poly (lactic acid), this reduction may explain the good
tissue compatibility of the tyrosine derived polymers [1]. A comparison ofthe degra-
dation and tissue response to extruded pins made from a tyrosine-derived polyary-
lates (poly(DTE-adipate), a tyrosine derived polycarbonate and PLLA (poly (L-
lactide)) in a subcutaneous rat model by Hooperet al [4] showed that the tyrosine-
derived polyarylates elicited the mildest inflammatory response and that as degrada-
tion of the polymer proceededtissue in-growth into the pins followed.
Early tyrosine containing polyarylates had slow degradation times of monthsto years,
but for applications such as DESa faster rate of degradation is required. The proper-
ties of the polymer can be altered by varying the length of the diacids (such as suc-
cinic acid, adipic acid or sebatic acid) in the polymer backbone and/or the length of
the alkyl ester pendant chains. The arylate bond within the backbone of the polymer
structure introduces a site within the structure that is susceptible to hydrolysis [1].
Tyrosine-derived monomers which are produced during degradation are notreadily
water soluble and mass loss from these polymers occurs very slowly and only to-
wardsthe end of the degradation process[1, 4].
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Previous studies have shownthat lengthening the pendant chain haslittle effect on
degradation rate of thin films of poly(DTE adipate), poly(DTH adipate) and
poly(DTO adipate). Changes in pendant chain length affect the glass transition tem-
perature and the hydrophobicity of the polymer and these effects may counteract
each other with respect to the degradation rate in these polymers[5]. Increasing the
pendant chain length decreases the glass transition temperature (7,) and increases the
hydrophobicity of the polymers. The hydrophobicity of the polymers is increased
with increasing pendant chain length leading to lower degradation rates. But at 37°C
polymers with the shorter pendant chains were glassy, while those with longer chain
length were rubbery. Polymers with lower 7, and in the rubbery state have faster
degradation rates as compared with those in the glassystate.
T, also has implications for the diffusion rate and controlled release of drugs;
Poly(DTH adipate) and poly(DTO adipate) which are rubbery at 37°C eluted a model
compound (p-nitroaniline) 10 times faster than poly(DTE adipate) whichis glassy at
37°C [5], possibly due to the fact that in the rubbery state polymers have a higher
free volume than polymers in the glassy state, therefore more readily allowing the
diffusion of small free molecules [5-6]. Previous studies have showna diffusion con-
trolled release mechanism of low molecular weight drugs from the adipic acid series
of tyrosine-based polyarylates [5]. Additionally, tyrosine-derived polyarylates have
been used for the release of water soluble peptides [7] and for the release of antico-
agulants from polymer coated carbonfibres [8] cited by [1].
Given the good mechanical strength, coating properties, biocompatibility (especially
important considering the concern surrounding the possible role of any residual
polymerin eliciting unfavourable late cardiac events in DES) and low toxicity of
their degradation products tyrosine-derived polymers may have significant future po-
tential for use as a polymerfor a DES.
The aim of this study was to examine the degradation profile of TyRx P22-10 (Fig-
ure 2.1) in an in-vivo rat model to evaluate its potential as a coating and drug deliv-
ery polymer for use on coronary stents. TyRx P22-10 is a tyrosine-derived polyary-
late with a succinate diacid monomer with an ethyl ester pendant group and 10% free
acid in the pendant groups and a 7, of 84°C (S.Zhong. pers comm.).
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Figure 2.1 Structure of TyRx P22-10: A tyrosine-derived polyarylate containing suc-
cinate
This study tested the hypothesisthat the introduction of a succinic acid monomerinto
the polymer backbone with 10% free acid in the pendant chain would increase the
degradation rate of the polymerand elution of paclitaxel and be of a suitable duration
for DES. Thesuitability of the polymer wasassessed by determining the degradation
profile of TyRx P22-10 polymer coated onto coronary stents with and without pacli-
taxel in a rat in-vivo model using Gel Permeation Chromatography (GPC) and using
Light Microscopy (LM), Scanning Electron Microscopy (SEM)to assess the visual
condition of the polymercoatas it degraded. In this modelthe stent is contained in a
sealed in a PMMAchamberwhich provides an acellular environment and the degra-
dation media is derived from the host as extracellular exudate which collects into the
chamber. Acid degradation products were measured by monitoring the pH of the ex-
planted chamberexudate.
2.2 Materials and methods
2.2.1 Materials
Tetrahydrofuran (THF): Romil-SpS Super Purity solvent, 99.9% destabilised
Methanol: Romil-SpS Super Purity solvent, 99.9%.
Paclitaxel from Taxus yannanensis: Sigma-Aldrich
TyRx coated Liberté™ WH 16mm stents obtained from Boston Scientific
Implantation chambers: prepared from medical grade 20mm lengths of 10mm diame-
ter medical grade polymethyl methacrylate (Goodfellows UK).
Chamberseals: 22um cellulose nitrate milliporefilters.
2.2.2 Preparation of stents and implant devices
400ug of TyRx P22-10 with or without 2.5% paclitaxel was coated onto a Liberté
16mm WHcoronary stent. The stents were placed in PMMA chambers which were
4]
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then sealed with a 0.22um millipore filter using medical grade silicon glue (Nusil
Silicone Technology, USA) (Figure 2.2) and weresterilised by autoclaving.   milliporefilter seal
cellular exudate
20
mm
stent
PMMAchamber
Figure 2.2 PMMAchambercontaining a stent with cellular exudate
Implantation of the test chambers was performed as described by Baldwin and Hunt
[9]. Four test chambers containing one stent each were implanted subcutaneously
into the backs of male Wistar rats, two either side of the spine, locating them on top
of the dorso lumbar muscles and also below the shoulders. At the appropriate time
points the implants were removed for experimental analysis. The stents were washed
by quickly dipping the stent twice into ELGA Purelab UHQ water. Excess moisture
was quickly blotted off the stent and the sample wasplaced into a clean polystyrene
vial, and dried under vacuum at room temperature. The samples were weighed every
24 hours until a stable weight was achieved and the samples were dry. The sample
vials were then tightly capped and stored at 4°C in polythene sealed bags containing
Silica desiccant. Four stents were recovered from each animalat each time point. All
stents were examinedusing optical light microscopy. Three stents were used for GPC
analysis and one for SEM.
2.2.3 Gel permeation chromatography: 
For GPC analysis each stent was added to 1ml of solvent containing 9:1 v/v THF and
Methanolin a capped glass vial and shaken gently for 3 hours to extract the polymer.
GPC was performed using three 300 x7.5mm, Sum Polymer Laboratories PLgel
columns with pore sizes 500A, 10°A and 10°A with a flow rate of Iml per minute
using THF as the mobile phase and a Polymer Labs ELS 1000 evaporative light scat-
ter detector. Calibration standards were prepared using Easi-Cal PS-2 (Polymer Labs)
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polystyrene standards, with a molecular weight range of 580 — 377400, dissolved in
THFto give a 0.1% solution. Calibration standards were run in triplicate and a cali-
bration was performed at the beginning, middle and end of every GPC run. Raw
polymer wasprepared by weighing an amountof polymer and adding THF/Methanol
mixture to give final concentration of 2mg/ml and gently mixing at 120rpm at room
temperaturefor 3 hrs.
The injection volume was 250ul with a polymer concentration of approximately
400ug/ml solvent for the stent samples and 100u1 for the raw polymer and Easi-Cal
standards) with three measurements per sample. Quantitative analysis was performed
using Caliber Software (Polymer Labs). Paclitaxel analysis was determined using
peak area of the samples and quantified using a calibration curve prepared using
standards containing 5, 10, 20, 50 and 100ug/ml paclitaxel dissolved in 9:1
THF/Methanol. 2501 of the standards were injected onto the GPC and the peak area
was analysed in the same methodas the stent samples.
2.2.4 pH measurements.
Cellular exudate recovered from the chambers was measured using a pH meter (Met-
tler Toledo) and the visual appearance of the exudate noted and recorded asclear (in-
dicating an intact chamberseal), cloudy, red (indicating presence of red blood cells
and presenceoftissue in-growth(indicating severe loss of chamberseal integrity.
2.2.5 SEM and light microscopy
The explanted stents were examined bylight microscopy by two methods;stereo dis-
section microscope and reflected light microscopy using differential interference
contrast and standard reflectance. SEM wasperformed using a Leo 1550 Field Emis-
sion Scanning Electron Microscope (Zeiss). For SEM, one stent from each animal
was mounted onto an aluminium stub using double sided adhesive carbon tape sput-
ter coated with chromium using an EMITECH K575X coater.
2.2.6 Massloss assessment.
The weight of polymer coated onto each stent was recorded prior to implantation.
The mass of the polymer remaining on the stent after implantation was determined
after the explanted stents had been dried using a Sartorius CP2P balance.
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2.3 Results
2.3.1. GPCdata.
2.3.1.1 TyRx molecular weight data
A calibration graph of log molecular weight versus retention time was generated and
used to determine the following for each sample:
e Peak molecular weight (M,) — the molecular weight of the highest peak and
therefore the mode of the molecular weight distribution.
e Weight average molecular weight (M,,) — this takes into account the molecu-
lar weight of the chains in determining the contributions to the molecular
weight average
e Numberaverage molecular weight (/,) — is the mean molecular weightof all
the chains in the sample
e Polydispersity Dispersity Index (PDI) - is a measureofthe distribution of mo-
lecular mass in a given polymer sample and is calculated by dividing the
weight average molecular weight by the number average molecular weight
e Peak Height
e Peak Area.
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Figure 2.3 Typical GPC Calibration Graph for TyRx degradation Studies.
The X-axis is the retention time on the column for the maximum peak from the polymer
standard. The Y-axis is the log of the molecular weight of the calibration standard. The plot
is 3“ order polynomial.
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A typical calibration is shown in Figure 2.3. An R? 0.999 wasrequired for thecali-
bration to be acceptable. The GPC data obtained is given in Table 2.1 and refers to
the polymer remaining on the stent. Data for M,, M,, M, and PDI is shownin Fig-
ures 2.4 to 2.7.
Table 2.1 GPC data: Degradation of TyRx with and without paclitaxel (Ptxl).
The data refers to the My, M,, M, and PDI of the polymer remaining on the
stent.sd=standard deviation.
 
 
          
implant Mean
time polymer M. sd Mean M, sd Mean M, sd PDI
(days) "
14 TyRx+Pctxl 25558.44 2366.10 36357.50 1465.57 47919.08 3332.89 1.53
TyRx 24615.86 187.36 36930.11 176.20 46373.56 1976.57 1.50
30 TyRx+Pctxl 19720.00 269.08 25350.89 133.91 25377.33 730.61 1.31
TyRx 16767.78 216.15 23623.56 166.63 25048.56 946.83 1.41
60 TyRx+Pctxl 9391.00 360.09 12930.89 481.23 12631.94 643.93 1.37
TyRx 8747.31 259.96 11594.53 290.92 12163.31 638.33 1.33
90 TyRx+Pctxl 7445.44 54.17 10285.61 81.74 9800.13 405.36 1.35
TyRx 7174.26 150.90 9157.30 111.23 9405.63 474.72 127]
120 TyRx+Pctxl 5790.44 78.95 7148.48 68.11 6680.22 327.03 1.23
TyRx 5187.60 74.50 6425.02 67.54 6101.54 283.69 1.24
150 TyRx+Pctxl 4558.70 163.06 5537.52 211.36 5245.89 257.78 121
TyRx 4268.78 33.85 5045.41 40.31 4751.22 94.00 1.18
180 TyRx+Pctxl 4118.11 41.83 4611.44 53.29 4032.81 196.15 1.12
TyRx 3559.11 59.33 4224.52 46.18 3544.59 147.64 1.19
220 TyRx+Pctxl 3463.85 135.29 3927.67 112.95 3356.15 220.67 1.13
TyRx 3553.15 64.45 3921.70 (ene) 3192.04 277.48 1.10
250 TyRx+Pctxl 3804.37 54.49 4436.67 57.54 3662.04 94.27 L.17
TyRx 3316.37 69.21 3820.88 77.00 2989.25 239.66 1.11
280 TyRx+Pctxl 3517.03 33.37 3921.33 38.43 3110.36 89.49 1.11
TyRx 3161.04 21.36 3494.30 26.56 2815.59 19.42 1.10
The change in molecular weight in TyRx polymerin implanted stents is shown in
Figure 2.4. Analysis by ANOVA showedthat addition of paclitaxel had no effect on
the M,, change in TyRx (p=0.082). The degradation of the polymer was over two
phasesconsisting of an initial rapid phase to 60 days followed by a period of slower
degradation. The original MM, of the polymer was 59,000 and by 14 days this had de-
graded by 40% to approximately 37,000 and by 60 days the M,, had further degraded
to 12-13,000. By 150 days implantation the M,, had degraded to approximately 5,000
after which degradation proceeded more slowly to approximately 3,500 to 4,000 by
280 days, equivalent to 6-7% of the original M,, at the end of the study period.
a)
 
Chapter 2
 
 
 
   
75,000 -
. 60,000
=i)2 45,000
S
a
2 30,000
2 —¢—TyRx+pctxl
2 15,000 4 —a-TyRx
0 T T T T T 1
0 50 100 150 200 250 300
Impantation time (days)
Figure 2.4. Molecular weight change of TyRx polymer during implantation
The graph shows the change in weight average molecular weight of the polymer (with and
without paclitaxel) remaining onthestent. pctxl=paclitaxel.
There was nosignificant difference (p=0.356) in the polydispersity (PDI) during the
trial due to the presence of paclitaxel in the polymer but PDI decreased significantly
(p<0.001) with increasing implant time. The PDI of the polymer is shown in Figure
2.5. The PDI of the raw polymer was 1.572. At 14 days the PDI was 1.515 but by
180 days it had reduced to 1.207. The PDI continued to decrease after 180 days to
1.150 at 280 days but the decrease wasnotsignificant.
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Figure 2.5 Polydispersity of TyRx polymer coated onto coronary stents (combined
data from TyRx with and without paclitaxel) during implantation. Figure shows the
PDI of polymer remaining on the stent. Error bars are the standard deviation.
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Figure 2.6 Changes in peak molecular weight (M,), weight average molecular
weight (M,,) and number average molecular weight (M,) during degradation of TyRx
polymercontaining paclitaxel.
The changes in peak molecular weight (M,), weight average molecular weight (M,)
and number average molecular weight (/,) of TyRx polymer coated on stents with
and without paclitaxel are shown in Figures 2.6 and 2.7. During the first 90 days the
values for M,, My and M, are different indicating differences in the length of the
polymer chains that comprise the polymer, but as degradation progresses M,, M, and
M,, becomesimilar indicating that the polymer chains become moreuniform in size
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Figure 2.7 Changes in peak molecular weight(M,), weight average molecular weight
(M,,) and number average molecular weight (MV,) during degradation of TyRx poly-
mer.
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2.3.1.2 Paclitaxel assessment
Attempts were made to quantify the amount of paclitaxel remaining on the stent us-
ing peak area data from GPC analysis. A peak for paclitaxel can be seen on the GPC
chromatogramsbut at the concentrations in the set of stents in this trial the peak is
small on the ELS detector. Paclitaxel has a molecular weight of 853. But due to loss
of integrity of the seal in a large numberof the chambers cellular exudate and tissue
in-growth occurred and peaks with molecular weights of around 600 to 1100 where
observed on the chromatograms which often overlapped or completely obscured the
paclitaxel peak (see Appendix, Figures Al-A4). Thus paclitaxel quantification was
difficult and only possible in a small numberofcases.
The calibration data for paclitaxel assay is shown in Figure 2.8 and the amount of
paclitaxel remaining on the stent after implantation is shown Table 2.2 & Figure 2.9.
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Figure 2.8 Paclitaxel Calibration. Peak area data derived from GPC chromatograms.
Function is 3“ order polynomial. Error bars = standard deviation.
At thestart of the trial the stents contained 10ug of paclitaxel. Recovery of paclitaxel
in this assay was 109% for the controls. Analysis using ANOVA showed that over
the trial period the concentration of paclitaxel decreased significantly (p=0.003).
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 Table 2.2 Paclitaxel concentration on TyRx coated stents.
 
 
Paclitaxel Concentration number .Implant % Pacli-
Time (days) (up)stent) of taxelmean St dev stents
Controls 10.96 1.00 4 100
15 10.91 1.75 2 99.5
90 8.75 0.37 2 79.8
120 6.64 0.00 1 60.6
150 8.47 0.40 3 77.3
220 10.55 1.79 2 96.2
250 6.87 2.60 7 62.7
280 3.08 0.54 2 28.1       
Controls data from un-implanted stents analysed as other stent samples. Percentage pacli-
taxel is the amount of drug remaining on the stent as a % of the controls, St dev=standard
deviation
At 15 days there was negligible elution of paclitaxel. After 90 and 150 days implan-
tation, 20% and 23% respectively of the paclitaxel had been eluted but analysis using
ANOVAshowedthat the decrease in paclitaxel was not significant as compared the
controls (90 days, p=0.185 and 150 days p=0.096). At 250 days approximately 38%
of the paclitaxel had been eluted and this was significantly lower than the control
values (p=0.003). After 280 days implantation 72% of the paclitaxel had been eluted
and this wassignificantly lower than at 250 days (p=0.021) and all other time points.
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Figure 2.9 Elution of Paclitaxel from TyRx coated stents during implantation.
Graph shows the mean value ofpaclitaxel remaining on the stent. Error bars represent the
standard deviation of the mean. Thefirst data point is from control (unimplanted)stents.
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2.3.2 pH data.
In total 216 chambers were sampled and the pH of the chamber exudate is shown in
Figure 2.12. Approximately 35% of the stents had a clear exudate indicating that the
chamberseal retained its integrity while 14% had a cloudy exudate. The remainder
had and exudate that waseither yellow through to red from the presence of red blood
cell, some samples had tissue adheredto the stent indicating a loss ofintegrity of the
chamberseal.
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Figure 2.10 pH of cellular exudate collected in the PMMA chambers. The exudate
from chambers containing stents coated with TyRx with or without paclitaxel. Error bars
show +/- the standard deviation.
The mean pH of the exudate was 7.72 (SE=0.02) and 7.69 (SE=0.2) for the TyRx
polymer group and TyRxplus paclitaxel groups respectively. Analysis by ANOVA
showedthat paclitaxel had no significant effect on exudates pH (P>0.05). At 14 days
and 150 days time points the pH (7.96 and 7.95 respectively) was significantly higher
than the other time points p<0.001 but no trends in pH over time were observed and
the significance of the 14 day and 150 day data was unclear.
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2.3.3 Light microscopy & SEM.
Data from Light Microscopy (LM) and SEM is shownin Figures 2.11 to 2.13. Simi-
lar changes in appearance were seen in both the TyRx and TyRx+ paclitaxel groups.
With increasing time the appearance of the polymer coating changed from smooth
and clear to opaque, white and chalky with areas of exposed bare metal where the
polymer had degraded and solubilisation of polymer chains had occurred. The slow
erosion of polymerfrom the stent is evident by the slow change in appearanceofthe
stent coating over time with a trend of increasing areas of bare metal occurring stead-
ily over time but with large areas of intact polymer evenat the later stages of degra-
dation at 280 days (Figure 2.11.d).
 
Figure 2.11 Light microscopy images of explanted stents.
Clockwise from top left: a:30 days, b:150 days,c: 250 days and d:280 days. Magnification
x1.6
Blistering on the polymer wasobserved at 30 days and had become more extensive
at 60 days. By 90 and 180 daysareas of bare metal could be observed and the opacity
of the polymer had increased and by 250 dayslarge areas of the metal stent were ex-
posed, where degraded polymerhad either been dissolved or had become detached
from the stent (Figure 2.12). However, despite the occurrence of areas of bare metal
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and apparent deterioration of the polymer, large areas ofthe stent remained coated by
degraded, but intact polymer.
 
 
Figure 2.12 Light microscopy images of explanted stents showing deterioration of
the polymer coating. Areas of bare metal(silvered areas) increase as implant time pro-
gresses. a: 60 day, b:90 day, c:180 day and d:250 days Implantation. Images taken at x5
magnification using filter 2.
 
Figure 2.13 shows SEM images of a 120 day implanted stent. The layer of polymer
revealed a porous/honeycomb appearance with areas of bare metal visible with some
small deposits of polymerstill adhered to the metal. The porous honeycomb appear-
ance of the polymerwasindicative of hydrolytic degradation.
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Figure 2.13 SEM Images of 120 day implant stents showing polymer coating and
areas of extensive erosion revealing the bare metal of the stent. Images taken using In-
Lens and EHT=SKV.
 
2.3.4 Massloss data.
After explanation cellular exudate and host tissue was present on the stent, much of
which was not removed using the given washing protocol. Thus it was impossible to
obtain accurate post explanation massdataforthestents.
The peak height and peak area data from GPC is dependant on the amountofpoly-
mer in the samples and gives an indication of the amount of polymer remaining on
the stent. Due to overlapping peaks on the chromatogramsfrom either cellular exu-
date and/or host tissue components, peak area would not give reliable data in this
trial (see Appendix 1). But peak height should be unaffected by the presence of other
peaks and gives an indication in changes in polymer massonthestent.
Peak height data from GPC analysis is shown in Figure 2.14. Analysis by ANOVA
showednosignificant difference in peak height during the study between the TyRx
group and the TyRx + paclitaxel group (p= 0.719), but implant time significantly af-
fected peak height (p<0.001).
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Figure 2.14 Effect of implantation time on peak height of TyRx polymer.
Peak Height data taken from GPC data. Control data from un-implanted stents is shown at 0
days.  
 
Mean peak height data from the TyRx and TyRx + paclitaxel groups combined is
shown in Figure 2.15. Overall the peak height decreases over time indicating that
massloss is occurring. But the data showslarge variation about the mean values.
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Figure 2.15 Peak height of TyRx during implantation.
Combined data from TyRx and TyRx + paclitaxel groups. Error Bars are the standard devia-
tion. Thefirst data point is from control (un-implanted)stents.
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Analysis using ANOVA showedthat by 150 days implantation the peak height had
decreased significantly compared to that of the controls (p<0.001) indicating that
massloss had occurred. Significant (p=0.015) reduction in peak height continued af-
ter 150 days from 4.42mV (stdev=1.7) to 3.4mV (stdev=1.53) at 220 days. At 280
days peak height was 2.89mV (stdev=0.6) but this was not significantly different to
peak height at 220 days.
2.4 Discussion.
The presence of 2.5% paclitaxel (w:w) had no effect on the degradation profile, exu-
date pH or mass loss of TyRx polymer. The original molecular weight of the polymer
was 59,000 and by 60 days this had decreased by approximately 80% to around
12,000. The degradation rate then slowed and at the end of the 280 day study period
the molecular weight was about 6% ofthe initial My. (approximately 4,000).
The degradation of TyRx P22-10 is affected by two opposing effects. Tyrosine con-
taining polyarylates with short diacid components and short pendant chains (such as
TyRx) have higher 7, and are glassy at 37°C, decreasing the degradationrate. But the
shorter pendant chain decreases the hydrophobicity of the polymer which should re-
sult in higher degradation rates [5]. 10% carboxyl acid was included in the pendant
chain to increase the degradation rate of the polymer. The degradation rate of TyRx
P22-10 in this study was faster than that for thin films of poly(DTE adipate),
poly(DTOadipate) and poly(DTH adipate) which degraded to 30-40% oftheir origi-
nal molecular weights in 180 days when incubated in vitro in PBS at pH7.4 at 37°C
[5] whereas in the present study TyRx P22-10 degraded to about 7% of the original
molecular weight over 180 days. Initial degradation rate to around 220 days was
faster for TyRx P22-10 than for for poly(DTE adipate) implants [4] but at around
280-290 days the polymers had degradedto a similar degree.
The peak molecular weight (M,), weight average molecular weight (M,,) and the
mean number average molecular weight (M,) of the polymer were different in the
early stages of thetrial but by 60 days their values becamesimilar as a result of de-
gradation generating molecular chains of similar length and molecular weight. The
decrease in polydispersity as implantation time increased also indicated a trend to-
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wards greater uniformity in the length of the polymerchainsas a result of hydrolytic
degradation. This is in contrast to the changes in polydispersity seen during in vivo
degradation of poly(DTE adipate) and poly(DTE carbonate), tyrosine derived pol-
yarylates and polycarbonates respectively, which showed an increase in polydisper-
sity as implant time increased due to degradation via random hydrolytic chain cleav-
age [4]. The reason and significance for this difference between TyRx and poly(DTE
adipate) is unclear.
Onefeature of the degradation of tyrosine-derived polyarylates is a slow rate of mass
loss, possibly due to the hydrophobic nature of the polymers which retards permea-
tion of water into the polymer bulk and the insolubility of the degradation products in
aqueous media [5] and occurs only at the very end of the degradation process [1].
Fiordeliso et al [5] found that the mass of polyarylate films when incubated in
physiological buffer solution at 37°C was unchanged after 26 weeks while Hooperet
al [4] found that mass of poly(DTE adipate) pins incubated in buffer and in vivo de-
creased by <5% over 295 days.
In vitro studies using TyRx have shown a massloss of approximately 20% by 120
days but in vivo data from the same laboratory showed that TyRx P22-10 pellets and
coated stents in PMMA chambers had negligible mass loss up to 90 days despite a
reduction in the molecular weight to around 15% of the original (unpublished data).
It is unclear if there were any problemsdueto cellular exudate or adhered tissue con-
taminating the pellets or stents which would increase the weight of the explanted
stent and mask any polymer mass loss and explain the differences between the in
vivo and in vitro data.
In this study the presenceofcellular exudate and/or host tissue on someofthe stents
made measurements of massloss using stent weight unreliable. But the peak heights
of the polymers on the GPC chromatogramsgave an indication of loss of mass over
implant time. A clear trend could be seen of reduced polymer peak height with in-
creasing implant time, suggesting that mass loss was occurring after about 60 days
implantation and continued to 280 days. However, the relationship between amount
of polymer and peak height from the ELS detector is not linear and small changes in
concentration causes large increases in signal intensity and a 50% reduction in peak
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height does not correspond to a 50% reduction in polymer mass. Further evidence of
mass loss from the polymer could be seen by the visual deterioration of the stent
coating using LM with areas of bare metal of the stent becomingvisible after 60 days
and more bare metal becoming exposed as the polymer chains slowly solubilised as
implantation time increased. SEM revealed a porous microstructure indicative of hy-
drolytic degradation within the body of the polymer suggesting that bulk erosion was
occurring. But despite the degradation much of the polymer remained intact on the
stent at 280days.
Due to presence of overlapping peaks in the GPC chromatogramsand the low re-
sponse on the ELS for paclitaxel which resulted in small peaks making peak detec-
tion difficult on some occasionsit was difficult to quantify paclitaxel concentration
in some samples. But the data that was obtained showeda three phaserelease of the
drug from the polymer coating. An initial slow phase of the release up to 15 days was
followed by a moresteady release of drug. Approximately 2ug (approx. 20% ofini-
tial loading) of paclitaxel had been released by 90 days and at 250 days approxi-
mately 6-7ug (approx. 38% ofinitial loading) had been eluted. Elution rate was then
faster to 280 days by which time over 70% of the drug had been eluted.
A numberoffactors govern the elution of a drug from a polymer during degradation
[6]. The mobility of drug molecules within the polymer matrix increases as the
polymer molecular weight decreases resulting in faster drug release [10] since small
chains offer less restriction for drug diffusion than long chains [6]. Erosion of the
polymer mass enhanceselution of a drug as drug molecules are carried along with
the eroded polymer products out of the polymer matrix. Additionally creation oflar-
ger pore spaces and vacuolesincreases the diffusional space within the polymer bulk
accelerating the release of the drug by diffusion [11]. Glass transition temperature (7,)
also influences drug elution rate. Rubbery polymers have a higher free volumefrac-
tion than glassy polymers andthis mayfacilitate faster diffusion through the polymer
matrix [5]. The elution ofp- nitroaniline was 10 fold faster from films of poly(DTH
adipate) and poly(DTO adipate) which have a 7, of <37°C and were rubbery as com-
pared with poly(DTE adipate) which wasglassy [5].
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Release ofp- nitroaniline from films coated with the polyarylates poly(DTEadipate),
poly(DTH adipate) and poly(DTO adipate) was via diffusion controlled release
mechanism as shownbythe release kinetics, i.e. linear correlation between release
and the square root of the release time [5]. Figure 2.18 showsthe release of paclitaxel
from TyRx 22-10 plotted against the square root of the release time. The data sug-
gests a linear relationship between cumulative paclitaxel release and the square root
of time between 15 and 250 days implantation time, indicating diffusion controlled
release of the drug during this period as has been seen in other studies [5]. The rate
of diffusion increases after 250 days possibly as a result of more extensive massloss
and an increased porousstructure of the polymercoating after this period.
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Figure 2.16 Release of paclitaxel from TyRx 22-10 plotted against the square root of
the implant time. The black dashed line showsrelease of paclitaxel during the study pe-
riod. Thesolid blue line is the trendline for the points from 15 to 250 days.  
Figure 2.17 showsthe relationship between molecular weight change in the polymer,
paclitaxel release and change in peak height during implantation. The reasonsfor the
initial slow release phase are unclear but may be due to a numberoffactors. At 15
days implant time the polymer had degraded by only about 35% ofits initial molecu-
lar weight indicating larger polymer chains which hinders drug elution. The elution
of paclitaxel appears to be diffusion controlled from 15 days to 220 days. During this
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period the polymer molecular weight degrades from around 40,300 to approximately
4,200 but despite this degradation only around 4g (approx. 38% of original amount)
of paclitaxel wasreleased.
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Figure 2.17 Molecular weight change, paclitaxel elution and peak height expressed
as percentage of original value during implantation. MM, = polymer molecular weight,
pctxl= paclitaxel elution. The peak heightis height of the paclitaxel peak from GPC chroma-
tograms
The slow rate of paclitaxel elution despite the extensive degradation of the polymer
up to 220 days may beattributed a number of factors. The 7, of TyRx P22-10 is
84°C and conditions within the chamber would therefore be below the 7, and the
polymer would be in a glassy state. This glassy state is associated with less mobile
polymer chains and less free volume and slower elution rates [6]. The hydrophobic
nature of polyarylates may retard ingress of aqueous media which mayalso slow dif-
fusion of drugs through the polymer matrix. Other studies have indicated low water
uptake by tyrosine containing polyarylates. Hooperef al [4] found less than 2% wa-
ter uptake in poly(DTE adipate) implants. But Schachter and Kohn [7] found that
thin films of poly(DTH adipate) adipate absorbed 10% of their initial weight after 2
hours when incubated in PBS buffer, pH7.4, at 37°C. Finally, the rate of mass loss
tends to be minimalin tyrosine containing polyarylates and occurs only at the end of
the degradation process [4]. The present data showsindirect evidence that mass loss
was occurring slowly and steadily during implantation and paclitaxel elution appears
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to mirror polymer erosion. As polymer erosion becomes extensive a more porous
structure of the polymer coating is created allowing for easier and more rapid diffu-
sion of a drug into the external environment. At 280 days there was visual evidence
of extensive degradation of the polymer coating and presence of a porousstructure
within the polymer body (from SEM data, Figure 2.13) and bythis time point 38% of
the paclitaxel had been eluted.
The importance of the therapeutic window for drug delivery following stent place-
ment was discussed in Chapter 1 and refers to the dosage and duration of paclitaxel
required to be effective in preventing restenosis whilst not causing toxic effects or
delaying arterial healing [12]. Studies by Serryuset a/ [13] and Kammathert al [14]
indicate a minimum period ofpaclitaxel delivery of approximately 30 days and dur-
ing this time span between 8.5ug (7.5% of total drug loading) and 23.6ug (11.9%
total drug loading) respectively of paclitaxel would be delivered from the SR and
MR Taxus™coronary stent. In the present study approximately 2.2ug and 4.0ug of
paclitaxel had beenreleased at 90 days and 250 days respectively. Only by 280 days,
when 7.912 had been released, had an equivalent amountofpaclitaxel been eluted as
compared to that of the Taxus™ SR stent at 30 days. Serryus et al [13] found that
drug loadings of 101g/stent released over 30 days to be efficacious in reducing ISR
and had low indices of injury to the vessel wall. Further studies would be required to
test whether the release of paclitaxel in the present formulation of TyRx P22-10
would be effective in preventing or reducing ISR but based on the observations of
Kammath [14] and Serryus et al [13] the present formulation of TyRx P22-10 does
not appear to have a suitable elution profile of paclitaxel.
Cellular exudate recovered from the PMMA chambers had a mean pH of 7.72
(SE=0.013). Adding paclitaxel to TyRx had nosignificant effect on pH and overall
there was no significant change in pH overtime(although at time points 14 days and
150 days pH wassignificantly higher than at other time points). Succinic acid is a
degradation product from TyRx P22-10, and the pH of the exudate remainedslightly
basic throughoutthetrial indicating that the buffering capacity of the exudate was
not exceeded by the accumulation of breakdown products within the PMMA cham-
ber.
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Degradation of tyrosine-derived polymers has been shown to produce less acidic
degradation products than poly (lactic-co-glycolic acid) and poly (lactic acid) and
this reduction in acid degradation products may explain the good tissue compatibility
of the tyrosine derived polymers [1]. A comparison of the degradation and tissue re-
sponse to extruded pins made from a tyrosine-derived polyarylates (poly(DTE-
adipate) a tyrosine derived polycarbonate and poly (lactic acid) in a subcutaneousrat
model by Hooperet al [4] showedthat the tyrosine-derived polyarylates elicited the
mildest inflammatory response andthat as degradation of the polymer proceededtis-
sue in-growth into the pins was evident. Given that the presence of polymer remain-
ing on the currently used implanted stents has been suggested as a cause for an ex-
tended and enhanced inflammatory response a polymer with better biocompatibility
mayproveanattractive alternative coating material for arterial stents.
2.5 Conclusions
Degradation of TyRx P22-10 was advanced by 9 months but mass loss was minimal
and dissolution was incomplete and the stent retained a largely intact coating of low
molecular weight polymer. Paclitaxel elution was slow and occurred over the 280
day study period with approximately 3ug of the drugstill retained in the polymer
coating of the stent at the end of the study period and maynotbereleased at a suit-
able dosage or duration to prevent ISR. There wasno significant shift in interstitial
fluid pH as a consequence of degradation and TyRx P22-10 is expected to have good
tissue compatibility as has been seen in other tyrosine containing polyarylates.
Someof the requirements of a coating for a DESis that it must provide goodstruc-
tural integrity throughout degradation, consistent and controlled drug delivery at the
desired concentration, be non-thrombogenic and generate as benign a response from
the host as possible or no more adverseeffects as that from a BMS[15]. The coating
of TyRx P22-10 exhibited good structural integrity but the presence of undissolved
polymer containing some paclitaxel over a time scale of 9 months reducesits suit-
ability as a polymer for DES. Further work on the polymer to enhance degradation,
massloss and drug elution would be required to address these issues.
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The Degradation and Paclitaxel Elution Profile of
Poly(p,-lactide-co-glycolide) (PLGA).
3.1 Introduction
Devices such as DES in which a drug is dissolved or dispersed within the polymer
coating are termed monolithic devices. Release of drugs from such devicesisvia dif-
fusion of the drug through the polymercoating, by erosion of the polymer or a com-
bination of both [1]. Lactic acid homopolymers and copolymers of lactic acid and
glycolic acid have been the subject of muchinterest in the medical and pharmaceuti-
cal field due to their biodegradability and toxicological safety; poly(p,1-lactide-co-
glycolide) (PLGA) has been approved for humanclinical use [2] .
PLGA polymersare aliphatic biodegradable, bulk eroding polymers that have been
used in a numberofapplications for sustained drug-release [1]. PLGA has excellent
biocompatibility and is considered safe [3] cited by [4] and [5-6] cited by [1]. In ad-
dition to being biodegradable they are biocompatible and bioabsorbable and their
degradation products are non-toxic, nonimunogenic and noncarcinogenic. They are
easily processed, have good mechanical properties and can besterilized [7]. PLGA
polymers are copolymers based on repeating units of glycolic acid (HO-CH)-
COOH)andlactic acid (HO-CH(CH3)-COOH)[8] and theratio of lactic acid (LA) to
glycolic acid (GA) in the copolymer largely dictates the degradation of the device
[2]. PLGA is named according to the percentage of lactic and glycolic units in the
copolymer;- e.g. PLGA 75:25 comprises 75% lactic and 25% glycolic units [9]. A
wide range of thermal, mechanical and biological properties can be obtained by vary-
ing the chemical and configurational structures in the polymer chains. PLGA de-
grades into the natural metabolites glycolic and lactic acid which can then bere-
movedbythe body via normal metabolic pathways[1, 8-11].
Biodegradation of PLGA occurs through 4 main steps [12]:
e Hydration; the aqueous media penetrates into the polymer matrix resulting in
relaxation of the polymer and a reduction in the glass transition temperature
(7)
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e Initial degradation; hydrolysis commences in the hydrated regions of the
polymer matrix cleaving the polymer backbonethereby reducing the polymer
molecular weight (MWt). Degradation continuesresulting in further decrease
in MWtbut without any appreciable loss in polymer mass.
e Further degradation; as the decrease in molecular weight continuesthere is an
associated rapid loss in polymer bulk and oligomeric fragments and forma-
tion of soluble monomers.
e Solubilisation; continued polymer chain cleavage results in the formation of
soluble monomers and molecules resulting in extensive polymer erosion and
massloss and ultimately complete solubilisation of the polymer.
Degradation of PLGA is via hydrolysis of the ester bonds during which polymer
chains are cleaved into oligomers and finally monomers[2, 13]. The rate of degrada-
tion is affected by a numberof factors including the polymer composition (ratio of
LA to GA moieties), molecular weight, hydrophilicity, crystallinity, specimen size
and the nature of the hydrolysing medium including pH,ionic strength and tempera-
ture of external medium,[12] & [14-16] cited by [11].
Degradable polymers are described as being either surface eroding or bulk eroding
polymers. Surface erosion occurs when the rate of polymer degradation is much
faster than water penetration into the polymer bulk [17] and hydrolysis is confined to
the outer surface and the interior matrix of the polymer remains essentially un-
changed [2]. PLGAis a bulk eroding polymer since the rate of water penetration into
the polymer matrix is faster than the rate of polymer degradation. Asa result, poly-
mer degradation is not confined to the surface of the polymer but occurs throughout
the whole of the polymer matrix [4, 17]. Degradation of the polymerchainsresults in
creation of carboxylic end groups within the matrix of the polymer which can further
increase ester hydrolysis via autocatalysis and increase the rate of degradation within
the bulk of the polymer as comparedwith the surface [11, 18].
Increasing the GA content of PLGA copolymersis associated with faster degradation
rates. Wu and Wang[12] studied PLGA with similar molecular weights but with dif-
ferent GA:LA ratios and found that the biodegradation rate constant increased with
64
Chapter 3
increasing GA content. The composition of the PLGA determines the hydrophilicity
and wettability of the polymer and increasing the GA content increases the hydro-
philicity and hence the hydration of the polymer [12]. The pendant methyl group on
the lactic acid moieties sterically hinders the attack of water molecules and increases
the hydrophobicity of the polymer [12]. Hydrolytic scission of the ester bonds occurs
morereadily on the linkage between GA and LA or GA [18] andthe inclusion of GA
units in the polymer introduces vulnerable points on the macromolecular chains [9]
since the GA units are hydrolysed much faster than lactic units due to their higher
hydrophilicity [2].
It is generally accepted that higher MWt PLGA polymers degrade slower than poly-
mers with smaller MWt’s [2]. But Wu and Wang [12] found the opposite - that
higher MWt polymers degrade faster than those of similar composition but with
lower MWt’s. They speculated that the increased length of the polymer chains in-
creased the chances of hydrolytic attack by water molecules. Crystallinity is affected
by MWtandthe effect of crystallinity on degradation is unclear with some reports
suggesting faster degradation as crystallinity increases while others report the oppo-
site [2]. Increasing the proportion of ,-LA units in the copolymerincreases the crys-
tallinity of the polymer andresults in lower degradation rate constants [19]. Li et al
[9] found that the preferential degradation of the GA units enriched the remaining
polymer fragments with respect to ,-LA units resulting in an increase in polymer
crystallinity. In general polymer degradation and drug elution are accelerated by
greater hydrophilicity and less crystallinity which can be achieved byincreasing the
GA content of the copolymer. Slower drug release and degradation are associated
with hydrophobic, crystalline PLLA polymers[2]
Polymer device size has been shownto affect the degradation rate of PLGA. Dunne
et al [13] and Kloseet al [20] showedthat larger microspheres have a faster degra-
dation rate than smaller ones while Grizzi et al [14] demonstrated that the degrada-
tion rate of various devices prepared from the same PDLLA polymer depended on
the size of the device with larger devices degrading at a faster rate than smaller ones.
This is thought to be due to differences in length of the diffusion pathways within
different sizes of polymer matrices which affects the diffusion rate of shorter chain
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degradation products out of the polymer and autocatalysis rates within the polymer
with the effect being more pronouncedin larger devices [17, 20].
Other factors affecting degradation of PLGA are the nature of the release medium
and the temperature of the conditions. PLGA degradation is affected by pH of the
release medium. Hydrolysis of the ester linkages is catalyzed by protons and induced
by bases [21] and both strongly acidic and strongly alkaline conditions accelerate
degradation [2]. The rate of degradation and drug elution from PLGA microspheres
also increases with increasing temperature [13, 21-22].
The temperature in which the device is degrading could be important in termsof the
polymersglass transition temperatures (7,) and hence, the drug delivery properties of
the polymer, although given the intended application of many devices in the human
body any temperature effects other than at temperatures of around 37°C are possibly
unimportant. Park and Jonnalagadda [23] showed that 7, appears to decrease with
increasing glycolic acid ratio and found 7, values of 55°C for PLGA 85:15 and
75:25 and 45-50°C for PLGA 65:35 and 50:50 which are greater than physiological
temperatures of 37°C. 7, decreases as degradation proceeds. As average molecular
weight decreases the degree of entanglement of the polymer chains is reduced and
the mobility of the polymer chains increases leading to a reduction in 7, [20]. Blasi
et al [24] showed that 7, decreased in hydrated PLGA devices to values below 37°C
indicating that such devices may bein the rubbery state once they become hydrated
whenimplanted in their target tissues or organs. Thetransition from the glassy state
to the rubbery state should lead to increased rates of drug elution since the drug
molecules can moreeasily diffuse through the polymerin the rubbery state
The release of drugs from such monolithic devices is via diffusion of the drug
through the polymercoating, by its erosion, or by a combination of both [1]. Drug
release profiles from PLGA devices is complex since the polymer phase properties
change continuously during degradation resulting in changes in drug diffusivity and
permeability [6] and polymerdruginteractions canalso becritical in controlling drug
elution profile [1-2].
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The nature of the drug will be important if it has an effect on polymeric properties
such as degradation and hydration rate. Li et a/ [25] found that adding caffeine (a
basic molecule) in low concentrations such that the molecule was dissolved and dis-
persed within the polymer matrix, accelerated PLLA degradation. Other basic mole-
cules such as diazepam have been found to increase degradation rate of PLGA [2].
Lidobase was found to accelerate early degradation rate of PLGA as comparedto
lidosalt resulting in a bi-modal elution profile for the base as compared with tri-
modal release pattern for lidosalt [26]. Hydrophilic drugs such as aspirin may in-
crease the hydration rate of PLGA devices butin a study by Siegel et a/ [27] this did
not affect the degradation rate of the PLGA device. In that study the drugs Corticos-
terone, Haloperidol, Hydrochlorothiozide and Ibuprofen slowed PLGA degradation
while Thiothixene accelerated degradation [27]. Haloperidol was found to change
PLGAdegradation from bulk eroding to surface eroding in this study. The chemical
properties of the drug and their effect on the polymer degradation are therefore of
critical importance in explaining drug-release mechanisms from PLGA polymers[2].
Drugrelease profile from PLGAdevicesis typically tri-modal consisting of an early
burst release phase in which drug molecules deposited close to the surface of the
polymerare rapidly released, followed by a slower release phase as drug molecules
further within the matrix diffuse through the device. Finally there is a period of more
rapid release as residual drug is eluted during the later stages of polymer degradation
and erosion [6]. The rate of elution of a drug from any polymer may depend onthe
physicochemical properties of both the polymer andor the drug [1]. Release of Gan-
ciclovir from a 75:25 PLGA polymerwastri-modal consisting of an initial burst as
surface deposited drug was released followed by a slow release stage as deeper de-
posited drug diffused through the polymer matrix and a final rapid release during the
later stages of degradation of the polymer [28]. Release of sirolimus from a PLGA
multilayer system consisted of 2 stages — a slowerinitial diffusion controlled stage
and then a faster stage associated with polymer mass loss. Elution of 5-Flouridine
from simple monolithic PLGA film implants also showed a biphasicrelease profile
but in this case it comprised an initial burst phase in which 24% of the drug was
eluted followed by slower secondaryrelease phase [1].
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In this study we sought to examine the potential use of PLGA as a polymer coating
for a paclitaxel DES by examining the degradation of the polymer andthe release
profile of the drug in an acellular in-vivo rat model as described in Chapter 2. We
tested the hypothesis that increasing the glycolic acid component in PLGA would
increase the hydrophilicity of the coating and introduce moresites susceptible to hy-
drolysis therefore increasing water ingress and hydrolysis resulting in different pacli-
taxel release profiles dependant on polymer degradation rate. Three blends of PLGA
were chosen, 50:50, 75:25 and 85:15. Additionally the effect of coating thickness on
degradation and elution properties was investigated using 50:50 PLGA. Effects of
PLGAdegradation on the pH of the surrounding media was determinedusing cellu-
lar exudate collected in the PMMA chambers.
3.2 Materials and methods
Chloroform: SpS SuperPurity solvent, 99.9% stabilised (Romil Pure Chemistry).
Paclitaxel from Taxus yannanensis (Sigma-Aldrich)
50:50, 75:25, & 85:15 poly(p,.-lactide-co-glycolide) (Sigma-Aldrich)
PLGAcoated Liberté™ WH 16mm stents obtained from Boston Scientific.
Implantation chambers: prepared from medical grade 20mm lengths of 10mm diame-
ter medical grade polymethyl methacrylate (PMMA) (Goodfellows UK).
Chamberseals: 45um cellulose nitrate millipore filters.
3.2.1 Preparation of stents and implant devices
For the comparison of polymerthickness and release of paclitaxel in the 50:50 blend
400g of the PLGA with or without 5% paclitaxel (Sigma-Aldrich) and for one set
200ug 50:50 PLGA with 5% paclitaxel was coated onto a Liberté 16mmWH coro-
nary stent. For the 75:25 and 85:15 blends 400ug of the PLGA with 5% paclitaxel
was coated onto a Liberté™ 16mmWHcoronary stent. The stents were placed into
PMMAchambers which weresealed using a 0.45um millipore filter as described in
Chapter 2 page 41, Figure 2.2. Two test chambers each containing one stent were
implanted subcutaneously into the backs of male Wistarrats, either side of the spine.
The number of animals used for each time point is shown in the Appendix, Table
A.l.
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At the appropriate time points the implants were removed for analysis. The stents
were washed by quickly dipping the stent twice into ELGA Purelab UHQ water. Ex-
cess moisture was quickly blotted off the stent and the sample was placed into a
clean polystyrene vial, and dried under vacuum at room temperature. The samples
were weighed every 24 hours until a stable weight was achieved and the samples
were dry. The sample vials were then tightly capped and stored at 4°C in polythene
sealed bags containing Silica desiccant.
3.2.2 Gel permeation chromatography:
For GPC analysis at early sampling times 2 stents were added to 1ml of chloroform
in a capped glass vial and shaken gently for 3 hours to extract the polymer. Forlater
time points more stents were combined and added to 1 ml of chloroform to ensure
there was sufficient sample to get a detectable signal. GPC was performed using four
7.8x300mm, Sum Waters Styragel columns (1. HRO.5 MWt range 0 to 1000, 2. HR2
MWtrange 500 to 20,000, 3. HR3 MWtrange 500 to 30,000 and 4. HR4 MWt range
5,000 to 500,000) with a flow rate of 1ml per minute with chloroform as a the mobile
phase and using a Polymer Labs ELS 1000 evaporative light scatter detector (ELS)
and Polymer Labs LC1200 UV/VISultra violet (UV) detector. Easi-Cal PS-2 (Poly-
mer Labs) polystyrene standards, with a molecular weight range of 580 — 377,400
were dissolved in chloroform to give a 0.1% solution. Raw polymer was prepared by
weighing an amount of polymerand adding chloroform to give a final concentration
of lmg/ml and gently mixing at 120rpm at room temperature for 3 hrs. The injection
volume was 2501 with a polymer concentration of approximately 800pg/ml solvent
for the stent samples and 1001 for the raw polymer and Easi-Cal standards) with
three measurements per sample. Quantitative analysis and calculation of weight av-
erage molecular weight (My) was performed using Cirrius Software (Polymer Labs).
Paclitaxel concentration was measured using the area under the peak using data from
the UV detector and comparing with standards prepared by dissolving paclitaxel in
chloroform and diluted to give concentrations of 2, 5, 10, 20, & S5Oug/ml. 250ul of
each standard was injected and measured three times. Quality control (QC) checks
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containing 0.8mg/ml 50:50 PLGAandeither 10 or 20ug/mlpaclitaxel were also pre-
pared and analysed via GPC.
3.2.3. SEM andlight microscopy 
The explanted stents were examined bylight microscopy by two methods;stereo dis-
section light microscope and upright reflected light microscopy using differential in-
terference contrast microscopy and standard reflectance. SEM was performed using a
Leo/Zeiss 1550 Field Emission Scanning Electron Microscope. Onestent from each
group was mounted onto an aluminiumstub using double sided adhesive carbon tape
and sputter coated with chromium using an EMITECH K575X coater.
3.2.4 pH measurements.
Cellular exudate recovered from the chambers was measured using a pH meter (Met-
tler Toledo) and the visual appearance of the exudate noted.
3.3 Results
3.3.1 GPC data
The chromatograms obtained from GPC revealed a monomodalplot for PLGA and a
single sharp peak for the paclitaxel.
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Figure 3.1 Paclitaxel Calibration (data from UV detector).
The graph showsthe combined data from all of the GPC runs throughout the trial. Standard
deviation is shownaserror bars
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Paclitaxel concentration on the 75:25 and 85:15 PLGA coated stents was measured
using data from GPC from the UV detector. Combined calibration data from all the
GPCruns performedduringthetrial is shown in Figure 3.1.
Control stents (not implanted) had paclitaxel concentrations of 19.85ug (stdev=1.61)
and 20.97 (stdev=2.6) per stent respectively for the 75:25 and 85:15 polymer coat-
ings (expected value was 20ug/stent). QC checks for 10ug/ml and 20ug/ml pacli-
taxel was 10.81 g/ml (stdev=0.89) and 20.71 ug/ml (stdev=0.66) respectively.
Paclitaxel concentration on the 50:50 PLGAstents was derived using data from the
ELSdetector. A typical calibration curve is shown in Figure 3.2. Control (not im-
planted stents) had values of 17.68ug/stent (stdev=2.9) and 8.65,1g/stent (stdev=1.11)
respectively for the 400ug coating (expected value = 20ug) and 200ug coating (ex-
pected value = 10g).
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Figure 3.2 Paclitaxel Calibration Data.
Data from the ELS detector and used in paclitaxel determination for the 50:50 PLGAcoated
stents. Function: y= -205.9910+197.5421exp(0.0130*x)
3.3.1.1 Degradation and paclitaxel elution of 50:50 PLGA: Effect of paclitaxel and
coating thickness.
The degradation of 50:50 PLGA andthe elution profile of paclitaxel is shown in Fig-
ure 3.3. At the start of the trial the molecular weight of the polymer was 55,958,
56,098 and 58,236 for the stents with 400g coating with and without paclitaxel and
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the 200ug coating with paclitaxel respectively. During the trial period the degrada-
tion of the polymerin the 400ug coating per stent group wasfaster than in the 200ug
coating per stent but with a slower elution rate of paclitaxel. Over the first 15 days
the polymer degraded rapidly and the molecular weight of the polymer remaining on
the stents had decreased to approximately 16,000, 18-19,000 and 23,000 in the
400ug coating with no drug and with paclitaxel and the 200ug coating with pacli-
taxel respectively.
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Figure 3.3 Degradation and Elution of Paclitaxel of 50:50 PLGA.(a) Weight average
molecular weight (M,,) of polymer and paclitaxel remaining on the stent expressed asa per-
centage ofthe original during the implantation study. (b) Actual M,, and amount(11g) of pa-
clitaxel remaining on the stent during the implantation study.
Error bars= standard deviation (pctxl = paclitaxel)
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Paclitaxel was eluted faster from the 200ug coated stents with 64.4% of the pacli-
taxel remaining on the stent at 15 days while some 93.2% of the paclitaxel remained
in the 400ug coated stents. After 15 days the degradation rate decreased and by 30
days the molecular weight was 23%, 22% and 31% of the original in the 400yg
coated stents with and without paclitaxel and the 200ug coated stents with paclitaxel
respectively. At 30 days no paclitaxel could be detected in the 200ug coating group
but on some samples in the 400ug coating group 2.39ug of paclitaxel (13.5% of
original) wasstill present on the stent. At 45 days implantation time neither polymer
nor paclitaxel could be detected using GPC for any of the coating formulations.
ANOVAon the molecular weight data for coating and implant time showedthat
there was no significant difference in degradation rate between the 400ug coating
with and without paclitaxel, but over the time period from 15 to 30 days the molecu-
lar weight of the remaining polymerin the 200ug coating with paclitaxel wassignifi-
cantly higher than that in the 400ug coatings. This data suggests that the difference
in degradation rate was not due to the presence of paclitaxel but is associated with
initial coating volume.
3.3.1.2 Comparison of degradation and paclitaxel elution in 400ug stent coatings of
50:50, 75:25 & 85:15 PLGA.
At the start of the trial the M, of the 50:50, 75:25 and 85:15 polymers was 56,098,
49,363 and 43,696 respectively (figure 3.4). The 50:50 polymer degraded fastest and
by 30 days the molecular weight had reduced by 70% to around 12,000 to 13,000.
The molecular weight of the 75:15 and 85:15 coatings had reduced by approximately
70% by 60 and 90 days respectively to a molecular weight of around 12-13,000. In
both the 75:25 and 85:15 coatings the polymer molecular weight stabilized after fal-
ling to around 13,000. After 105 days implantation 75:25 polymer could not be de-
tected by GPC while 85:15 polymer remained detectable with a molecular weight of
approximately 13000 onthe stent until the end of the study period at 120 days.
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Figure 3.4 Degradation of 50:50, 75:25 & 85:15 PLGA
The graph showsthe molecular weight (My) of the polymer remaining on the stent as im-
plantation time increases. Error bars= standard deviation.
Elution of paclitaxel was fastest in the 50:50 PLGAandslowest in the 85:15 PLGA
(Figure 3.5). Paclitaxel was released from the 50:50 and 75:15 PLGAstent coatings
in a two phase manner:an initial period of slow release followed by a rapid loss of
paclitaxel. At 15 days 93% of the paclitaxel remained on the 50:50 PLGA coated
stent despite the degradation of the polymer to a molecular weight of 18,751. But by
30 days only 22% ofthe paclitaxel remained and the molecular weight of the poly-
merhad further degraded to 12,483. At 30 days the 75:15 PLGA molecular weight of
the polymer had degraded to approximately 22,000 and 84% of the paclitaxel re-
mainedonthestent.
Morerapid release of paclitaxel occurred from the 75:15 polymerafter 45 days as the
molecular weight degraded to below 16,000 and paclitaxel could not be detected us-
ing GPC at 75 days despite polymer with a molecular weight of around 13,000 re-
maining on the stent. At 60 days the My of the 85:15 polymer was approximately
18,000 but there was very little measurable elution of paclitaxel during this period.
At 90 days the polymer M,, had degraded to approximately 13,000 and around 50%
(10ug) and 75% of the paclitaxel had been eluted by 90 and 105 days respectively.
At 120 days 95% of the paclitaxel had been eluted with no further significant degra-
dation of the polymer M,,. At 120 days data for paclitaxel was measurable in only 2
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of the 3 samples (the paclitaxel in the third sample could not be read due to peaks
from the cellular exudate or other sources overlapping the paclitaxel peak).
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Figure 3.5 Elution of paclitaxel from 50:50, 75:25 & 85:15 PLGAstent coatings
The graph shows the amount of paclitaxel (in ug) remaining on the stent as implantation
time increases. Error bars= standard deviation
3.3.2 SEM andlight microscopy.
SEM and LM analysis are demonstrated in figures 3.6 to 3.12.
In the early stages of degradation the polymer was an intact coating (figure 3.6.a,
3.7.a & 3.7.e). With time polymer degradation and erosion occurred and the coating
became compromised eventually revealing gaps in the coating, exposing the bare
metal of the stent (Figure 3.6.b-d) & 3.7.b,d,f). The changes observed in the stent
coating as degradation proceeded were similar in all three PLGA polymers but the
changes occurred overdifferent time scales (Figure 3.7).
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Figure 3.6 SEM and LM images showing deterioration of the polymerstent coating.
a) SEM micrograph 15 day implant time 50:50 PLGA ,b) SEM micrograph 30 day implant
50:50 PLGA, c) SEM micrograph 85:15 PLGA 120 day implant, d) LM image 85:15 PLGA
120 day implant
In the early stages of degradation the polymer was an intact coating (figure 3.6.a,
3.7.a & 3.7.e). With time polymer degradation and erosion occurred and the coating
became compromised eventually revealing gaps in the coating, exposing the bare
metal of the stent (Figure 3.6.b-d) & 3.7.b,d,f). The changes observed in the stent
coating as degradation proceeded were similar in all three PLGA polymers but the
changes occurred overdifferent time scales (Figure 3.7).
As with the molecular weight data the visual appearance of the stents indicated a
trend of a faster rate of degradation and mass loss from the 50:50 PLGA coating as
compared with 75:25 PLGA while 85:15 PLGA coating degraded the slowest of the
polymersontrial. (Figure 3.7 & 3.8).
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Figure 3.7 LM images showing changes in PLGA polymercoating integrity at differ-
ent implantation times.
50:50 PLGA coated stent a) 15 day, b) 30 day
75:25 PLGAcoatedstent c) 45 day, d) 90 day
85:15 PLGAcoatedstent e) 90 day, f) 120 day
At 15 days implantation the polymer coating appeared to be intact on the 50:50
PLGA(Figure 3.7.a) despite the degradation of the polymer chains but surface pit-
ting was evident at 15 days and at 30 days extensive loss of polymer bulk had oc-
curred creating cavities and vacuoles in the polymer bulk (Figure 3.8.a&b) and gaps
becameevidentin the coating exposing the metal struts ofthe stent (Figure 3.7.b).
77
Chapter 3
 
‘alfCIS cageeZ ‘eT eeeyJ # 7 F
Sr ae 5 eoamet’. OE©| ae
J es om 3
  ae    3.
C
e W
aA
oy
%*+
¢
*
r
e
 
Figure 3.8 SEM imagesofthe surface of different PLGA polymers showing differ-
ent time scales and degradation. Magnification= 20k. a) 15 day 50:50 PLGA,b)30 day
50:50 PLGA, c) 75:25 PLGA 30 day, d) 60 day 75:25 PLGA,e) 60 day 85:15 PLGA,f) 105
day 85:15 PLGA.
 
At 45 daysthe bulk ofthe polymercoatingis still intact in the 75:25 coated stents but
by 90 days extensive areas of the bare metal of the stent were visible (Figure
3.7.c&d). Deterioration of the 85:15 coating was over a longer time period and at 90
days the polymer coating wasstill intact but by 120 days polymer erosion was ad-
vanced and large areas of bare metal of the stent were exposed (Figure 3.7.e&f). As
compared with 50:50PLGA,surface pitting appeared later for the 75:25 and 85:15
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PLGAat 30 and 60 days respectively while extensive loss of polymer bulk with the
appearance of larger cavities and vacuoles in the polymer bulk was seen at 60 days
and 105 days in the 75:25 and 85:15 PLGArespectively (Figure 3.8.c-f).
PLGAis a bulk eroding polymer and as such degradation proceeds faster within the
body of the polymer than at the surface. Bulk degradation at 15 days was evident in
the 50:50 PLGA stent coating where a fissure in the apparently intact polymer coat
revealed a highly vacuolated area where polymer degradation and massloss had oc-
curred beneath the surface of the polymer (Figure 3.9).
 
 
Figure 3.9. SEM images of 50:50PLGAafter 15 days implantation. a) low magnifica-
tion image of a stent showing intact coating. b) high magnification image of an area of (a)
where the surface was scratched, showing bulk degradation within the bulk of the polymer.
 
Evidence of ‘blistering’ was seen on part of the surface of the 75:25 and 85:15 PLGA
coating after 30 days (Figure 3.10.a). Rupture of the blisters at 30 days and 60 days
on the 75:25 and 85:15 coating respectively revealed cavities below the polymersur-
face indicating bulk erosion and polymer massloss (Figure 3.10.a&b). Similarly,
blistering of the stent coating was seen in the 85:15 PLGA polymerat 45 days and
becoming more extensive at 60 and 90 days implantation time (Figure 3.10.c&d).
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 a&b 75:25 PLGA coating after 30 days implantation. c&d 85:15 PLGA coating after 60 and
90 day implantation respectively.
Progressive polymer degradation and erosion leading to mass loss in 85:15 PLGA
coated stents can be seen in figure 3.11. At 45 days the polymercoating is intact but
with areas of blistering and at 90 days the blistering is extensive but the coating re-
mainsintact (Figure 3.11.a&b). By 105 days polymererosion had occurred and gaps
in the polymer coat and rupture of the blisters was evident (Figure 3.11.c). By 120
days extensive polymermassloss had occurred and the polymer coating appeared as
a highly degraded covering with a meshlike appearance revealing extensive areas of
the bare metal ofthe stent (Figure 3.11 c&d).
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Figure 3.11. SEM Images of 85:15 PLGA coated stents
a) after 60 days implantation, b) after 90 days implantation, c) after 105 days implantation
and d) after 120 days implantation.
After 45 days and 105 days for the 50:50 and 75:25 respectively, polymer could not
be detected using GPC. Light microscopy gave the impression of a metallic stent
with no polymerattached but at high magnification SEM showedresidue of polymer
still adhering to the stent (Figure 3.12.a-d). At 120 days 85:15 polymercouldstill be
detected using GPC. But SEM and LM indicated that the polymer was extensively
degraded, with evidence of advanced polymer erosion and. mass loss (Figure
3.12.c&d).
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 rsFie
Figure 3.12 SEM and LM images: Later stages of degradation of the polymer coat-
ing. a) LM, b)SEM,50:50 PLGAcoating after 45 day implantation, c) LM, d) SEM, 75:25
PLGAcoating after 105 days implantation, d) LM e) SEM, 85:15 PLGA coating after 120
days implantation.
3.3.3 Chamber exudate pH.
3.3.3.1 50:50 PLGA 200ug and 400ug coatings.
Figure 3.13 shows small changes in pH between the groups and over implantation
time. Statistical analysis by ANOVA showedthat at 15 and 30 days there was no
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significant difference in pH between the groups, but the pH of the exudates wassig-
nificantly higher in all groups at 15 days than at 30 days (p<0.001 for the 400ug
coating with and without paclitaxel, p=0.002 for the 200ug + paclitaxel coating).
ANOVAdemonstrated that implant time significantly affected pH (p<0.001).
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Figure 3.13 pH of exudate from chamber containing 50:50 PLGAcoatedstents.
A= 400ng coating, B= 400g coating + 5%w/w paclitaxel, C= 200g coating + 5% pacli-
taxel.nb After 45 days there was no polymerdetected on the stents
At 15 days the pH acrossall groups was 8.16, but over thetrial the pH gradually de-
creased to 7.69 by 90 days, although the data from the 75 day time points did notfit
in with this trend. There wasa slight decrease in the pH of the chamber exudates af-
ter 45 days but given that there was no detectable polymer on the stents after this
time point the pH change is unlikely to be associated with polymer degradation
products. Whether the change is associated with the presence of the exposed metal
surface of the stent is unclear since there wasa slight, but significant (p=0.018) in-
crease in the pH of exudates from chambers containing BMSfrom 7.46 at 45 days to
7.75 at 90 days.
3.3.3.2 400ug stent coating with 5% paclitaxel.
Anincrease in pH over time was observed in exudates from chamber containing
BMS(Figure 3.14) and analysis by ANOVA showed that at the pH at 45 days was
significantly lower than at 90 and 120 days (p<0.05).
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Figure 3.14 pH of chamber exudate from stents coated with 400ug polymer with 5%
paclitaxel.
Dataset for 50:50 PLGAis taken from 400pg coating with 5% Paclitaxel.
The pH of the chamber exudates from 50:50 PLGAcoatedstents at 15 days wassig-
nificantly higher than all the other sampling points and groups. There was no obvious
trend in change of exudate pH from chambers containing 75:25 PLGAcoated stents
but the pH wassignificantly lower at 90 days (p<0.001) than the earlier time points.
Likewise there was no obvious trend in exudate pH from chambers containing 85:15
PLGAcoatedstents but analysis by ANOVA showedthat at 7, 30, 90 and 105 days
the exudate pH wassignificantly lower than the other time points. Overall there was
no difference in exudate pH and implant time between the 75:25 and 85:15 coated
stents.
3.3.4 Massloss data
Massloss wasto be determined by comparing the weight of polymeronthe stent af-
ter implantation with the original weight of polymeron the stent. Following recovery
of the stents from explanted chambers cellular exudate was found to adhere to the
stent. This exudate was not completely removed by the washing protocol therefore
making the weight measurement of the explanted stent unreliable. Data shown in
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Figure 3.15 is from anothertrial using the same protocol for 400g polymer coating
using an in vitro model.
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Figure 3.15 /n vitro polymer mass loss from PLGA coatedstents.
Graph showsthe massofpolymer remaining onthe stent after implantation.
Figure 3.15 shows that mass loss was fastest in the 50:50 PLGA and overall, was
slowest in the 85:15 PLGA. In all three polymers massloss wasinitially slow with a
lag phase lasting approximately 15 days in the 50:50 PLGA and 30-60 days in the
75:25 and 85:15 PLGA.After 15 days implantation mass loss was morerapid in the
50:50 PLGA declining to around 30% of the original mass remaining by 60 days. In
this model polymer could still be measured at 90 and 120 days by which time ap-
proximately 10% of the mass remained. In the 75:25 PLGA coated stent group the
lag phase lasted 60 days by which time 85-90% of the mass remained after which the
rate of mass loss increased and at 120 days approximately 30% of the polymer mass
remained. 75:25 PLGA wasstill detectable on the stent at 180 days. Mass loss from
85:15 PLGAcoated stents mirrored that from the 75:25 coated stents to 60 days. Af-
ter 60 days mass loss declines steadily and faster in the 75:25 PLGA coatings as
compared with 85:15 PLGA coating. As such the 60 days time point for 75:25 PLGA
days showing slower massloss than the 85:15 PLGAcoatings is counterintuitive and
may beerroneous. After 90 days mass loss from the 85:15 PLGA coated stents was
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slower than the 75:25 PLGA coatings and approximately 45 and 25% of the mass
remainedat 120 and 180 days respectively.
3.4 Discussion.
The effect of glycolic acid content of PLGAandthe thickness of coating applied to a
coronary stent on the degradation of the polymer and the release of paclitaxel has
been demonstrated. The suitability of any of the PLGA polymers tested as coronary
stent coatings will depend on the degradation profile and residency timeofthe poly-
mer, the drug delivery properties and that the erosion of the polymer coating is via
steady removal of solubilised oligomers with the less degraded polymer remaining
adhered to the stent with no peeling orloss of larger fragments of the coatings.
Using a 400ug coating of 50:50 PLGA there wasno difference in the degradation of
the polymer with or without 5% paclitaxel. Since the degradation of PLGAisvia hy-
drolysis, degradation rate is governed both by the ingress of water into the device and
the rate of hydrolysis. The presence of a drug within a PLGA matrix has been dem-
onstrated to affect the degradation rate possibly by altering the rate of water diffusion
into the polymer bulk. Paclitaxel is a hydrophobic drug but inclusion of 5% w/w of
the drug into 50:50 PLGA had noeffect on degradation of a 400ug stent coating.
Hydrophilic drugs such as aspirin have been found to increase the ingress of water
into a device and thus increase the polymer degradation rate whereas more hydro-
phobic drugs decreased water uptake and consequently reduced the degradation rate
[27].
The degradation rate in a 200ug 50:50 PLGA + 5% paclitaxel coated stent was
slowerthan in the 400ug 50:50 PLGA + 5% paclitaxel stent coating while the elution
of the paclitaxel was faster. This effect has been observed in other studies on PLGA
showing that increasing the size of a device increases the degradation rate of the
polymer[2, 13-14, 20].
Differences in the degradation rate may beattributable to a couple of factors. The
release rates of the short chain degradation products is slower in larger devices and
their contribution to the average molecular weight of the polymerwill be greater for
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larger devices as compared with smaller ones. Consequently the average molecular
weight of the thicker (400g) coating will decrease faster than in the thinner (200g)
coating from which short chain degradation products will be more rapidly released
[20]. Secondly rates of autocatalysis within the PLGA coating could be greater in the
400ug coating as compared to the 200ug coating. Short chain alcohols and acids
produced from ester bond hydrolysis within the polymer can diffuse out of the matrix
of the polymer into the release medium where they are neutralized. Additionally
bases, such as hydroxide ions, from the fluids of the release medium can diffuse into
the device neutralizing the generated acids. The rate of diffusion of these two proc-
esses will be slowerin the thicker (400ug) coating as compared with the 200g coat-
ing. Ester bond hydrolysis is catalyzed by protons and if the diffusion of bases into
the device is not sufficient to neutralise the acids formed during PLGA degradation
there will be a decrease in the micro pH within the polymerleading to increased rates
of autocatalysis, the effect being more pronounced in larger devices [17, 20]. In the
thicker coating there would be a larger diffusion pathway for soluble oligomers and
an increased tendency for the oligomers to be trapped in the polymer matrix, thereby
increasing the number of carboxylic acid groups in the coating giving an increased
rate of autocatalysis as comparedto the thinner coating. Additionally the shorter dif-
fusion pathwayofthe thinner 200g coating will enable faster diffusion of hydroxide
ions and other bases from the external medium as compared to the 400ug coating.
The neutralising effect would be expected to be greater in the 200g PLGA coating
contributing further to lower rates of autocatalysis as compared with the thicker coat-
ing [17, 20]. The elution of a drug is affected by a numberoffactors including poly-
mer chain length with smaller chains offering less restriction for drug diffusion and
the length of the diffusion pathway, with smaller diffusion pathways expected to en-
able faster drug diffusion out of the device [17, 20]. In our study faster rates of
polymer degradation was seen in the 400ug coating as compared with the 200pg
coating but paclitaxel was released faster from the thinner (200ug) coating. Faster
elution of paclitaxel from the 200pg coating as compared to the 400ug coating pos-
sibly indicates the relative importance of diffusion distance and polymerchain length
in the elution of paclitaxel from PLGA polymer matrices.
Comparison of the 50:50, 75:25 and 85:15 PLGA 400ug coatings revealed that mor-
phological changes and degradation of the polymer were similar but occurred in a
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time dependant mannerrelated to the glycolic acid content of the copolymers and in
this study 50:50 PLGAstent coating degraded the fastest and had the fastest mass
loss and 85:15 PLGA coating the slowest with the slowest mass loss. Glycolic acid
units constitute vulnerable points in the polymer chains and degradation occurs pref-
erentially on the glycolic acid bonds [9] and increasing glycolic acid content of the
polymerincreases the degradation rate. Additionally increasing the glycolic acid con-
tent of the polymer increases hydrophilicity of the polymer coating and the conse-
quent higher water uptake increases the rate of hydrolysis [29-30].
The relationship between molecular weightloss, paclitaxel elution and polymer mass
loss are shown in Figure 3.16. Initially, degradation of the stent coating was via hy-
drolysis resulting in a reduction in the M, of the PLGA to around 12,000 to 13,000
after approximately 30, 60 and 90 days for the 50:50, 75:25 and 85:15 PLGArespec-
tively. Whereas the M,, of the coatings decreased steadily after implantation of the
device there was an early phase in which the release of paclitaxel and mass loss was
minimal. This was followed by a phase in which M, reduction was slowerbut poly-
mererosion and paclitaxel elution wasfaster.
After 15 days implantation 95% of the polymer mass remained on the stent and only
approximately 7% of the paclitaxel had been eluted in the 50:50 PLGA coatedstents.
After 30 days implantation the polymer had degraded to a molecular weight of
around 12-13000 and some 30% of the polymer mass had been eroded in the 50:50
PLGAcoated stents and SEM revealed a highly porousstructure of the polymercoat-
ing (Figure 3.8). This period of rapid mass loss wasassociated with rapid elution of
paclitaxel and after 30 days 85% ofthe paclitaxel had been eluted.
A similar pattern was seen for the 75:25 and 85:15 PLGA coated stents but over
longer time periods. After 30 days implantation only 5% of the polymer mass had
been eroded in the 75:25 PLGAcoated stents despite the reduction in polymer M,, to
around 22,000 and surface pitting was observed using SEM (Figure 3.8). At this
point about 15% of the paclitaxel had been eluted. After 30 days a period of more
rapid massloss wasassociated with a faster rate of paclitaxel elution, and by 60 days
average M, was approximately 14,000, approximately 70% of the polymer massre-
mained on the stent and some 71% of the paclitaxel had been eluted in the 75:25
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PLGA coated stents. At 60 days SEM revealed a surface with large pores and a
highly vacuolated structure within the body ofthe coating (Figure 3.8).
Rate of mass loss increased in the 85:15 PLGAcoatings after 30 days at which point
the M, of the polymer was approximately 30,000 and paclitaxel elution was negligi-
ble. At 60 and 90 days SEM revealed a polymersurface that was largely intact with
only minimum pitting (Figure 3.8 and 3.11). After 60 days implantation mass loss
and paclitaxel elution was rapid by which point the MM, had degraded to 14,500. After
105 days 80% of the paclitaxel had been eluted and only 50% of the polymer mass
remained on the stent and SEM revealed a highly vacuolated and porousstructure of
the stent coating (Figure 3.8). The Average M, of the 85:15 PLGA polymer re-
mained at about 13,000 after 60 days.
At 45 days and 105 days polymer could not be detected on the 50:50 and 75:25
PLGAcoated stents respectively using GPC. Polymerfrom the 85:15 PLGA coating
wasstill detectable up to 120 days using GPC and wasvisible as a thin covering over
the stent with areas of the bare metalvisible.
Other studies [28, 31] have demonstrated a similar 2 phase pattern of degradation of
PLGA matrices consisting of an initial phase of reduction in molecular weight fol-
lowed by an erosion phaseresulting in mass loss. Mass loss of PLGAis believed to
occur when the molecular weight of the polymer fragments have decreasedto a criti-
cal value such that they can dissolve in aqueous media and that the polymer bulk is
sufficiently porous to allow the fragments to escape to the surrounding media [18,
29]. A ‘critical molecular weight’ of 10,000 was seen during the degradation of
50:50 and 75:25 PLGA microspheres after which mass loss of the PLGA occurred
[29].
89
Chapter 3
 
 
 
 
 
     
100 50:50 PLGAcoated stents
= 802 —¢ -% massloss
5 60 ——% Mwapq ‘ -#-0 :2 0 NN % Paclitaxel
5 \.2 ‘\,x 20 “.,7ey _
0 T T T T — = >
60 90 120 150 180
implant time (days)
100 75:25 PLGAstent coating
= 802 —¢ -% massloss
6 60 —e% Mwap .= - @-% Paclitaxel
Ss 40 :5 Sex 20 om, iy
0 T T 1
30 60 90 120 150 180
implant time (days)
85:15 PLGAstent coating
100 -<$ fs a a
+ , ig *,
3 80 —* -% massloss
n
5 60 - —o% Mw
2 - @-% PaclitaxelS‘a 40 Fe aisx 20 4 ~
0 "I T T T ——} T
30 60 90 120 150 180
implant time (days)  
Figure 3.16. Relationship between weight average molecular weight (M,), mass loss
and paclitaxel elution in degrading PLGA stent coatings. The graphs show the molecu-
lar weight, mass and paclitaxel remaining on the stent expressed as a percentage of the origi-
nal amount. Data for molecular weight and paclitaxel is taken from the in-vivo study. Mass
loss data is from an in vitro study (unpublished data provided by Boston Scientific)
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Data from this study and others (e.g. [8, 13, 18, 32-33]) indicate a mechanism
whereby products from PLGA degradation are unable to diffuse out of the polymer
matrix and that paclitaxel only initially diffuses out of the matrix very slowly. During
the second phase of degradation, the My changeis less rapid and becomesstable, but
the structure of the coating becomeshighly vacuolated and surface pitting appears on
the stent coating. SEM micrographs reveal a highly vacuolated structure within the
body of the coating and the existence of surface pitting at implantation periods asso-
ciated with polymererosion and paclitaxel elution. It is during this phase that pacli-
taxel elution is most rapid.
A possible explanation for this is given by Gépferich [33] and Park [18]. When the
polymer chains degrade within the bulk of the coating they cannot erodeif they have
no connection to the external medium via a system of pores. Since PLGA is a bulk
eroding polymer, degradation is occurs at a faster rate within the coating than at its
surface. The surface layer acts as a semi-permeable diffusion barrier for the en-
trapped oligomers but allows diffusion of low molecular weight molecules such as
water. A system of cavities within the polymer bulk is created as the polymer de-
grades and osmotic pressure builds up within the polymer bulk. As the surface layer
gradually degrades and becomesthinnerit will break at some point whena critical
osmotic pressure builds up within the device due to the accumulation of degradation
products [32]. Only after a critical degree of degradation is reached and a network of
pores and cavities are created within the device can the release of degraded polymer
(resulting in mass loss) and the erosion phase of drug release commence[32].
Elution rate of paclitaxel was dependant on the degradation and massloss of the
PLGAstent coating. Release of the paclitaxel consisted of an initial lag phase in
which only small amounts of the drug was released followed by a more rapid phase
during which the remainder of the drug was released. The elution of the drug was
similar in all three PLGA polymers but occurred over different time scales with the
shortest lag phase occurring in the 50:50 PLGA coating and the longest in the 85:15
PLGAcoating. The length of the lag phase wasrelatedto the initial phase of polymer
degradation via hydrolysis and during this period elution of paclitaxel would be via
diffusion through the polymer matrix. As the PLGA entered the second phase of deg-
radation in which mass loss was occurring, the formation of cavities and largerair
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spaces created a more porousstructure facilitating a more rapid release ofpaclitaxel.
Wanget al [31] observed a similar pattern for release of sirolimus from PLGA films.
Interestingly in our study and that of Wangef a/ [31] there was noinitial burst of
drug release as has been seen in otherstudies(e.g. [1, 28, 34]) but the reason for this
is unclear.
The effect of polymer degradation and erosion on the integrity of the stent coating
could be seen using SEM and Light microscopy images. Good adherenceofthe stent
coating was observed throughout the study in all PLGA blends used. The polymer
coating initially appeared intact but as time progressed areas of degradation could be
seen and eventually areas of bare metal could be observed resulting in an appearance
of a light meshwork of polymer coating with extensive patches of bare metalvisible.
Therate of deterioration was related to the rate of polymer degradation. During the
study period the coatings remained attached to the stents, with no obvious areas of
peeling or flaking occurring in any of the PLGA blendsbut at later sampling points
the coating often appeared to have areas where the coat wasonly loosely attached to
the metal stent.
Degradation of PLGAcanincreasethe acidity of the release medium. Wu and Wang
[12] found that when PLGA wasincubatedin distilled water, the pH ofthe distilled
water decreased to a pH2, while Li et a/ [8] found that the pH ofan saline incubating
medium dropped after 5 weeks eventually falling to pH2.6 at 10 weeks. Liet al [9]
found that the pH of an incubating medium of PBS (pH7.4) remained stable for 7
weeksafter which a slight drop in pH to 6.4 was observed. Although there were
small differences in pH in the cellular exudate in the PMMA chambers between
groups (some of which werestatistically significant) it was difficult to discern any
real pattern to the changes or to demonstrate any significance to the observations.
There was a small but significant change in pH from 8.16 to 7.69 by 90 daysin the
exudate from 50:50 PLGA chambers and the pH of exudate from 75:25 PLGA
chambers wassignificantly lower at 90 days than at earlier time points whereas there
wasnosignificant change in pH exudate from 85:15 PLGA chambersovertime. To
further complicate matters, the exudate from the chambers containing BMS was
more acidic than those containing PLGA coated stents. It may be expected that the
production oflactic and glycolic acid during degradation of PLGA would affect the
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exudate pH if the production of acidic groups exceeded the buffering capacity of the
cellular exudate and perhaps the changes seen reflect differing degradation rates.
This was not the case in this study and the pH remained within the normal physio-
logical rangefor interstitial fluid.
Delivery of the paclitaxel from the coating must be at a sufficient concentration and
duration to be effective in preventing restenosis but preferably not cause toxic effects
or delay arterial healing. A minimum period of 30 dayselution of paclitaxel from the
implanted stent has been suggested and during that period between 8- 8.5ug (7.5% of
total drug loading) and 23.6ug (11.9% total drug loading) respectively of paclitaxel
would be delivered from the currently used SR and MR Taxus™coronary stents [34-
35]. Of the PLGA polymers studied, the 400g 50:50PLGA and 75:25 PLGAcoat-
ing delivered comparable amounts of paclitaxel over the first 30 days but drug elu-
tion did not follow zero order kinetics and only small amounts of paclitaxel were de-
livered up to 15 days: the consequences of this on restenosis is unknown but data
from Kammath [34] indicate that only small amounts of the SR formulation were re-
leased from the Taxus™coronary stent during the first 10 days and yet this formula-
tion is effective in reducing ISR. Butall of the paclitaxel (20g) is eluted within 45
and 75 days from the 50:50PLGA and 75:25 PLGA coatings respectively. 85:15
PLGA coatings delivered its paclitaxel loading over a period of 120 days, but the ef-
fectiveness of this formulation in preventing ISR may be impaired due to the ex-
tended lag phase of about 60 days. Further studies would be required to determine
the required duration ofdrug elution from these PLGA polymercoatings.
3.5 Conclusions
The effect of varying glycolic acid content on degradation rate and drug eluting pro-
file in PLGA stent coatings was determined. Additionally the effect of adding 5%
paclitaxel to a 400ug coating of 50:50 PLGA on the degradation rate and the differ-
ences in size of coating of 50:50 PLGA wasdetermined. The addition of 5% pacli-
taxel to a coating of 50:50 PLGA had noeffect on rate of degradation. But a 200pg
coating of 50:50 PLGA degraded more slowly than a 400g coating, but elution of
paclitaxel wasfaster from the thinner coating.
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Increasing the glycolic acid content of the PLGA coating increased the degradation
rate of the polymer andthe elution of paclitaxel by increasing the hydrophilicity of
the polymer and the numberofsites with increased susceptibility to hydrolytic cleav-
age. Reduction in polymer molecular weight, mass loss and visual signs of morpho-
logical deterioration occurred in all PLGA polymers investigated but occurred over
differing time scales. Degradation of polymer wasfastest in the 50:50 PLGAcoating
and slowest in the 85:15 PLGA coating. Using GPC, no detectable polymer remained
on the stents coated with 50:50 PLGA and 75:25 PLGA after 45 and 105 days re-
spectively but small quantities of 85:15 PLGA coating were detected after 120 days.
Theelution rate of paclitaxel was dependant on the degradation state of the PLGA. A
two phase profile was observed with an initial diffusion controlled slow release
phase as the molecular weight of the PLGA decreased by hydrolysis and a second
faster phase associated with mass loss of the polymer and morphological changes in
the stent coating with the appearance of cavities and air spaces creating a more po-
rous structure. Paclitaxel was eluted fastest from the 50:50 PLGA and slowest in the
85:15 PLGA coating. Complete elution of the drug had occurred by 45 and 75 days
from the 50:50 and 75:25 PLGAcoatings respectively. An extended lag phase of 60
days was observed for the 85:15 PLGA coating but by 120 days 95% of the pacli-
taxel had been eluted.
Small changes in pH in the chamber exudate were observed during the study and
may have been associated with polymer degradation but no clear patterns were ob-
served and the pH of exudate from chambers containing BMS was moreacidic than
those containing PLGAcoatedstents.
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Chapter 4
The Effect of Blending Different PLGA Polymers and Addition of
Pluronics on Polymer Degradation and Paclitaxel Elution.
 
4.1 Introduction
The goal for successful drug delivery from polymer coated devices and microspheres
is a constant and controlled delivery of the contained drug at the required concentra-
tion at the appropriate time and for a sufficient duration (the therapeutic window).
Release of drugs from PLGAis closely associated with the degradation of the poly-
mer and typically showsa tri-phasic release profile consisting of an initial rapid re-
lease phase followed by a second phase of slower release and a final rapid release
phase,or a biphasicrelease profile consisting of either aninitial burst phase followed
by a phase ofsustained release [1] cited by [2], [3] or a initial lag phase followed by
a period of faster drug elution [4]. The initial rapid release or burst phaseis a fre-
quent feature of drug release from monolithic polymer controlled release systems and
is considered to be dueto the dissolution or diffusion of drug particles located on or
near to the surface of the polymer device [2]. The second phase(initial lag phase in
somebi-phasicrelease profiles) is generally attributed to diffusion controlled release
of the drug from within the polymer matrix and the final faster release phase is asso-
ciated with polymer erosion and breakdownof the polymer matrix [4-5]. Kunou ef al
[6] found that release of ganciclovir from PLGA microspheres wastri-phasic consist-
ing of an initial fast release phase (burst phase), a second slower diffusion release
controlled phase followed by final rapid release phase. Release of sirolimus from a
PLGAdevice consisted of 2 stages — but in this case a slower, initial diffusion con-
trolled stage was by followed a second phase of faster drug release [4]. Data from
chapter 3 of this thesis demonstrated a biphasic release profile of paclitaxel from
PLGA comprising of an initial lag phase in which very little paclitaxel was eluted
followed by a second phase of morerapid drugrelease.
For coronary stents sufficient anti-restenoic drug needs to be delivered forthe first
few days following stent deployment and for a period of at least 3 weeks to prevent
restenosis [7], but the lag phase observed in PLGA coatings mayresult in insufficient
drug being delivered to the vascular wall duringthis critical period. In chapter 3 of
this thesis, shorter lag phases were seen using 50:50 PLGAcoatings but the duration
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of paclitaxel delivery was probablyinsufficient to prevent restenosis over the longer
term. Paclitaxel delivery from 85:15 PLGA coatings was of a suitable duration but
insufficient drug may have beenreleasedin the first few days following implantation
due to the extended lag phase that was observed.
A numberof approaches have been used to modify the degradation rate and drug elu-
tion properties of PLGAto eliminate the phases seen in the drug elution profile and
to fine tune release profiles to suit the clinical requirements of the device. Methods
include co-polymerizing PLGA with polyethylene glycol (PEG), blending different
molecular weights of the same polymerand blending with polymersofdifferent hy-
drophilicity /hydrophobicity [8]. A summary of some ofthe trials and approaches
used to alter the drug elution profile from PLGA polymersis shownin Table 4.1.
The rate of drug release is predominantly determined bythe rate of hydrolysis of the
polymer matrix and the ability of the drug to diffuse through the pores and spacesas
the polymer degrades [5]. Degradation of PLGA polymersis via hydrolytic breakage
of the ester bonds in the polymer chainsand the accessibility of water to these bonds
will determine the rate of degradation [9]. The drug eluting properties of PLGA are
also affected by the glass transition temperature (7,) of the polymer and faster drug
elution occurs when the polymeris in the rubbery state due to the high mobility of
the polymerchainsin this state. The 7, of a glassy polymer can be decreased by
blending low molecular weight substances (plasticizers) with the PLGA.If the 7, of
the plasticized polymeris lower than the environmentthe polymerwill be in the rub-
bery state [10].
Addition of hydrophilic copolymers such as polyethylene glycol (PEG) to the PLGA
matrix can have a two fold effect on drugrelease profile: increased water uptake and
therefore potentially increasing hydrolytic degradation of the polymer and secondly
decreasing the 7, of the polymer which mayresult in transition of the polymer from a
glassy to a rubberystate [4]. Wateritself has been shownto have a plasticizing effect
on 50:50 PLGA [10]. Attempts to alter drug release profiles using copolymers as
plasticisers has had mixedresults (see Table 4.1). Wang e¢ al [4] foundthat sirolimus
elution from 53:47 PLGA occurred over two-phases with an initial slow release
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phase followed by a faster second phase. Addition of 5% or 10% polyethylene glycol
(PEG) increased the water uptake of the polymer while decreasing the glasstransi-
tion temperature (T,). This increased the initial rate of polymer degradation and con-
sequently increased theinitial rate of sirolimus release making the releaseprofile lin-
ear [4]. But addition of 5%w/w PEGto 80:20 PLGAfilmsdid not alter the drug re-
lease profile of heparin [11].
Paclitaxel release from PLGA films containing up to 20%w/w plasticisers such as
methoxypolyethylene (MePEG)or a diblock copolymer composed of PLLA-MePEG
was very slow with less than 5% of the paclitaxel being released over 2 weeks,al-
though addition of 30% w/w PLLA-MePEGtothefilms substantially increased pa-
clitaxel release [12]. Addition of a more hydrophobic diblock copolymerpoly (€-
caprolactone) (PCL)-MePEG increased paclitaxel elution as compared to PLGA
alone or PLGA blended with MePEG-PLLA[13].
Blending of PLGA polymers with differing lactide/glycolide (LA:GA)ratios and/or
differing molecular weights is another strategy used to modify drug release profiles
and someofthe studies utilising blends of PLGA polymers is shown in Table 4.1.
The biodegradation rate of PLGAis affected by the composition of the PLGA.In-
creasing the GA content of a polymer has a twofold effect on degradation: GA is
more hydrophilic than LA and hydration increases as the GA moiety content in-
creases resulting in faster degradation [14] and since GA units are more vulnerable
than the LA units to hydrolytic degradation, increasing GA content increases the
polymers degradationrate.
Blending polymers of different LA:GAratio or molecular weight may be expected to
produce a polymer with a degradation rate and drugreleaseprofile that is a compro-
mise between that of the PLGA polymers alone. Ganciclovir was released rapidly
from low molecular weight (8 kDa Daltons) 50:50 PLGA microspheres over ap-
proximately 10 days but by blending low molecular weight 50:50 PLGA with 65:35
PLGAaninitial fast release occurred over 5 days followed by a slower phase over
approximately 15 days with a final rapid release phase[15]. Blending low molecular
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weight 50:50 PLGA (8 kDa) with 75:25 PLGA increased the release of ganciclovir
as compared with 75:25 PLGAalone:blending at a ratio of 1:1 reduced the lag phase
from approx 50 days to approx 8 days andall the drug was released by 20 days as
opposed to 100 days for 75:25 PLGAalone[5].
Within a homogenous blend of two PLGA polymersgelling and solidification of the
constituent polymers occurs separately within the polymer matrix [18-19] cited by
[17]. Phase separated polymers can be obtained by blending polymers creating mor-
phologies, matrix characteristics and drug release profiles that are different to the
constituent polymers alone[9]. In a degrading polymer device comprising a blend of
polymers with different degradation profiles, hydrolysis of the domainsof the faster
degrading polymer mayleadto the creation of cavities and spaces within the polymer
matrix through which contained drugs maydiffuse out into the external medium [20].
Pluronics are surfactants made up of copolymers of poly(ethylene oxide) (PEO) and
poly(propylene oxide) (PPO) [9]. Hydration of PEO/PPO/PEOtriblock copolymers
is dependant on the PEO:PPOratio and increasing PEO content increases the hydro-
philicity of the copolymer [8]. When blended with PLGA they can form phase sepa-
rated morphologies with an intact surface morphology and different levels of hydra-
tion depending on the hydrophilicity of the pluronic and its concentration in the
blend [9]. Pluronic copolymers have been used in blends with PLGA to produce
films for controlled delivery of proteins [21] and have minimal toxicity and some are
presently in clinical use [9].
F-127 is a hydrophilic triblock pluronic [9] and has a molecular weight of approxi-
mately 12,300 daltons of which about 70% is PEO [8]. Yeh at a/ [21] found that
blending F-127 into PLGA microparticles resulted in a burst phase of protein release
followed by a short lag phase of 5 days and then a period of sustained protein deliv-
ery. Overall there was little difference in percentage cumulative release of protein
between 50:50 PLGA and 50:50 PLGA/F-127 (blendratio3:1) but percentage cumu-
lative release wasfaster at blendratios of 1:2 PLGA:PLGA/F-127. Raiche and Puleo
[8] found that blending 8% w/w F-127 was found to be optimum for hydration of
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50:50 PLGA microspheres and increased the in vitro degradation rate and protein
release as compared with 50:50 PLGA microspheres.
The prolonged lag phaseseenin the release ofpaclitaxel from 85:15 PLGA limitsits
use as a potential coating for coronary stents. In this chapter the hypothesis that faster
degradation andearly creation of a porousstructure within the matrix of 85:15 PLGA
devices should increase the initial release rate of paclitaxel thereby shortening the lag
phase resulting in a morelinear release profile of the drug. Addition of soluble hy-
drophilic copolymers such as pluronic F-127 to PLGA polymers should increase the
hydration of the polymer matrix resulting in faster degradation and fast degradation
and dissolution of the copolymer within the device should lead to creation of pores
and cavities through which the drug molecules can moreeasily diffuse. Blending of
low molecular weight PLGA and PLGA polymers with a higher GA content than
85:15 PLGAshould also introduce faster degrading domainsresulting in cavities and
pores within the polymer matrix through which paclitaxel molecules could be re-
leased more quickly. The abovestrategies should increase the early release of pacli-
taxel after the device is implanted or immersed in the release medium while pacli-
taxel molecules entangled in the slower degrading 85:15 PLGA domainswill be re-
leased more slowly thereby maintaining a steady elution of paclitaxel over the study
period.
The study comprised twotrials. In Teflon Disc Trial 1(TD1) the effect of adding 8%
w/w Pluronic F-127 to 85:15 and 50:50 PLGA, and blending 85:15 PLGA with
50:50 PLGA (1:1) on the elution of paclitaxel was studied. The second trial (TD2)
tested the effect of adding low molecular weight (LMWt) 50:50 PLGA to 85:15
PLGA comparedwith a blend of 50:50/85:15 PLGA and 65:35 PLGA.
4.2 Materials and methods
4.2.1 Materials.
Poly(p,-Lactide-co-Glycolide) (PLGA); 50:50 MWt 40-75kDa, 65:35 MWt 40-
75kDa, 85:15 MWt 90-126kDa, 50:50MWt5-15kDa: from Sigma-Aldrich. Pluronic
F-127, sodium azide (99.5%) and phosphate buffered saline (pH 7.4) from Sigma-
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Aldrich. Chloroform (SpS 99.9% Super Purity solvent, stabilised) from Romil Pure
Chemistry, UK. The paclitaxel was kindly donated by Boston Scientific Corporation,
USA.
4.2.2 Methods.
4.2.2.1 Preparation of polymerfilms
13mm diameter discs were cut from Teflon sheeting (Goodfellow 1.0mm thick
polytetraflouroethylene sheets). The discs were cleaned in 50% v:v ethanol water
mixture and allowed to dry. The dry discs were weighed using a Sartorius CP2 fine
balance and the weight was recorded.
Polymerblends containing 5% (w:v) Paclitaxel were prepared as follows PLGA,F-
127 and paclitaxel were dissolved in chloroform at a concentration of 100mg/ml.
PLGA,paclitaxel and F-127 were dissolved separately in chloroform by mixing on a
stirrer for 1 hour. The samples were then mixedin the proportions indicated in Table
4,2 and mixed for a further hour.
Table 4.2. Preparation of polymerfilms: the volume (mls) of each ingredient used in
each blend.
 
 
  
Polymer/ingredient (100mg/ml)
85:15 50:50 65:35 F- .Blend PLGA PLGA PLGA 127 Paclitaxel
85:15 PLGA 9.5 0.5
50:50 PLGA 9.5 0.5
65:35 PLGA 9.5 0.5
85:15 + 50:50 PLGA 4.75 4.75 0.5
85:15 + F-127 8.7 0.8 0.5
85:15 + LMWt 50:50PLGA 4.75 4.75 0.5
50:50 + F-127 8.7 0.8 0.5     
The mixture was then sonicated using a VWRultrasonic cleaner water bath for 30
minutes to aid mixing and to prevent formation of air bubbles within the polymer
solution. 1001 of polymer was added to a 13mm dia Teflon disc and coated using a
WS-400B-6NP Lite spin coater (Laurell Technologies Corporation) for 15 seconds
each at 1,000, 2,000, 3,000 and 4,000 rpm followed by 15 seconds each at 3,000,
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2,000, and 1,000 rpm. The samples were then left in the open overnight and then
dried under vacuum at room temperature until a constant weight had been achieved.
The dry weight of the polymer coated disc was recorded and the mass of polymer on
each disc determined. Samples were placed in 12 well polystyrene plates and 4 mls
of PBS containing 0.1% (w:v) sodium azide was added and placed on a shakerat 120
rpm at 37°C. The PBS release media was changed weekly. Samples werecollected at
3, 7, 14, 21, 30, 45 and 60 days in TD1 and 14, 21, 30, 45, 60 and 75 days in TD2.
4.2.2.2 Water content.
At the appropriate time points samples were recovered from the release media. Sam-
ples were carefully blotted dry using Kimwipestissue (Kimtech Science) and the wet
weight of the sample taken. Samples were then dried under vacuum at room tempera-
ture until a constant weight had been reached. The dry weight of the polymer was
recorded and used to calculate polymer mass loss and water content of the film using
the formulae:
Percentage polymer mass remaining =100*(mass of polymer at recovery/original
polymer mass)
Percentage water content = 100*(mass of water in the film/wt of polymer remain-
ing).
4.2.2.3 Gel permeation chromatography (GPC):
Equipment, columns and polymer standards used were as used in chapter 3. The
polymer remaining on each disc was recovered by adding 1ml of chloroform to the
disc(s) in a capped glass vial and shaking gently for 3 hours. The numberofdiscs
used for each GPC sample is shown in Table 4.3. In samples recovered at 3 and 7
days 1 disc was used for each GPC sample. At later times points and in TD2, two
discs were added to 1ml of chloroform for each GPC sample to ensure that sufficient
polymerandpaclitaxel would be present for quantification.
Table 4.3 Numberof discs used per sample for GPC
Aa sampling time (da
Trial N° 7 14 22 30
TD1
TD2
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GPC was performed using four 7.8x300mm, 54m Waters Styragel columns (1.
HRO.5 MWtrange 0 to 1000, 2. HR2 MWt range 500 to 20,000, 3. HR3 MWtrange
500 to 30,000 and 4. HR4 MWtrange 5,000 to 500,000) with a flow rate of 1ml per
minute with chloroform as a the mobile phase and using a Polymer Labs ELS 1000
evaporative light scatter detector (ELS) and Polymer Labs LC1200 UV/VIS ultra
violet (UV) detector. Easi-Cal PS-2 (Polymer Labs) polystyrene standards, with a
molecular weight range of 580 to 377,400 were dissolved in chloroform to give a
0.1% solution.
Raw polymer wasprepared by weighing an amount of polymer and adding chloro-
form to give a final concentration of I1mg/ml and gently mixing at 120rpm at room
temperature for 3 hrs. The injection volume was 2501 with a polymer concentration
of approximately 800ug/ml solvent for the stent samples and 100yl for the raw
polymer and Easi-Cal standards) with three measurements per sample. Quantitative
analysis was performed using Cirrius Software (Polymer Labs) and molecular weight
data is expressed as weight average molecular weight (M,).
Paclitaxel concentration was measured using the area under the peak using data from
the UV detector as in Chapter 3 using a calibration curve of 10, 20, 50, 100 and 200
ug/ml paclitaxel. Quality control (QC) checks containing 0.8mg/ml 85:15 PLGA and
20 or SOpug/ml paclitaxel in chloroform were also prepared and analysed via GPC.
4.2.2.4 SEM
Two discs from each sample point were mounted onto an aluminium stub using dou-
ble sided adhesive carbon tape and sputter coated with chromium using an
EMITECH K575X coater. SEM wasperformed using a Leo/Zeiss 1550 Field Emis-
sion Scanning Electron Microscope.
4.2.2.5 pH measurements.
The pH ofthe release medium from film samples and blank teflon disc samples (con-
trols) at each of the sampling time points was measured using a Mettler Toledo pH
meter.
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4.3 Results.
4.3.1 Coating of PTFE discs: amount of PLGA and concentration of paclitaxel.
The amount of polymer andpaclitaxelinitially added to each disc by group is shown
in Table 4.4. Overall the mean weight of polymer applied to each disc was 794ug
+139ug but there was variability within groups and between groups in the amount of
polymeron each disc with relative standard deviations of between 14-18%. The ini-
tial amount of 85:15/LMWt 50:50 PLGA at 680ug (stdev=114) was significantly
lower than that found on the other groups (p<0.001). But once the discs were ran-
domized with the respect to the sampling date it was found that there wasnosignifi-
cant difference in the weight of polymer betweenor within the groups.
Table 4.4 Initial Coating of Teflon discs. The table shows the mean and standard devia-
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tion (stdev) of the amount of polymer and paclitaxel coated onto the Teflon discs in each
 
group.
polymer(ug) Paclitaxel (ug)
group label mean stdev Mean Stdev
85:15 PLGA A 831 151 49.6 8.8
50:50 PLGA B 766 106 49.5 4.4
85:15/50:50 PLGA C 841 118 50.2 4.2
85:15 PLGA/F-127 D 892 132 54.4 6.1
50:50 PLGA/F-127 F 783 120 55.0 4.4
85:15/LMWt 50:50 PLGA G 680 115 45.8 9.8
65:35 PLGA H 820 154 57.0 13.0      
Data for the original amount of paclitaxel was derived from GPCstudies andis
shown in Figure 3.1. The mean amount ofpaclitaxel was 52.6ug (stdev=10) per Tef-
lon disc and there was no significant difference (p>0.05) between the groups in the
initial concentration of paclitaxel on each Teflon disc.
4.3.2 pH data.
Figure 4.1 showsthe pH changein the release media in TD1.
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Figure 4.1. pH change in the incubation media from polymer coated discs and con-
trols in trial TD1.
The pH changeis similarin all groups and steadily rises from approx 7.27atthe start
of the trial to approx 7.58 at the end of the study period. Analysis by ANOVA
showedthat there was no significant difference between the groups at the various
time points (p>0.05) and that there wasno significant difference between the control
media andthat of the samplesat any given time point (p>0.05).
The pH increased over timein all groups and controls. In the trial samplesin all the
groups pH hadincreased significantly at 21 days (p<0.001). This increase wasalso
seen in the control media. Stock control media had a mean pH of 7.3. By 21 days the
pH in the control wells had risen significantly (p<0.001) to 7.43. This would indicate
that the change in pH observed in the media from the PLGA coated samples may not
be due to release of degradation products, which tend to result in a slight decrease in
pH,butis due to otherfactors.
The pH changesseen in the release media from trial TD2 are shownin Figure 4.2.
There was no significant difference in the pH of the release media between the
groups of the polymer coated discs or between the controls and the polymer coated
discs in trial TD2. The pH ofthe release media in trial TD2 in both polymer coated
discs and controls was 7.36 and 7.37 respectively at 7 days. But at 22 days the pH
had risen significantly (p<0.001) as compared with 7 days to 7.73 and 7.71 respec-
tively in the controls and the polymer coated groups. There wasno further significant
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changes in pH in either the controls or the polymer coated groups and pH was >7.7
for the remainderofthe study.
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Figure 4.2. Change in incubation media pH during polymer degradation in trial TD2.
data uses combinedfigures from the all of the groups
4.3.3 Paclitaxel assay
The combinedcalibration data for the paclitaxel assay is shown in Figure 4.3. The
calibration was reproducible acrossall runs and the mean values (from all GPC runs)
for the QC checks (see below) indicated that the assay gave acceptable sensitivity.
> 20ug= 18.24ug (stdev =3.28), recovery = 91.22%
> 50yug= 49.93 ug (stdev = 2.48), recovery = 99.86%
Given the variation in original polymer mass on each disc, the following method was
used to calculate paclitaxel per disc for comparison between groups etc: the mean
concentration of paclitaxel (ug paclitaxel per mg polymer) was determined using the
paclitaxel data derived from control discs for each group. This figure was then used
to determine the original amountof paclitaxel per disc on the incubated discs using
the initial polymer weight. The actual amountof paclitaxel remaining on each disc
after incubation was then calculated as a percentageofits original concentration.
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Figure 4.3 Paclitaxel Calibration Curve. Data is derived from GPC chromatograms of
varying concentrations of paclitaxel. The figure represents the combined data taken from all
the GPC runsinthistrial.
4.3.4 Effect of pluronics on water uptake, polymer erosion, degradation and _pacli-
taxel elution
4.3.4.1 Water content
The water content of 85:15 PLGA and 50:50 PLGA with and without F-127 is shown
in Figure 4.4. In most cases the data has a large standard deviation but trends in wa-
ter uptake can still be discerned. Initially the water content of the PLGA films was
lower than in films containing F-127; 50:50 and 85:15 PLGA films had a water con-
tent of 2.5% and 3.3% water content whereas the 50:50 and 85:15 films with F-127
had a significantly higher (p=0.040 and p=0.013) water content of 8.5% and 9.5%
respectively. At 14 days the water contentof the films containing F-127 decreased to
approximately 5% and remained at between 4.5-6% water content to the end of the
study period. After 14 days there was no significant change in the hydration of the
films containing F-127. The water content of the 85:15 PLGAfilms increased stead-
ily to 45 days to 14% after whichit fell to just under 6%. Water content in the 50:50
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PLGAfilmsincreased to 8.6% after 30 days incubation and was 7.6% at the end of
the study period (45 days).
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Figure 4.4 Effect of degradation time on water content of PLGA films, with and
without pluronic F-127. Error bars= standard deviation
There was nosignificant difference (p=.996) between hydration in 85:15 and 50:50
PLGAfilms to 7 days, but from 14 days until the end of the study period the hydra-
tion of 85:15 PLGA wassignificantly higher (p<0.001) than the 5050 PLGA (except
at 30 days where p=0.208). At 30 and 45 days water content of the 50:50 PLGA
films was higher than with the addition of F-127 but the effect was not significant
(p =0.324 and p=0.193 at 30 and 45 days respectively). The water content of 85:15
PLGAfilms was significantly higher (p<0.05) at 30 and 45 days as compared with
films containing F-127.
4.3.4.2 Polymererosion (massloss).
The effect of adding of 8% w/w F-127 on the massloss of 85:15 and 50:50 PLGAis
shownin Figure 4.5. After 3 days 7-8% of the polymer mass had been eroded in the
85:15 PLGAfilms with and without F-127. Mass loss was slow in these two groups
and at the end of the study period (60 days) 90% of the polymer remained on the
PTFE disc. Addition of F-127 to 85:15 PLGA films had no significant effect on
polymer massloss overthe study period.
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Figure 4.5 Effect of addition of pluronic F-127 to PLGA films on massloss. Mass
remaining onthe film (as a percentage ofthe original amount of polymer) during polymer
degradation. Error bars show the standard deviation.
Massloss wasfaster in the 50:50 PLGA films with and without F-127 as compared
with 85:15 PLGAfilms (with and without F-127). The masslossprofile for films of
50:50 PLGA wassimilar to that 50:50 PLGA/F-127 films. At 3 days 91% and 88%
of the polymer remained on the PTFEdisc in the 50:50 PLGA and 50:50 PLGA/F-
127 films respectively. Polymer erosion then proceeded slowly in these groups until
30 days after which mass loss was more rapid and at 45 days (the end of the study
period) the amount of polymer remaining on the PTFE films had fallen to 78% in
both the 50:50 PLGA films and the 50:50PLGA/F-127 films. Mass loss occurred
significantly (p<0.001) faster in 50:50 PLGAfilms containing F-127 to 30 days but
at 45 days there wasnosignificant difference (p=0.976) in the mass remaining.
4.3.4.3 GPC data: effect of pluronics on polymer degradation and paclitaxel elution.
The change in molecular weightof films of PLGA with and without F-127 are shown
in Figure 4.6. 50:50 PLGAfilms degraded faster than the 85:15 PLGAfilms and ad-
dition of F-127 to either 50:50 PLGA or 85:15 PLGAslowedthe rate of degradation.
The initial molecular weight of the 50:50PLGA and 50:50PLGA/F-127 films were
44,000 and 40,254 respectively. As degradation proceeded the molecular weight of
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the 50:50 PLGA films decreased to 80% to 8,700 and by 70% to 12,100 in the 50:50
PLGA/F-127 films respectively at 45 days. Addition of F-127 to 50:50 PLGAsig-
nificantly slowed the rate of polymer degradation as measured by reduction in per-
centage molecular weight remaining on the disc from 14 days incubation (p=0.022)
and the effect remained significant at 45 days (p=0.011).
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Figure 4.6 Molecular weight change: Degradation of 50:50 and 85:15 PLGA~ effect
of adding pluronic F-127.Degradation is shown as the change in molecular weight of the
polymer remainingin thefilm. Error bars=standard deviation
Theinitial molecular weight of the 85:15 PLGA and 85:15/F-127 films was 76,734
and 68,222 respectively. Degradation of these films was slow in comparison with the
50:50 PLGAfilms andatthe end of the study period (60 days) the 85:15 PLGAfilms
had degraded by 35% to 49,900 and the 85:15 PLGA/F-127 films had degraded by
31% to 47,400. Addition of F-127 to the 85:15 PLGA films decreased the degrada-
tion rate but the difference was notsignificant at any of the time points (p>0.05).
Overall, paclitaxel was released more rapidly from films containing 50:50 PLGA
(with and without F-127) as compared 85:15 PLGA and 85:15 PLGA/F-127 films
but the difference was only significant at 45 days (p<0.001).
Aninitial rapid release of paclitaxel occurred and after 7 days incubation approxi-
mately 12% of the paclitaxel had been released from the 50:50 PLGAfilms. Pacli-
taxel elution was then very much slower and at 30 days 16% of the paclitaxel had
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been eluted from the films but the difference was not significant (p=0.989) as com-
pared with 7 days incubation. After 45 days degradation approximately 43% of the
paclitaxel had been released from the 50:50 PLGA films and the difference as com-
pared with 30 days was significant (p<0.05, p=0.002). F-127 had no effect on pacli-
taxel release to 30 days. But at 45 days 29% ofthe paclitaxel had been eluted from
the 50:50 PLGA/F-127 which wassignificantly less than that eluted from the 50:50
PLGAfilms (p<0.05, p=0.015).
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Figure 4.7 Effect of pluronics on elution of paclitaxel from 85:15 and 50:50 PLGA
films. The paclitaxel concentration is expressed as the amountofpaclitaxel remaining in the
film as a percentageofthe paclitaxel concentration at the start of the trial. Error bars = stan-
dard deviation.
There was very little elution of paclitaxel from the 85:15 PLGA and 85:15/F-127
films. There was no noticeable burst release over the first 7 days of degradation of
paclitaxel as seen in the 50:50 PLGAfilms and over the whole of the study period of
60 days only 9% and 5% of the paclitaxel was released from the 85:15 PLGA and
85:15PLGA/F-127 films respectively. Addition of F-127 to 85:15 PLGA films had
no significant effect on paclitaxel release at any time over the study period (p>0.05).
4.3.4.5 Effect of pluronics on polydispersity.
Changesin the polydispersity (PDI) of the polymerfilms as the polymers degrade is
shownin Figure 4.8. At the start of the trial the PDI of the 50:50 and 85:15 PLGA
films was 1.598 and 1.610. Addition of F-127 increased the PDI of the 50:50 PLGA
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and 85:15 PLGA films to 1.634 and 1.598 respectively but there was no significant
difference in PDI between any of polymerfilmsprior to the start of degradation.
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Figure 4.8 Effect of pluronic F-127o0n polydispersity (PDI) of 50:50 PLGA and 85:15
PLGAfilms. The graph shows the changes in polydispersity during polymer degradation.
Error bars show the standard deviation.
There wasverylittle change in the PDI of 50:50 PLGAand 50:50 PLGAF-127films
over the study period and at 45 days the PDI was 1.563 and 1.625 which wasnotsig-
nificantly different to the controls (p=1.563 and p=1.625 respectively). The PDI of
films containing 85:15 PLGA and 85:15 PLGA/F-127 increased over the study pe-
riod (60days) to 1.788 and 1.863 respectively which was significant as compared
with the controls (p=0.024 and p=0.025 respectively).
4.3.5 Effect of polymer blending on water uptake, polymer erosion, degradation
and paclitaxel elution
The effect of blending 85:15 PLGA with 50:50 PLGA wastested in trial TD1. In
trial TD2 the effect of blending a low molecular weight 50:50 PLGA with 85:15
PLGA on polymer degradation and drug elution was compared with 65:35 PLGA
and 85:15/50:50 PLGAfilms.
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4.3.5.1 Water content
The percentage hydration of polymerfilms of 50:50/85:15 PLGA and 65:35 PLGAis
shownin Figure 4.9. The hydration of 65:35 films was very similar to that of 85:15
PLGAfilms and water content increased from 6.7% at 14 days to 12.6% at 45 days
after which water content decreased to 7.6% at 60days. Despite the changes in hy-
dration of 65:35 PLGAfilms from 14 to 45 days the differences were not significant
(p>0.05). The hydration of a 1:1 blend of 85:15/50:50 PLGA films was similar to
that of 50:50 PLGA films, with water content increasing significantly (p<0.001) to
9.8% at 30 days after which the water content decreased to 2.9% and 1.6% at 45 and
 
 
60 days respectively.
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Figure 4.9 Change in percentage water content of 85:15, 65:35, 50:50 and
85:15/50:50 PLGA films during degradation. Standard deviation is represented by the
error bars
At 30 days the percentage hydration of the 65:35 PLGA films and 85:15/50:50
PLGAfilms was 11.2% and 9.9% but the difference was not significant (p=0.988),
but at 45 days the difference wassignificant (p=0.004). There wasnosignificant dif-
ference in the hydration of the 65:35 PLGA and 85:15/50:50 blend films to 30 days
(p>0.05) but the difference wassignificant at 45 and 60 days (p<0.001).The percent-
age water content in the 85:15/LMWt 50:50 PLGAfilms (data not shown) increased
with degradation time to 38.7% +£12.5.
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4.3.5.2 Polymererosion (massloss)
The mass loss during degradation on 85:15, 50:50, 65:35 PLGA, and blends of
85:15/50:50 PLGA and 85:15/LMWt 50:50 PLGA is shown in Figures 4.10 and
4.11.
 
 
100 4
r 
——50:50 PLGA
%
ma
ss
rem
ain
ing
oo oO L 70 7 ——85:15 PLGA——85:15/50:50 PLGA60 T T T 1
0 15 30 45 60
time (days)
Figure 4.10. Percentage Mass Loss in 50:50, 85:15 and 50:50/85:15 blend PLGA
polymerfilms during degradation. Data taken from trial TD1. Mass remaining on thefilm
(expressed asa percentageofthe original polymer weight) during polymer degradation. Er-
ror bars = standard deviation.
Initially there was a loss of between 7-8% of the polymer mass in 50:50, 85:15 and
50:50/85:15 blend PLGA polymer films during the first three days of incubation.
This was followed by a period of much slower massloss. At 30 days 87.8% of the
original polymer films mass remained on the discs in the 50:50 PLGA group and
90.5% remained in the 85:15 PLGA and 50:50/85:15 PLGA blend. At 30 days there
was no significant difference in mass loss between the 85:15 PLGA and the
85:15/50:50 PLGA blend (p=0.999) but the mass loss from the 50:50 PLGAfilms
was significantly higher (p<0.001) than the other two groups at 30 days. After 45
days degradation rate of mass loss was accelerated in the 50:50 PLGA and
50:50/85:15 PLGA films. Blending 50:50PLGAinto 85:15 PLGA increased the rate
of mass loss after 30 days and at 45 days 85% of the massof the 85:15/50:50 PLGA
blend remained as opposed to 90% in the 85:15 PLGAfilms and the difference was
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significant (p=0.015). Further mass loss in 85:15/50:50 PLGA blend occurred and at
60 days 22% of the polymer mass had been eroded.
Massloss data from trial TD2, comparing 65:35 PLGA, 50:50/85:15 PLGA blend
and 85:15/50:50 PLGAblend is shown in Figure 4.11. There wasaninitial rapid loss
of polymer bulk from all three types of films and after 14 days degradation, 93%,
91.3% and 92.4% of the polymer remained on the 85:15/50:50 PLGA, 85:15/LMWt
50:50 PLGA and 65:35 PLGArespectively.
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Figure 4.11 Polymer MassLoss in 65:35, 85:15/50:50 blend and 85:15/LMWt50:50
PLGA during degradation. Data fromTD2. Massloss is shown as weight of polymerre-
maining onthefilm as a percentage ofthe original polymer weight. Error bars = standard
deviation.
After the initial phase of rapid mass loss, polymer erosion was much slower from the
85:15/50:50 PLGA and 65:35 PLGAfilms and at 60 days 87.1% and 89.7% respec-
tively of the polymer remained on the films. The change in percentage mass remain-
ing from 14 to 60 days was not significant in the 85:15/50:50 PLGA and 65:35
PLGAfilms (p=0.254 and p=0.213 respectively) but at 60 days significantly more
mass loss had occurred from the 85:15/50:50 PLGA films as compared with the
65:35 PLGA films (p=0.015).
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Polymererosion was morerapid from the 85:15/LMWt 50:50 PLGA films as com-
pared with the other polymer films in TD2 and blending LMWt 50:50 PLGA with
85:15 PLGAsignificantly increased polymer erosion from 22 days onwards as com-
pared with the 85:15/50:50 PLGA films. From 14 days to 45 days degradation time
the percentage polymer mass remaining on the 85:15/LMWt 50:50 PLGAfilms de-
creased from 91.3% to 87.5% after which the rate of mass loss increased and at 60
and 75 days the mass remaining decreased to 80.3 and 72.2% respectively. The
change in percentage mass remaining on the 85:15/LMWt 50:50 PLGA films was
significant (p<0.001) between 45 to 60 days and 60 to 75 days degradation time.
4.3.5.3 GPC data: effect of polymer blending on degradation and paclitaxel elution.
Polymer degradation, as expressed as percentage change in molecular weight in the
polymer remaining on the film is shown in Figures 4.12 &13. The degradation of
85:15 PLGA and 50:50 PLGAfilmsis discussed in section 4.3.4.3
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Figure 4.12 Polymer degradation. Change of molecular weight (expressed as a per-
centage ofthe original My, remaining onthe film) in 85:15, 50:50 and 85:15/50:50
blend PLGA polymerfilms. Data from trial TD1 trial error bars = standard deviation
Blending 85:15 and 50:50 PLGAresulted in an original molecular weight of 56,372
but by 7 days the polymer had degradedsignificantly (p=0.007) to 49,399 and by 60
days the molecular weight was approximately 23,000 (Figure 4.12). The degradation
rate of 85:15/50:50 PLGAblendfilms was intermediate as compared to 50:50 PLGA
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and 85:15 PLGA films. After 7 days degradation time the M, of the 85:15/50:50
PLGAblend films were 87% of the original as compared with 80% on the 50:50
PLGAfilms and 93% on the 85:15 PLGAfilms. At this sampling point there was no
significant difference in the rate of degradation of the 85:15/50:50 PLGA blend as
compared with the other two groups (p=0.119 and p=0.352 respectively). At 45 days
the percentage My remaining on the 85:15/50:50 PLGA blends (46.5%) wassignifi-
cantly different to the other films (p<0.001 in both cases): the 85:15/50:50 PLGA
blend was more degraded than the 85:15 PLGA films where 69.5% of the original
molecular weight remained but less degraded than the 50:50 PLGAfilms which had
degraded to 21.5% of the original M,,. At 60 days the 85:15/50:50 PLGAblends had
degraded further to 41.2% of the original M,, as compared with 65% remaining on
the 85:15 PLGA films (p<0.001).
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Figure 4.13 Polymer degradation. Change of molecular weight (expressed as a per-
centage ofthe original M,,, remaining on thefilm) in 65:35, 85:15/50:50 blend and
85:15/LMWt 50:50 blend PLGA polymerfilms. Data from trial TD2. error bars = stan-
dard deviation. The blend of 85:15/LMWt50:50 PLGAproduced two peaks on the GPC
chromatograms.
The data comparing molecular weight change in films comprising 85:15/50:50
PLGA,65:35 PLGA and 85:15/LMWt 50:50 PLGAis shownin Figure 4.13.
At the start of the trial the My of the 85:15/50:50 PLGA blend and 65:35 PLGA
films was 60,360 and 50,262 respectively. After 14 days degradation the 85:15/50:50
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PLGAfilms the M,, of the films had degraded by 25%. After 14 days the films de-
graded significantly to 75 days (p<0.001) to a My of 28,501 (47% of the original). At
14 days the M, of the 65:35 PLGA films had decreased by 17% to 41,685. After 60
days degradation the M,, of the 65:35 PLGA films was 27,432 (54.5% ofthe
original) which wassignificantly lower than at 14 days (p<0.001). The rate of degra-
dation of the 85:15/50:50 PLGA films was faster than the 65:35 films overthe trial
with significant differences in percentage M,, change at 45 and 60 days (p<0.001).
The chromatogramsfrom 85:15/ LMWt 50:50 PLGAfilms were bi-modal consisting
of two polymer peaks which were measuredas distinct distributions (Appendix, Fig-
ure A.5). But the degradation of the peaks was very different. Peak 1 had an initial
M,, of 86,669 which degraded by 14% after 14 days to 72,800 and by approximately
40% over the 75 days of thetrial to 35,293. The percentage molecular weight change
was significant from 14 days to 45 days and onwards (p<0.001). Degradation was
slower in peak 2. The M,, of peak 2 was 6,605 andthestart of the trial and at 14 days
the M,, was 89% ofthe original. After 75 days degradation the M, of peak 2 had re-
duced by 17% to 5,523. The percentage M,, change in peak 2 wassignificant at 75
days (p=0.025) as compared with 14 days butnotat earlier time points (p>0.05).
Release of paclitaxel from 85:15/50:50 PLGA films was slow overthe first 45 days
of the trial followed by a phase of faster release by 60 days (Figure 4.14). After 7
days degradation there was no measurable release of paclitaxel but at 45 days ap-
proximately 7.5% of the paclitaxel had been released from 85:15/50:50 PLGA films
but there was no significant difference in the amount of paclitaxel released from 7
to 45 days degradation time (p>0.05). After 60 days 20% of the paclitaxel had been
released from the 85:15/50:50 PLGA films and the difference was significant as
compared to 7 and 45 days ( p<0.001 and p=0.043 respectively).
Elution of paclitaxel to 45 days from 85:15/50:50 PLGA films wassimilar to that of
85:15 PLGAfilms with 92.4% and 93.4% respectively of the paclitaxel remaining on
the film at 45 days and the difference wasnot significant (p=0.999). At 60 days more
paclitaxel had been released from the 85:15/50:50 blend films compared to the 85:15
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films (20% and 8.5% respectively) but surprisingly ANOVA showedthat the differ-
ence wasnotsignificant (p=0.054).
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Figure 4.14 Release of Paclitaxel from 85:15, 50:50 and 85:15/50:50 PLGA films.
Data taken from trial TD1. Error bars = standard deviation. Graph shows the concentration
of paclitaxel remaining on film expressed as a percentage of original (control) concentration.
Elution of paclitaxel was slower from the 85:15/50:50 PLGA films as compared to
the 50:50 PLGAfilms but the difference was only significant (p<0.001) at 45 days
when 7.5% and 42.5% ofthe paclitaxel had been eluted from the 85:15/50:50 PLGA
films and 50:50 PLGAfilmsrespectively.
Figure 4.15 showsthe elution of paclitaxel from 85:15/50:50 PLGA, 65:35 PLGA
and 85:15/LMWt50:50 PLGAfilms from study TD2. The data for paclitaxel release
in TD2 wassubject to large standard deviations at some sampling points but trends
could still be discerned in the data. In TD2 there was no measurablerelease ofpacli-
taxel during the study period (75 days) from 85:15/50:50 PLGAfilms. There was no
measurable release of paclitaxel from 65:35 PLGAfilms up to 30 days but at 60-
days 10.3% ofthe paclitaxel had been released from the 63:35 PLGA films butthis
wasnotsignificant (p>0.05) as compared with earlier sampling points. There was no
significant difference in release of paclitaxel from 85:15/50:50 PLGA films and
65:35 films up to 45 days degradation time but at 60 days significantly (p=0.033)
morepaclitaxel had been released from the 65:35 PLGAfilms.
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Figure 4.15. Release of Paclitaxel from 85:15/50:50 blend, 65:35 and 85:15/LMWt
50:50 blend PLGAfilms. Data taken from trial TD2. Error bars=standard deviation. Graph
showsthe concentration of paclitaxel remaining on film as percentage of the control concen-
tration.
There was no significant release of paclitaxel from the 85:15/LMWt 50:50 PLGA
films up to 45 days. But after 60 and 75 days degradation time the paclitaxel remain-
ing on the films decreased to 82.3% and 79.5% of the original amount respectively
but despite this decline there wasnosignificant difference in the amountofpaclitaxel
remaining on the films as compared to earlier sampling time points. At 60 and 75
days release of paclitaxel was significantly higher from the 85:15/LMWt 50:50
PLGAfilms (p=0.021 and p= 0.19 respectively) as compared with 85:15/50:50 blend
films but was not significantly different to the paclitaxel release from 65:35 PLGA
films at 60 days (p=0.906).
4.3.5.4 GPC data: polydispersity index (PDI)
Figure 4.16 showsthe effect of degradation of the PLGA films on the polydispersity
index (PDI) of the polymer films. The PDI of the 85:15 PLGA and 65:35 PLGA
films at the start of the trial was 1.651 and 1.552 respectively. The PDIincreased as
the polymer films degraded and at 60 days the PDI was 1.788 and 1.761 for the
85:15 PLGA and 65:35 PLGAfilmsrespectively: a significant increase as compared
to the controls (85:15 PLGA, p=0.024 and 65:35 PLGA p<0.001). There was nosig-
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nificant difference between the PDI of the 85:15 PLGA films and the 65:35 PLGA
films as the polymers degraded.
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Figure 4.16. The effect of degradation on polydispersity (PDI) The graph showsthe
changes in polydispersity during polymer degradation. Error bars show the standard devia-
tion.
The PDI of the 50:50 PLGAfilmsat the start of the trial was 1.639 but as the films
degraded the PDIincreased significantly (p=0.038) at 30 days to 1.882. Butafter 45
days degradation time the PDI was 1.562 which was not significantly different
(p=0.924) to the controls and was notsignificantly different to the 85:15 PLGA or
65:35 PLGAfilms at 45 days.
Degradation of the 85:15/50:50 PLGA films wasassociated with increased PDI. PDI
increased significantly (p=0.002) from 1.768 at the start of the study to 2.063 at 21
days. Rate of change of PDI increased after 21 days and at 45 days the PDI was
3.119 at 45 days. From 45 to 60 days degradation time there wasa slight increase in
PDI to 3.133. There was little change in the PDI of peak 1 and 2 from the
85:15/LMWt 50:50 PLGAfilms over the study period. At the start of the trial the
PDIof peak 1 was 1.378 and after 75 days degradation the PDI was 1.380, while the
PDI of peak 2 was 1.311 and 1.318 in the controls and after 75 days respectively
(data not shown).
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4.3.5 SEM analysis
The SEM analysis wascarried out using the In-Lens at EHV=Skv. The most reveal-
ing imagesare those taken at X20,000 andtheresults are displayed below.
Figure 4.17 shows a low magnification (X500) image of an 85:15 PLGA film. The
surface of the films prior to start of degradation appears as a smooth surface. But at
higher magnification the surface is revealed to have a rippled texture (Figures 4.18 -
4.22). The appearance of the 50:50 PLGA control films is of a rippled surface com-
parable with those seen on the 85:15 PLGA films at 20K magnification (Figures
4.18a and 4.19a).
Figure 4.17 Low magnification SEM im-
age: Control 85:15 PLGA film. The film
appears as a smooth flat surface at low mag-
nification
 
The effect of polymer degradation on the appearance of 50:50 PLGA films with and
without F-127 is shown in Figure 4.18. The control films (4.18 a and b) have a tex-
tured, rippled surface and the ripples appear more pronouncedin the 50:50 films. At
22 days (Figure 4.18 c and d) the rippled texture of the surface is evident but areas of
the 50:50/F-127 PLGAfilms have rippled areas and areas wheretheripplesare less
prominent. At 45 days (Figure 4.18 e andf) the surface of the films show extensive
pitting, with a highly porousstructure within the bulk of the films. Small surface pits
are evidentin the control and 22 day 50:50/F-127 films PLGA but there was novis-
ual evidence that they were part of a network of pores connected to the inner regions
ofthe film at those stages ofthetrial.
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Figure 4.18 SEM Images. 50:50 PLGA with and without F-127showing the effect of
degradation as incubation time increases. a,c,e 50:50 PLGA films b,d,f 50:50/F-127
PLGAfilms. Controls (a and b), 22day (c and d), 45 day (e and f). The films have a rippled
appearance up to 45 days and after 60 days the surface of the films becomes morepitted and
degraded.
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The effect of polymer degradation on the appearance of 85:15 PLGA with and with-
out F-127 is shown in Figure 4.19. Thereis little obvious change in the appearance of
the 85:15 PLGA films overthetrial, with the rippled surface seen in the controlsstill
apparentat 60 days.
 
Figure 4.19 SEM Images. 85:15 PLGA with and without F-127 showing the effect of
degradation time on the surface of the polymer films. a,c, 85:15 PLGA films, b,d,
85:15/F-127 PLGAfilms. Controls (a and b), 60day (c and d).The control films havea rip-
pled appearanceandthereislittle change in the appearance ofthe films the degradation time
increases.
Control 85:15/F-127 films (Figure 4.19b) have a similar appearance to those of the
85:15 PLGA films, but after 60 days degradation the ripples are not as pronounced
surface indentations are apparent and possible evidence of pore formation at the sur-
face ofthe film (Figure 4.19d).
Changes in the surface morphology were seen in films composed of a blend of
85:15/50:50 PLGAare shown in Figure 4.20. The control films had a rippled surface
similar to that seen in 50:50 and 85:15 PLGA control films. At 30 days the surface
appeared to be covered with small pits but at this stage they did not appear to form a
network of spaces with the inside of the film.
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Figure 4.20. SEM images showing effect
of degradation on 85:15/50:50 PLGA
films. a control, b 30 day, c 60 day. The film
appears more degraded as time increases with
morepits visible after 60 days degradation.
 
 
Figure 4.21. SEM images showing effect
of degradation on 85:15/LMWt_50:50
blend PLGA films. a 22day, b 45 day, c
60 day.
em 
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By 60 days evidence ofpitting was present revealing the inner portions of the poly-
merfilm (Figure 4.20c).
At 22 days the surface of the 85:15/LMWt50:50 films were similar to those in the
85:15/50:50 blend at 45 days. The surface wasrippled but the ripples formed shallow
pits which did not appear to connect to the inner regions of the film. Pits and pores
were not seen in the 85:15/LMWt50:50 films during the study period but at 45 and
60 days increasing amount of very small white deposits were visible on the surface
of the films. Similar deposits were seen in the other types of films but were less nu-
merous and their appearance wasnot associated with a particular stage of degrada-
tion.
 
 
Figure 4.22 SEM images showingeffect of degradation on 6535 PLGAfilms.
After a, 30 days & b, 60 days. Thereis little change in the surface of the films from 30 days
to 60 days degradation time.
The surface morphology of the 65:35 PLGAfilms did not change appreciably during
the study period. At 22 days the surface was rippled and was similar to control films
and at 60 days there waslittle change, although there was some evidence of the white
deposits seen in the 85:15/LMWt 50:50 blend PLGAfilms.
4.4 Discussion
The release rate of drugs such aspaclitaxel from bioerodible devices is both diffu-
sion-controlled and erosion-controlled [3, 22]. Chapter 3 of this thesis and otherstud-
ies e.g. [4, 23-24] have shown thatthe diffusion controlled phase is associated with a
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decrease in M,, of the polymer but with no corresponding massloss and slow release
of the contained drug. As degradation of the polymer continues the 4, decreases to
12-13,000 and soluble monomers are formed, and faster mass loss and polymerero-
sion occurs increasing the porosity of the device resulting in a phase of faster drug
release.
The aim of the studies in this chapter was to alter the degradation profile of 85:15
PLGA to reduce the lag phase in paclitaxel release seen in the diffusion controlled
release phase and to achievea linearrelease profile of the drug.
The methods used aimed to
I. Increase the hydration of the polymer by addition of more hydrophilic co-
polymers and thereby increase hydrolytic degradation rates of the polymer.
IJ. Increase the degradation by blending 85:15 with more hydrophilic, higher GA
content, faster degrading PLGA polymers.
In this study degradation and release of paclitaxel from 50:50 PLGA films was faster
than that seen in 85:15 PLGAfilms the reasons for which are described in Chapter 3
pp 86-91. Degradation of the 50:50 PLGAwasslow over 30 days but at 45 days the
molecular weight of the polymer had reduced to approximately 8,000 at which point
the monomerscansolubilise, leading to a period of faster mass loss and drug elution.
At the end of the study period (60 days) the M4, of the 85:15 PLGA films was 49,900
and degradation of the polymer chains was notsufficient to produce soluble mono-
mers. Mass loss was therefore minimal and release of paclitaxel was diffusion-
controlled and occurring at a very slow rate.
4.4.1 Effect of pluronics
F-127 is a hydrophilic copolymer and addition of up to 8% w/w to PLGA micro-
spheres has been shown to increase polymer hydration [8]. Degradation of PLGA
polymers is via hydrolytic breakage of the ester backbone bond. Increasing the hy-
dration of the matrix in the vicinity of the hydrolytically labile ester bond should in-
crease polymer degradation [9]. F-127 was addedto films of 85:15 and 50:50 PLGA
films with the intention to increase polymer hydration and consequently the polymer
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degradation. The addition of F-127 to 50:50 and 85:15 PLGAincreased the hydra-
tion of the polymerfilms for the first week following immersion ofthe films in PBS.
But after 14 days the water content PLGA/F-127 films decreased to 5-6% while the
water content of the 85:15 and 50:50 PLGAfilms continued to increase reaching a
maximum of 14% and 8.6% respectively. The increased amounts of hydration in the
first week of the trial did not affect the early degradation rate of the films and the
films containing F-127 degraded more slowly than films containing 85:15 or 50:50
PLGAalone.
Addition of F-127 decreased the rate of polymer degradation of 85:15 PLGA (the
effect was not significant) and had no effect on mass loss and paclitaxel elution of
85:15 PLGA films. Little change was seen in the surface morphologyof the films
using SEM. Massloss was faster over the first 30 days of the trial in 50:50 PLGA
films containing F-127 films but this was not associated with an increase in degrada-
tion rate of the polymerorfaster paclitaxel elution. At 45 days similar mass loss and
extensive erosion of the 50:50 PLGA films with and without F-127 had occurred
(Figures 4.5 and 4.18) but more paclitaxel had been released from the 50:50 PLGA
films without F-127.
Wanget al [4] found that the addition of PEG (5 & 10%) increased the hydration and
decreased the T, of 53:47 PLGAresulting in a faster initial degradation rate of the
polymer and eliminated the early lag phase associated with sirolimus release from
PLGA polymers. The lowering of the 7, increased the free volume within the poly-
mer matrix which is favourable for water diffusion into the polymer and the increase
in hydration increased the degradation of the ester bonds resulting in a faster mass
loss and sirolimuselution.
Raiche and Puleo [8] found that adding 8% w/w F-127 increased the hydration of
50:50 PLGA microspheres. Release of lysozyme wastriphasic but the lag phase dur-
ing diffusion controlled release was shorter for the microspheres containing F-127.
In that study hydration of >20% was found in microspheres containing 6% F-127 but
it is unclear how hydration varied(if at all) as the polymer degraded. Yeh atal [21]
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used a ratio of 1:2 PLGA:F-127 to substantially increase protein release from micro-
spheres.
In this study F-127 did not affect the degradation rate of the polymer despite increas-
ing the hydration of the polymer matrix in the early stages ofthetrial. Park er al [9]
found that the degradation rate of PLLA films was not affected by the addition of a
pluronic despite increasing the hydration of the polymer devices. This may be ex-
plained by two opposing effects occurring within the PLGA/pluronic blend. Addition
of the pluronic increases the hydration of the film which should increase the degrada-
tion rate of the polymer. But hydrogen bond formation between the pluronic and the
terminal carboxylic groups of PLLA/PLGA polymers reduces the contribution of
autocatalysis from free carboxylic acid resulting in a reduced rate of degradation.
Despite increased hydration resulting in hydrolytic cleavage of the ester linkage in
the PLGA,the terminal carboxylic groups generated by hydrolysis are not available
for further catalytic degradation because of immediate hydrogen bonding with the
ether bonds of the pluronic [9].
Hydrophilic pluronics such as F-127 can quickly leach out of PLLA films [9] and
this may explain the increased mass loss from 50:50 PLGA films containing F-127.
But there was no difference in mass loss seen between 85:15 PLGA films with and
without F-127. A possible explanation for this observation is that pluronics can ac-
cumulate towards the surface of PLGAfilms and the extent to which this occurs is
dependant on the type of PLGA and the hydrophobicity of the pluronic [25]. Surface
enrichment of pluronics in PLGA films decreases with increasing GA content [25]
and so there may havebeen less accumulation at or towards the surface of the 85:15
PLGA films as compared with the 50:50 PLGA films. If molecules of F-127 were
distributed more towardsthe surface of the 50:50 PLGAfilmsit is possible that these
molecules could have been leachedat a faster rate than F-127 molecules from within
85:15 PLGA films where there would be less surface enrichment of pluronic. The
molecules of F-127 may have been entangled with the 85:15 PLGA molecules within
the film and been unableto diffuse out into the release medium. Addition of F-127 to
85:15 PLGAfilmsresulted in higher PDI and lower molecular weights (Figure 4.6 &
4.8) during the study period indicating a widerdistribution of molecular weights of
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polymer chains in the film which may be due to the retention of F-127 molecules.
Rapid leaching of F-127 at or near to the surface of 50:50 PLGA films may explain
the initial high loss of polymer mass overthe first 3 days which was higher than in
the other films (Figure 4.5). But, interestingly this early mass loss was not associated
with an increased early burst release of paclitaxel (Figure 4.7). Overall there was no
difference in the PDI of 50:50 PLGA films with and without F-127, perhaps due to
early loss of the pluronic from the film.
Formation of liquid-crystalline regions within the polymer matrix of PLGA/F-127
blends occurs as the polymer becomes hydrated affecting the diffusivity of a drug
through the pores and channels of the polymer [9]. The PPO block of F-127 has been
found to form a strong hydrophobic interaction with PLGA while the PEO segments
orient way from the surface into the aqueousareas of the matrix [9, 26]. Hydropho-
bic drugs such as doxorubicin can belocalised into pluronic micelles by hydrophobic
interaction between the drug and the PPO blocks. Paclitaxel, being a hydrophobic
drug could similarly become associated with the PPO segment of a F-127/PLGA
blend affecting the ability of the drug to diffuse through the film into the release me-
dium [26]. In this present study 45% ofpaclitaxel was released from the 50:50 PLGA
films at 45 days. Addition of F-127 significantly reduced the release of paclitaxel in
50:50 PLGAfilms with only 29% being released at 45 days despite similar polymer
erosion rates to that of the 50:50 PLGAfilms. While it is unclear what the nature of
liquid-crystalline phases formed in the pluronic blend films in this study, if such in-
teractions between paclitaxel and the PPO blocks was present then this may explain
the difference between paclitaxel elution in 50:50 PLGA and 50:50 PLGA/F-127
blendfilms.
Addition of PEG had noaffect heparin release from 80:20 PLGA devices [11]. In
this case plasticisation occurred in the polymer reducing the 7, in the plasticized
polymerbutthis did notresult in faster drug elution despite a significant reduction of
M,, of the polymer. The authors attribute this to an increase in the melting enthalpy
of the polymer which in turn caused re-crystallization of residual polymer units that
were richer in lactide units which was not favourable to drug release [11]. Addition
of 10% w/w MePEGto 85:15 and 50:50 PLGAresulted in reduction of the 7, of the
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polymers to around room temperature but the effect on paclitaxel elution was mini-
mal. 30% w/w MePEGwasrequiredto significantly increase the release of paclitaxel
from 50:50 PLGA whentherelease profile became biphasic with a fast release phase
of around 7 days followed by a slower phase of diffusion controlled release. The ad-
dition of hydrophilic copolymers such as pluronics can hydrate and cause plasticiza-
tion of a polymer. But the effect on drug release behaviour is often a compromise of
a numberof processes within the matrix some of which enhance release while others
impededrugelution [9].
4.4.2 Effect ofPLGA blending
The degradation rate and massloss profile of the 85:15/50:50 PLGA films wasal-
most an average of that seen in the 85:15 and 50:50 PLGAfilms (Figures 4.10 &
4.12). The 85:15/50:50 PLGA films degraded at a faster rate than the 85:15 PLGA
films and onset of polymer massloss occurred after 30 days whereas there waslittle
change in polymer massof the 85:15 PLGA films. The delay in the onset of polymer
mass loss (30 days) was similar in the 50:50 PLGA films to that seen in the
85:15/50:50 blend but the rate of mass loss was then faster in the 50:50 PLGA films:
approximately 22% of the mass had been lost in the 50:50 PLGA films at 45 days
whereas comparable amounts of mass loss was only observed in the 85:15/50:50
PLGAblendfilmsat 60 days.
Elution of paclitaxel from 85:15/50:50 PLGA films commenced after the onset of
polymererosion and at 60 days 22% ofthe paclitaxel had been released as compared
with 8.5% from the 85:15 PLGA films. But paclitaxel release was delayed as com-
pared with the 50:50 PLGA films where approximately 43% of the paclitaxel had
been released by 45 days.
Increasing the GA content of a polymerincreases the hydrophilicity of a polymer and
the hydration of 85:15 PLGA films should be increased by blending 50:50 PLGA
into the film. But the water content of the 85:15 PLGA films was higher than that
seen in the 50:50 PLGA and the 85:15/50:50 blend PLGAfilmsin this trial (Figure
4.9). Since the rate of water diffusion into a PLGAfilm is generally greater than the
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rate of hydrolysis, the polymer degradation may notbe affected by the hydration rate
[8]. The GA units are more hydrophilic than the LA units and hydrolysis occurs pref-
erentially on the GA linkages because the methyl pendant group on the LA unit steri-
cally hinders hydrolysis [14, 24, 27]. Hence faster degradation is associated with
higher GA content. In this study overall matrix hydration appears to be less impor-
tant to PLGA degradation than the GA content of the polymerfilm andthe ability of
the water molecules within the hydrated device to attack the ester linkages.
The rationale behind blending 50:50 PLGA into 85:15 PLGAfilms wasto create a
matrix with areas of higher GA content to create faster degrading regions within the
polymer matrix. Faster degradation of these regions would lead to spaces and cavities
through which the paclitaxel could diffuse at a faster rate relative to 85:15 PLGA
films. The overall GA:LA ratio in a 1:1 blend of 85:15/50:50 PLGA is 32.5:67.5,
comparable to 65:35 PLGA. But there was no obvious difference in polymer mass
loss and paclitaxel elution between the 85:35/50:50 blend PLGA films and 65:35
PLGAfilms during the course of this study. However the PDI change and surface
morphologyofthe 85:15/50:50 blendis different to that of the otherfilms.
Figure 4.16 showsthe change in PDI during the degradation study. Atthe start of the
trial the 85:15/50:50 blend PLGA,85:15, 65:35 and 50:50 PLGA films had a similar
PDI. As degradation proceeded the PDI of the 85:15/50:50 blend PLGA films in-
creased significantly to 3.133 at 60 days. The PDI of the other films increased
slightly during degradation with a PDI of 1.788 and 1.76lat 60 days for the 85:15
and 65:35 PLGAfilms respectively. This indicates a wider distribution of MWt’s of
the polymerchains within the 85:15/50:50 blends and the distribution increases with
degradation time. It has been shown that within a degrading polymer the slow de-
grading surface of the polymer matrix can act as a semi-permeable diffusion barrier
leading to entrapment of degraded oligomers within the device [28]. It can be envis-
aged that in a PLGAblend, lower molecular weight fragments created by hydrolysis
of the 50:50 PLGA chains may becomeentrapped within the polymer bulk by a sur-
face of less degraded 85:15 polymer chains resulting in a wider distribution of
MWt’softhe polymerchains in the film and hence an increased PDI.
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The surface morphology as revealed by SEM showed differences between the
85:15/50:50 blend PLGA films as compared with the other films. At the start of the
trial the films had a textured and rippled appearance. There waslittle change in the
surface of the 85:15 and 65:35 PLGAasthe films degraded in this study (Figure 4.19
and 4.22). But as degradation proceeded the surface of the 85:15/50:50 blend films
changed and the textured appearance ofinterlocking ripples was replaced by a more
open, cratered appearance at 30 days (Figure 4.20) and by 60 days larger pores could
be seen connecting to the inner regions of the film. The reason for the appearance of
the ‘craters’ is unclear, but it may represent faster solubilisation of polymer from
50:50 PLGAthat was located at the surface of the film while the slower degrading
85:15 polymerretains its structure. There were no pits or pores seen on the 65:35 or
85:15 PLGA filmsandit is conceivable that had the degradation time been extended
faster massloss and paclitaxel elution may have becomeapparent in the 85:15/50:50
blend films.
Blending of polymers of differing composition or molecular weight mayalter drug
diffusion properties of the device by creation of water channels in the device created
by faster degrading regions of the device where faster degrading polymersare pre-
sent. Kunouet a/ [16] found that in a PLLA blend of 5kDA and 70kDa PLLA,in the
faster degrading 5kDa PLLA regions water channels were formed connecting the
surface to the inner regions of the implant device resulting in faster ganciclovir elu-
tion as compared with PLLA (70kDa). Faster degradation of _LMWt 50:50 PLGA
regions in a blend with 65:35 PLGAresulted in the creation of cavities and spaces
within the polymer matrix through which the ganciclovir molecules could diffuse out
into the external medium [20]. Duvvuri et al [5] reduced the diffusion controlled re-
lease phase of ganciclovir from 79 days to just under 10 days by blending a 1:1 ratio
of 8 kDa 50:50 PLGA with 75:25 PLGA. Addition of 8 kDa 50:50 PLGA had a plas-
ticizing effect on 75:25 PLGAandthe biggest reductions in 7, occurred with higher
content of 8 kDa 50:50 PLGAin the blend.
GPC data from degrading 85:15/LMWt 50:50 PLGA was bi-modal with 2 distinct
peaks (Appendix, Figure A.5) and molecular weight change in both peaks was de-
termined. The faster eluting peak was from the 85:15 PLGA componentandthis de-
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graded from 86kDa to 35kDa over the 75 day study period. The slower eluting peak
wasfrom the 50:50 PLGA component which degraded slowly from a M,, of 6.6kDa
at the start of the study to 5.5kDa after 75 days degradation. Mass loss only takes
place when the MWtof the PLGA has degradedto a critical value, usually around
10kDa [28-29]. The polymer chains from the 50:50 PLGA component in the blend
films would be below this critical value and would therefore be expected solubilise
readily and create spaces and cavities within the film to enable release of paclitaxel.
Addition of low molecular weight (LMWt) 50:50 PLGA to 85:15 PLGAresulted in
faster mass loss and paclitaxel elution as compared with 65:35 PLGA and the
85:15/50:50 blend PLGA films. The surface morphology after 22 days incubation
was comparable with that of the 85:15/50:50 blend at 30 days with a cratered appear-
ance on the surface of the films. There was no evidence of pores or pitting on the
films, as degradation proceeded but increasing mounts of a white deposit was visible
at 60 and 75 days. It was not possible in this study to determine the nature of the
white deposits.
Acid degradation products have been shownto lower the pH of release media con-
taining degrading PLGA devices [27]. Although the PBS release media was changed
weekly, the pH of the release medium in trials TD1 & 2 was found to increase
slightly as degradation time increased (Figures 4.1 and 4.2). The pH change wasthe
samein all groups and wasalso seen in the controls (where a blank Teflon disc had
been incubated in PBS) andsois unlikely to be an effect of PLGA degradation. The
pH of release media can have an effect on PLGA degradation, but such effects are
only seen with release media with very acid or very basic pH [27] and the changes
seen in TD1 and TD2are unlikely to have had an effect on polymer degradation or
drug elution.
The degradation rate of 85:15/50:50 blend was measured in both TD1 and TD2 and
the data shows that in TD2 degradation rate was slower with equivalent stages in
degradation, mass loss and paclitaxel elution being delayed by approximately 15
days. The reason for this difference is possibly due to problems encountered in the
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warm room and for a large portion of TD2 the incubation temperature was a few de-
grees below 37°C.
Despite this standard procedure of film production there was some difference both
between the groups and within groups in terms of original mass of polymer. How-
ever once the samples had been randomisedinto the various time points there was no
difference in the original amount of polymer. Thus it is safe to assume that differ-
ences in the degradation rate and drug release were due to the composition of the
polymerand not dueto differences in thicknessofthe film or drug loading.
4.5 Conclusions.
The addition of F-127 had no effect on PLGA degradation and may have reduced
paclitaxel elution in this study. Addition of 8% w/w Pluronic F-127 to 85:15 or 50:50
PLGAcanincrease the hydration of polymerfilms. The increased hydration may in-
crease the rate of hydrolysis of the polymerfilm but rates of autocatalysis within the
matrix of the polymer are reduced due to hydrogen bonding between the carboxylic
end groups of PLGA and the PPO segment of F-127 resulting in no overall effect on
the degradation rate. Release of paclitaxel from PLGA films containing F-127 may
be reduced due to a hydrophobic interaction between the drug and micelles of PPO
and the polymersurface. Inclusion of F-127 in PLGA polymers does not appear to be
an effective method to reducethe diffusion controlled release phase ofpaclitaxel.
Blending a 1:1 ratio of 50:50 PLGAinto 85:15 PLGA advanced the onset of polymer
erosion and reduced the length of diffusion controlled release (lag phase) of pacli-
taxel as compared with 85:15 PLGA. The onset of polymer erosion was further ad-
vanced and the diffusion controlled release phase of paclitaxel was shortened by us-
ing a low molecular weight 50:50 PLGA blended with 85:15 PLGA. This demon-
strates that polymer blending can be used to effectively increase the release of pacli-
taxel from PLGA devices. Further work could be doneto fine tune the ratio of poly-
mer blends utilized in order to optimise release profile for coronary stent applica-
tions.
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Discussion
Despite the successful use of DES since their introduction in 2002 in reducing rates
of in-stent restenosis (ISR) and the need for subsequent revascularisation (TVR)
procedures as compared with BMSand balloon angioplasty [1-2], concerns have
arisen regarding late stent thrombosis (LST) which may be due to delayed arterial
healing and re-endothelialisation of the artery wall [1, 3-5] which may be an unin-
tended result of the action of the drugs currently used in DES. Additionally in a small
number of cases hypersensitivity reactions to the polymer coatings used on DES
have been reported [6-9].
For paclitaxel, differing release profiles can have a profound impact on efficacy [10]
and a principal target of current research is on the development of biocompatible,
biodegradable polymers that would permit controlled drug release whilst minimizing
effects such as delayed arterial healing [1]. Complete bioresorption of the stent coat-
ing would reduce the tissue exposure to the polymer and reduce any short and long
term inflammatory and thrombotic events associated with exposure to the currently
used durable polymers [11]. Additionally complete elution of the contained drug
would ensurethat there are no long term consequences with the large amountof drug
that remains in the polymer coating of the currently used Taxus DES[10].
In this study the degradation and paclitaxel elution profile of two biocompatible, bio-
degradable polymers, TyRx, a tyrosine based polyarylate and Poly(p,-lactide-co-
glycolide) was assessed for their potential as coatings for DES. The degradation of
the polymers was determined using GPC and related to polymer erosion and pacli-
taxel elution and to the physical appearanceofthe stent coating.
5.1 In vivo tissue chamber models andin vitro testing of DES.
The rat subcutaneous tissue chamber modelfacilitates the study of degradation and
drug elution of DES coatings in complete interstitial exudates fluid environment. In
this model polymer degradation and drugreleaseis in in vivo physiological medium
at body temperature and pH. Howeverthis model, in commonwith in vitro models,
does not take into account all of the conditions experienced by a stent in situ and
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does not replicate the effect of factors such as flow dynamics, shear stress, conti-
nuouspulsatile effects and strut encapsulation by SMC.
The polymerundertest in this study, namely TyRx and PLGA,are degradedvia hy-
drolysis. Some polymersare also susceptible to degradation via enzymatic cleavage.
There are no studies indicating the susceptibility of TyRx to enzymatic degradation.
There are conflicting reports on the role of enzymes in degradation of PLGA with
some suggesting enhanced degradation rates in the presence of enzymes while other
have demonstrated no effect (for review see [12-13]). However there was no differ-
ence in the degradation and paclitaxel elution profile of PLGA or TyRx coated stents
from the rat tissue chamber model as compared with an in vitro study using a release
medium comprising PBS and Tween, pH 7.4 at 37°C (unpublished data). This sug-
gests that in this study degradation was predominantly by hydrolysis with negligible
effects due to enzymatic cleavage.
The effects of flow dynamics are not assessed in the tissue chamber model (or in
most in vitro models). Models incorporating flow have shown that degradation of
PLGAfilms and scaffolds is faster under static conditions than in flow conditions
[14-15]. Additionally the tissue chamber model is unable to replicate the effect of
placementof the stent adjacent to the artery wall on polymer degradation and drug
delivery. Models have been developed to replicate the effects of arterial contact by
placing the stent in flow chambers and using hydrogels as a simulated artery wall
[16]. Lower release rates of doxorubicin were observed when the stent was placed
adjacent to the hydrogels as compared with the stent having no adjacent compart-
ment in the flow chamber[16].
Howeverdespite these limitations with the in vivo tissue chamber model and stan-
dard in vitro models these tests have a high value for anticipating in vivo drug release
in a clinical setting [16]. Kammather a/ [17] foundthat the release rates of paclitaxel
from the Taxus coronarystent in in vitro studies using PBS/Tween 20 medium was
comparable to that observedin stents implanted into rabbit iliac arteries. DES which
posses favourable properties in terms of drug release, polymer coating integrity and
dissolution in the rat tissue chamber model are promising candidates for further in
vivo testing in animal artery models. The tissue chamber modelis an equivalent pre-
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dictive model to the in vitro models using physiological conditions in predicting the
degradation and drug elution of PLGA and polyarylate stent coatings. The modelis
likely to be a better predictor of in vivo pharmacokinetics when the test polymer is
degraded both hydrolytically and enzymatically.
5.2 Degradation and paclitaxel elution of TyRx stent coatings.
Tyrosine derived polyarylates have been used for the release of water soluble pep-
tides [18], anticoagulants [19] and show a diffusion controlled release mechanism of
low molecular weight substances [20]. Tyrosine derived polymers tend to have a low
uptake of water and since the monomerscreated during degradation are not readily
water soluble polymererosion is very slow and occursonly at the end of the degrada-
tion process [19].
In chapter 2 the degradation and drugelution profile of a 400g coating of a tyrosine
based polyarylate (TyRx) containing 2.5%w/w (10g) paclitaxel on al6mm Liberté
stent was determined using an acellular in-vivo model. As the polymer degraded the
molecular weight (Mw) of the polymer decreased from around 36,000 to 12-13,000
after 60 days implantation (Figure 2.4). After 100 days the degradation rate de-
creased and the Mw remainedat around 4,000 from 150 days onwards. Addition of
paclitaxel had no effect on the degradation rate of the polymer (Figure 2.4), but pa-
clitaxel elution was very slow dueto the slow erosion of polymer from the stent
(Figure 2.9). There was no measurable release of paclitaxel after 15 days degradation
and after 250 days 6.87 +2.6 ug of paclitaxel remained on the stent. Release was
faster after 250 days as polymererosion occurred and at 280 days approximately 7
ug of the paclitaxel had been released.
5.3 Degradation andpaclitaxel elution from PLGAstent coatings.
PLLA and PLGA are among the most commonly used biodegradable polymers for
sustained drug release. They are biocompatible and degrade by simple hydrolysis of
the ester bondsinto natural metabolites, lactic and glycolic acid, which are easily re-
moved from the body by normal metabolic pathways[21].
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The elution of hydrophobic drugs such as paclitaxel is diffusion controlled and ero-
sion controlled from PLGA devices and the duration of each phaseis dictated by the
degradation rate of the polymer matrix. Increasing the GA content of PLGA in-
creases the degradation rate and the drug elution properties of the device [12]. In-
creasing the thickness of the stent coating increases the polymer degradation rate but
reduces the elution rate of paclitaxel (for the same drug: polymerratio). The drug
itself can affect the degradation of the polymerandthusits elution [22].
In chapter 3 the effect of adding 5%w/w (20ug) paclitaxel on the degradation of a
400ug coating of 50:50 PLGA on a 16mm Liberté stent was examined and addition
of the drug was found to have no effect on the degradation rate of the polymer (Fig-
ure 3.3) or cause cracking and delamination of the coating as the polymer degraded.
Secondly it was shown that elution of paclitaxel was bi-phasic with an initial lag
phase in which elution was diffusion controlled followed by a faster release phase
(erosion controlled) associated with polymer mass loss. The lag phase lasted about
15 days, and only about lug of paclitaxel was released during that period. After 30
days implantation approximately 15.5ug of paclitaxel had been released and at 45
days all the polymer had been solubilised from the stent along with the remaining
paclitaxel.
A lag phase was not detected using a 200pg coating of 50:50 PLGA with 5%w/w
paclitaxel possibly because at the first sampling time erosion controlled release had
already commenced.Elution of paclitaxel was faster in the thinner coating and at 15
days approximately 4.8ug of paclitaxel had been eluted. All of the paclitaxel (8.512)
had been eluted after 30 days and the polymer had been completely solubilised at 45
days.
Increasing the GA content of the polymerincreased the duration of the lag phase and
the residency time of the polymer (Figure 3.4 & 3.5). A lag phase of 30 and 60 days
wasseen for the 75:25 and 85:15 PLGA coated stents respectively. During this phase
there was no measurable release of paclitaxel from the 85:15 coatings but around
3g of paclitaxel was released from the 75:25 coatings. The remainderof the pacli-
taxel (approx 17g) was eluted over the following 45 days and after 75 days pacli-
taxel could not be detected on the 75:25 PLGA coated stents. The paclitaxel wasre-
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leased over 60 days from the 85:15 PLGA coatingsin a linear release profile follow-
ing the lag phase. Complete solubilisation of the 75:25 PLGA coatings had occurred
by 105 days but 85:15 PLGA wasstill detectable on the stent at 120 days which was
the end of the study period.
The elution of paclitaxel was dependent on the degradation of the PLGA coating.
During the lag phase the Mw of the polymer was decreasing rapidly but there was
little loss of polymer mass during this period (Figure 3.16) and the polymer coating
remained intact (Figure 3.7 and 3.8) and the release of paclitaxel was slow. Once the
polymer Mw haddecreased to around 12,000-13,000 the polymer fragments become
soluble in the aqueous media and the rate of polymer erosion increased creating a
porous structure within the stent coating which facilitated faster diffusion of pacli-
taxel. The dependence of polymer mass loss and drug elution on the degradation
state of polymer has been demonstrated in other studies [23-26].
5.4 Paclitaxel elution profiles of DES compared with PLGA and TyRx coated
stents.
Inhibition of ISR using stents with high doses of paclitaxel is associated with incom-
plete arterial healing and cytotoxic effects of paclitaxel [27]. The rapid elution (63%
within 14 days) of paclitaxel from stents coated with poly(lactide-co-L-caprolactone)
with an initial drug content of 207ug of paclitaxel resulted in reduced rates of ISR
but was associated incomplete healing and low rates of re-endothelialization [28]. A
10g dose of paclitaxel released over 10 days was found to have higher indexes of
injury (such as fibrin deposition and eosinophilic deposits) as compared with the
same dose released over 30 days [10].
Lower doses of paclitaxel delivered over a minimum period of time may provide
similar efficacy as the existing paclitaxel DES in preventing ISR but with reduced
effects such as delayed endothelial healing, inflammation, and LST, while complete
bioresorption of the polymer coating may reduce short and long term inflammatory
and thrombotic events caused by hypersensitivity reactions to the durable polymer
coatings currently used [11].
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The amount and duration of paclitaxel released from the DES has an effect on both
the efficacy of the stent in reducing ISR and on delayedarterial healing and vascular
re-endothelialization. Rapid release of a 8.6u.g dose of paclitaxel over about 1 week
from a chondroitin coated stent did not reduce neointimal thickening in New Zealand
White rabbits but a higher dose (20ug) of paclitaxel released within 1 week was
found to reduce ISR for up to 90 days but was associated with incomplete healing,
local artery inflammation and fibrin deposition [29]. Jabara et a/ [30] found that re-
lease of approximately 10ug of paclitaxel from a PLGA coated stent over 80-100
days waseffective at reducing ISR in a porcine model at one month, but wasnotbet-
ter than BMSat 3 months. Release of the drug wasvia a rapid release phase over 20
days in which approximately 3.5ug of paclitaxel was released, followed by a period
of slowerrelease to 60 days after which the remainderof the paclitaxel wasreleased.
Slowing the rate of release was found to mitigate the toxic effects of paclitaxel seen
in higher drug loadings [30]. Studies from animaltrials do not translate directly to
humansandthereis a 1:6 ratio for time effects in pigs to humans(i.e. an effect of 90
days in pigs is equivalent to 18 months in humans) [31-32].
The PICEStrial explored the effect of variable dose and release rates of paclitaxel on
humans using the Conorstrut-filled paclitaxel eluting stent. The results showed that
shorter delivery of a 10ug dose over a week resulted in no improvement over BMS
but the same dosage released over 30 days resulted in inhibition of ISR. The results
were confirmed in the EUROSTAR and COSTARI trials but the formulation was
inferior to the Taxus SRstent after 30-90 days in reducing in-stent neointimal hyper-
plasia in the COSTARII trials [10-11, 32]. The slow release (SR) Taxus stent con-
tains a total of 108g of paclitaxel and mostof the drug that is released is in the form
of an initial burst release over the first few days after implantation and after 14 days
approximately 1-2ug of paclitaxel are released from the SR formulation [33]. By 30
days approximately 7.5% (8ug) of the paclitaxel is released [10, 32] but approxi-
mately 90% of the drug remains sequestered within the polymer coating without fur-
ther measurable loss at 6 months after implantation [32, 34]. There appears to be lit-
tle difference in paclitaxel dose and release rate between the Conor stent and the
Taxus SR stent in COSTARII, andit is unclearif the difference in efficacy is due to
differences in stent designs or due to any further anti-restenoic effect of the paclitaxel
remaining on the Taxus SRstent after 6 months.
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The ideal elution rate for paclitaxel has yet to be elucidated [32], but it would appear
from the studies outlined above that between 10-20ug of paclitaxel needs to be
eluted in a steady mannerduringthe first 30 days following implantation and perhaps
further release is required over 90 days to maintain performance.
The paclitaxel elution data from the TyRx and PLGAstudies is summarised in Table
5.1. In the formulation used in chapter 2, TyRx would not appear to be a good candi-
date as a coronary stent coating. Although tyrosine based polyarylates have demon-
strated good biocompatibility and are not cytotoxic [19] complete bioresorption of
the polymeris very slow and polymerwasstill evident on the stent at 280 days. This
leaves the possibility of polymer fragmentation causing blockage of small capillaries
and maylead to long term inflammatory and thrombogenic events [35].
Table 5.1 Degradation of polymer stent coatings. Summary of effect of polymer on
elution of paclitaxel.
 
 
       
. Duration Paclitaxel Duration of Complete Completeug Pacli- . ‘of lag (ug) erosion Elution of polymer
polymer names phase eluted in controlled paclitaxel solubilisation
/SeeML (days) lag phase phase(days) (days) (days)
TyRx
400ug 10 240 3.1 >50 >290 >290
coating
50:50
PLGA none not
200ug LY detected applicable a0 ou 45
coating
50:50
PLGA400ug 20 15 1.4 15 45 45
coating
75:25
PLGA400ug 20 30 3.2 45 75 105
coating
85:15
PLGA Non de-400ug 20 60 saeied 60 120 >120
coating.
Paclitaxel per stent refers to the initial amountof paclitaxel on the stent. The amountof pa-
clitaxel eluted in the lag phase is shown in ug. The duration of the erosion controlled phase
is the time from the end of the lag phase to the complete elution of paclitaxel. Complete
solubilisation of the polymerrefers to the time at which no polymercould be detected on the
stent using GPC.
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No burst release of paclitaxel was observed but, significantly there was no measur-
able release of paclitaxel in the first 15 days of the trial and at 90 days only about
2.25 ug had been released. Based on previousstudies, this would suggest that insuf-
ficient amounts of paclitaxel are released overthe desired timescale to be effective in
reducing ISR.
Elution of paclitaxel from PLGA was muchfaster than from TyRx. The higher drug
loading in PLGA as compared to TyRx (5% and 2.5% respectively) maybepartially
responsible but it is more likely to be due to the faster degradation with more rapid
massloss due to the higher water solubility of the degraded monomers of the PLGA
polymer coatings as compared with TyRx [19].
A 5%w/w doseofpaclitaxel in a 200pg coating of 50:50 PLGA hadbeen eluted by
30 days with complete polymerdissolution by 45 days which wassimilar to that seen
in COSTAR I, EUROSTARand PISCEStrials which were efficacious in reducing
ISR [10-11]. But based on the observations of the COSTARII trial [11] and the work
of Jabara et al [30] this may beinsufficient to maintain prevention of intimal hyper-
plasia for longer periods up to 90 days and beyond. Additionally, approximately
4.8ug of paclitaxel was eluted overthe first 15 days of implantation which is higher
than that from a SR Taxus DESand as such may cause problemsassociated with de-
layed arterial healing and slow re-endothelialization although release rates of a simi-
lar magnitude from PLGAcoated stents did not have a detrimental effect on healing
in porcine arteries [30]. Additionally, assuming a steady release of drug from a
10ug/30 day DES formulation, 5yg of paclitaxel would be expected to be released by
15 days and no adverse effects were reported from such a release profile from the
PISCEStrial [10].
Release ofpaclitaxel (approximately 15ug) from the 400yg coating of 50:50 PLGA
with 5%w/w paclitaxel over 30 days, is greater than the 10ug/30 day duration dose
released from Conorstents [10-11, 36] and from PLGA coated stents in a porcine
model [30] and so would be expected to significantly reduce ISR at least to 3
months. But paclitaxel release was slow to 15 days when only |g of paclitaxel was
released which may reduce the formulations effectiveness in reducing ISR while the
rapid release phase of approximately 15g of the paclitaxel over the following 15
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may have adverseeffects such as delayedarterial healing and re-endothelialization.
The effectiveness of the formulation mayalso be limited due to the duration of pacli-
taxel releasesinceall the paclitaxel had been released from the stent by 45 days.
A longer duration of paclitaxel release of 75 and 120 days respectively for 75:25 and
85:15 PLGA coatings was observed using 400ug polymer coating with 5%w/w pa-
clitaxel. But there waslittle or no release of paclitaxel from these two formulations
during the first 30 days following implantation and it is during this period that the
drug needsto be released to be effective in preventing proliferation of the smooth
muscle cells [10].
5.5 Modification of paclitaxel elution from PLGA devices.
Therelease profile of paclitaxel from PLGA in the study by Jabara et al [30] con-
sisted of a rapid release phase over the first 20 days of implantation during which
approximately 30% of the drug was released This was followed by a slower phase of
release lasting for about 25 days, a second rapid release phase of approximately 10
days in which some 40% ofthe drug was released anda final period of slow release
in which the remainder of the paclitaxel was released. This is at odds with the bi-
phasic release profile from PLGA coatings seen in chapter 3 of this study and from
other drug release studies e.g. [26]. The GA:LAratio is not given in the study by Ja-
bara et al [30] and so direct comparison with the paclitaxel release studies from
PLGAin chapter3 is difficult. Howeverthe release profile of PLGA can be modi-
fied to reduce or eliminate the lag phase and produce a more evenelution of the drug
over the desired release period [26, 37-39]. A reduction in the duration of the lag
phase while maintaining the overall duration of drug release would improve the use-
fulness of both the 85:15 and 75:25 PLGAcoatings. 85:15 PLGA waschosenfor fur-
ther study dueto its longer duration of drug release of over 90 days.
Blends of polymers form phase separated regions within the polymer matrix and can
exhibit advantageous properties for the desired drug release profile that the individ-
ual polymers do notposses [40]. In chapter 4 of this study two approaches were used
to modify the paclitaxel elution profile from 85:15 PLGA films by (i) blending low
molecular weight hydrophilic copolymers(ii) blending PLGA polymers with higher
148
Chapter 5
GAcontent with different molecular weights, into 85:15 PLGA films. The study was
carried out in vitro using polymerfilms on coated onto PTFE discs incubated at 37°C
in PBSat pH7.4.
The rationale behind polymer blending wasthat including more hydrophilic copoly-
mersinto the films would increase the hydration ofthe films and so increase the rate
of ester bond hydrolysis within the PLGA polymer, leading to faster early degrada-
tion rates and consequently faster drug release. Blending 85:15 with PLGA polymers
of higher GA content would increase degradation rate due to the increased hydro-
philicity of the GA units as compared with the LA component, and since the GA
componentis more easily degraded than the LA units increasing GA content should
lead to faster degrading areas within the polymer matrix. Additionally, the solubilisa-
tion of the faster degrading PLGA domainsor leaching out of the matrix of the solu-
ble F-127 chains would create a series of small pores and channels through which
paclitaxel would more quickly and easily diffuse out of the film and into the incubat-
ing medium [41].
The pluronic F-127 is a hydrophilic triblock copolymer of poly(ethylene oxide)
(PEO) and poly(propylene oxide) (PPO) with a MWtof 12,300, 70% of which is
made up from PEO, and hydrophilic and hydrophobic pluronics been used to modify
release of proteins from PLGA matrices [40, 42-43].
Raiche and Puleo [42] found that blending 8%w/w F-127 was optimum for improv-
ing water uptake into PLGA devices and so a ratio of 92% PLGA:8% F-127 was
chosen for this study. In chapter 4 of this thesis it was found that the addition of F-
127 increased the hydrationrate of the films but after 14 days incubation the blended
films had lower water content than the 85:15 or 50:50 PLGA films. But despite the
increase in hydration overthe first 14 days ofthetrial, addition of F-127 had nosig-
nificant effect on the degradation rate, polymererosion or paclitaxel elution of 85:15
PLGAfilms. Increased mass loss occurred in 50:50 PLGAfilms blended with F-127
but this was not associated with an increase in polymer degradation or paclitaxel elu-
tion. Higher concentrations of pluronics of up to 75% w/w have been used in PLGA
matrices to alter degradation and drug releaseprofiles resulting in more release ofthe
contained drug during the burst period followed bya period of slow drugrelease, the
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extent of the burst being dependant on the content of pluronic in the PLGA device
[40, 43]. Such an elution profile would not be suitable for paclitaxel release from
coronary stents especially if toxic amounts of drug were released during the burst
period. Thereis also concern about the creation of domainsof pluronics dueto load-
ing high fractions of pluronic into PLGA devices. F-127 is highly water soluble and
will easily dissolve creating a highly porous structure [42]. While such a structure
may enhancepaclitaxel elution there is a risk that this would weaken the remaining
polymer coating making it more prone to delamination.
The effect of blending polymers with differing GA content and MWton the degrada-
tion and paclitaxel elution of 85:15 and 50:50 PLGA wasstudied in trial TD1. The
length of the lag phase in paclitaxel release and the time for the onset of polymer
erosion was slower by about 15 days from 50:50 PLGAfilms in the PTFE in vitro
trial as compared to that seen in 50:50 PLGA coated stents in the in vivo trial in
chapter 3 (Figure 3.4, 3.5, 4.12 and 4.14). The reasonsfor the slower degradationrate
seen in TD1 are unclear. The in vivo degradation rate and drug release profile of
PLGAhasbeen shownto befaster than in in vitro models due to the presenceoflip-
ids and enzymes in the former system [30] but this is contentious [12]. The
drug:PLGA ratio was the same for both trials but there was about 3.7ug/mm? of
polymeron the stents as compared with approximately 6ug/mm’ of polymer on the
PTFE discs and as shownin chapter3, polymer erosion and drug release is faster
from thinner coatings. Additionally due to the geometry of the stent there may be a
higher surface area of the polymer exposed to the aqueous media on the stent as
compared with the PTFE films which mayfacilitate faster diffusion of degraded
soluble oligomers into the release medium andhenceincrease paclitaxel elution.
A 1:1 ratio blend of 50:50PLGA and 85:15 PLGAincreased the degradation rate,
rate of mass loss and reduced the length of the lag phase ofpaclitaxel elution of the
films as compared with 85:15 PLGA (Figures 4.10, 4.12, 4.14). The lag phase before
onset of paclitaxel elution was 45 days, some 15 days slower than for the 50:50
PLGAfilms. There was a lag phasein paclitaxel release from the 50:50 PLGA and
85:15/50:50 blend PLGAfilms of 30 and 45 days respectively. Onset of mass loss
was after 30 days degradation and was slower in the blended films than in 50:50
PLGAfilms. Taking into account the delay in the onset of drug release and polymer
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erosion of about 15 days in the PLGA films as compared with PLGAcoatedstents, a
lag phase in paclitaxel release of a 1:1 blend of 85:15/50:50PLGA on a stent would
be about 30 days in a comparable in vivo model as used in chapter 3. While this
would represent a large reduction in the length of lag phase in paclitaxel release as
compared to 85:15 PLGAit maystill be too long for an effective formulation for a
coronary stent application.
The overall ratio of GA:LA of 65:35 PLGAis similar to that in a 1:1 blend of
85:15/50:50 PLGA but it may be expected that in the blend polymer there may be
areas of higher GA:LA ratio within the polymer matrix where 50:50 polymer chains
are located resulting in faster degrading areas within the film. But there was no dif-
ference in the duration of the lag phase in paclitaxel elution and onset of polymer
erosion in 85:15/50:50 PLGA films as compared with 65:35 PLGA films, possibly
due to the miscibility of the two polymers resulting in good dispersion of the poly-
mer chains within the film matrix with no areas with predominantly 50:50 PLGA
chains.
Replacing the 50:50 PLGA (MWt=40,000) with a low molecular weight (LMWt)
50:50 PLGA (MWt=6,600) in the blend with 85:15 PLGA (85:15/LMWt 50:50
PLGA)resulted in faster onset of paclitaxel elution and polymer mass loss as com-
pared with blended 85:15/50:50 films and 65:35 PLGA films (Figures 4.11 and
4.15). Onset of polymer massloss and paclitaxel release was advanced by about 15
days in the 85:15/LMWt50:50 PLGA blendfilms as compared with the 85:15/50:50
PLGA films. This would indicate that comparable early release rates of paclitaxel
from a coronary stent coated with 50:50 PLGA could be achieved using a blend of
85:15/LMWt 50:50 PLGA. The formulation could be useful if a satisfactory duration
of paclitaxel elution is also maintained.
Other studies have shownthat drug release profiles from PLGAdevices can be modi-
fied by blending LMWt PLGA polymers. The duration of the lag phase seen in the
release of ganciclovir from 75:25 PLGA microspheres was reduced from 60 days to
around 7 days by blending low molecular weight (8,000) 50:50 PLGA into the mi-
crospheresat a ratio of 1:1. But the duration of ganciclovir elution was reduced by a
quarter to around 25 days. A blend of 3:1 75:25PLGA:LMWt50:50 reduced duration
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of the lag phase to approximately 15 days and maintained duration of release for
around 65 days [39]. Addition of LMWt 50:50 PLGA to 75:25 PLGA microspheres
increased the amount of peptide released in the initial burst phase in a dose depend-
ant mannerbuthad little effect on the duration of the subsequent lag phase [38].
Blending fast degrading LMWt PLGA into films of a tyrosine polyarylate
(poly(DTH adipate) reduced the duration of the lag phase in the release of a water
soluble peptide (integrilin) [18]. Further work would be required to determine if
blending water soluble LMWt copolymers such as PEGorpluronics or LMWt 50:50
PLGAwouldalter the paclitaxel elution profile from TyRx to makeit a suitable coat-
ing for coronary stent coatings. Thinner coatings and higher drug loadings wouldal-
ter the drug release profile but further work would be required to determineifa satis-
factory drug elution profile can be achievedbyaltering these parameters.
Blending LMWt 50:50 PLGAinto 85:15 PLGA polymercoatings offers a promising
method to fine tune paclitaxel elution from coronary stents. Further work would be
required using polymer coated stents to determine the ratio of LMWt 50:50 PLGA
required to achieve the desired elution profile. Alternatives to blending polymers
would be to create a layer of fast eroding PLGA such as LMWt 50:50 PLGA to de-
liver a dose of paclitaxel in the early days following implantation, over a layer of
slower degrading PLGA such as 85:15 PLGA containing paclitaxel to deliver the
drug for the more extended periods that may be required. A similar mechanism is
currently in use in the Cypher stent where an outer layer of polymeracts as a barrier
to reduce the amountofsirolimusreleased in the early burst phase following implan-
tation [32]. Kothwala et al [44] used layers of 50:50 PLGA and 75:25 PLGA and
poly vinyl pyrrolidone to control release of paclitaxel from a coronary stent. In this
system there was no lag phasein paclitaxel release but the initial amount of drug on
the stent was high (200g) which can effect release kinetics and further work would
be needed to determine if the release profile is maintained at lower drug loadings.
Further work would be required to determine the drug loadings and thickness of each
layer for a stent comprising LMWt 50:50 PLGA and 85:15 PLGArequired to obtain
the desired release profile.
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Conclusions
PLGAand Tyrosine derived polyarylates, such as TyRx (P22-10) are biocompatible
and biodegradable polymers that are suitable for use in biomedical applications and
_ some drug delivery devices. Polymer coatings for a DES must provide good
structural integrity throughout degradation, consistent and controlled drug delivery at
the desired concentration, have good vascular compatibility, be non-thrombogenic
and generate as benign a response from the host as possible or produce no more
adverse effects as that from a BMS. Complete solubilisation of the polymer coating
is also desirable to avoid any late thrombotic events that may be due in part to the
presence of undissolved polymer on the stent. For DES a steady release of paclitaxel
during the first 30 days following implantation and complete elution of the drug over
a period of 30 to 90 days is probably required to prevent ISR over the long and short
term.
Theelution profile of paclitaxel from PLGA or TyRx stent coatings is dependant on
the degradation of the polymer and comprises two phases: an initial diffusion
controlled slow release phase (lag phase) as the molecular weight of the polymer
coating is degraded by hydrolysis and a second faster phase associated with mass
loss of the polymer and morphological changes in the stent coating with the
appearance of cavities and air spaces creating a more porousstructure within the
stent coating.
Massloss from tyrosine derived polyarylates occurs very slowly and only at the end
of the degradation process due to low watersolubility of the degraded monomers and
the release of paclitaxel from such polymers will only occur when degradation is
advanced and polymererosion is occurring. The rates of degradation and massloss
for TyRx P22-10 were more rapid than that seen in other tyrosine containing
polymers and after 30 days implantation the polymer had degraded by some 50% to
approximately 25,000. But dueto the low solubility of the degraded polymer chains
mass loss was minimal until the polymer had degraded to a molecular weight of
4,000-5,000 after 150 days. Polymer dissolution was incomplete and the stent
retained a coating of low molecular weight polymer but with areas of exposed bare
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metal where the polymer had been eroded. As a result of the slow rate of polymer
erosion, paclitaxel elution was slow with an extended lag phase of 240 days in which
only approximately 3g of the paclitaxel was released. Release of paclitaxel occurred
over the 280 day study period but approximately 3g of the drug wasstill retained in
the polymercoating ofthe stent at the end of the study period.
There wasno significant change in the pH ofthe interstitial fluid as a consequence of
degradation and TyRx P22-10 is expected to have good tissue compatibility as has
been seen in other tyrosine containing polyarylates. TyRx P22-10 exhibited good
structural integrity but the presence of undissolved polymer on the stent over a time
scale of 9 months reducedits suitability as a polymer coating for DES. Additionally
since the release of paclitaxel was minimaloverthe first 30 days after implantation,
the elution of paclitaxel may not be at a suitable dosage or duration to prevent ISR
while the presence of paclitaxel in the stent coating in excess of 9 months may have
unknown consequences. Further work on the polymer to enhance degradation, mass
loss and drug elution would be required to address these issues.
Faster degradation rates and drug elution was seen using PLGA polymercoatings.
The degradation of PLGA coated stents and drug elution profile of paclitaxel from
PLGAcoated stents can be controlled by varying the GA:LAratio and by the coating
thickness. Hydrolysis occurs more readily at the GA bonds and the increased
hydrophilicity of PLGA polymers with higher GA moieties results in increasedrates
of hydrolysis and faster degradation of the polymer matrix. Release of paclitaxel is
slow until the hydrolytic cleavage of the polymer chains has reduced the molecular
weight of the monomersto critical point and the onset of mass loss and polymer
erosion occurs. Polymer erosion and mass loss occurs when the polymer chains have
degraded to a molecular weight of around 12,000 resulting in the formation of pits
and larger areas of erosion within and on the surfaceof the stent coating. As polymer
erosion proceeds increasing amounts of pitting is evident with formation oflarger
cavities connecting the bulk of the polymer matrix to the surface of the coating
resulting in faster diffusion of paclitaxel from the polymer matrix into the external
medium.
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Polymer degradation, erosion and visual signs of morphological deterioration
occurred in all PLGA polymers investigated but occurred over differing time scales.
Ofthe three PLGA polymers studied, 50:50 PLGA had the highest GA content and
consequently degraded the fastest with the shortest time to onset of mass loss and lag
phase in paclitaxel elution. 85:15 PLGA coatings degraded the slowest with the
longest time to the onset of polymer massloss resulting in the longest lag phase in
paclitaxel elution. The integrity of the polymer during degradation was maintained in
the PLGA coated stents with no obvious loss of larger polymer fragments or
delamination and there were only minor, insignificant pH changesin the interstitial
fluid. Complete solubilisation of 400ug coatings had occurred from the 50:50 and
75:25 PLGA coatings after 45 and 105 days of implantation respectively while only
traces of polymer could be detected on the 85:15 PLGA coatings at 120 days which
wasthe end of the study period.
Noneof the three PLGAblends studied with a coating of 400ug containing 20ug of
paclitaxel produced a completely satisfactory release profile of the drug. 50:50
PLGAcoatings have a shorter duration lag phase of around 15 days but complete
elution of the drug had occurred by 30-45 days which maybean insufficient duration
to effectively prevent ISR over longer time periods. No lag phase was observed for
paclitaxel elution from the 200g coating of 50:50 PLGA but complete elution of the
drug had occurred by 30 days which may limit the ability of that formulation to
prevent ISR over longer periods of time. Paclitaxel elution was over a longer period
of time, 75 and 120 days respectively, from 75:25 and 85:15 PLGA coatings.
However, the extended lag phase of paclitaxel release from the 75:25 and 85:15
coatings of 30 and 60 days respectively would be likely to severely limit their
effectiveness since studies have indicated that a minimum amountof paclitaxel,
possibly between10-20ug, needs to be released overthe first 30 days of implantation
to prevent ISR.
Howeverthe drug release properties of PLGA can be modified by blending PLGA
with low molecular weight hydrophilic copolymers or with PLGA polymers with
different GA:LA content or low molecular weight PLGA polymers.In this study the
addition of a pluronic, F-127, had no effect on PLGA degradation and may have
reduced paclitaxel elution. Addition of 8% w/w F-127 to 85:15 or 50:50 PLGA can
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increase the hydration of polymer films. But any increase in hydrolysis as a result of
faster hydration are nullified by reduced rates of autocatalysis within the matrix of
the polymer due to hydrogen bonding between the carboxylic end groups of PLGA
and the PPO segment of F-127 resulting in no overall effect on the degradation rate.
Furthermore paclitaxel elution from PLGA films containing F-127 may be reduced
due to a hydrophobicinteraction between the drug, micelles of PPO and the polymer
surface. Therefore inclusion of F-127 in PLGA polymers does not appear to be an
effective method to reducethe lag or diffusion controlled release phase of paclitaxel.
Blending 50:50 PLGA into 85:15 PLGA matrices increases the overall GA content
of the device thereby increasing the hydrophilicity of the device and introducing
more sites in the polymer chain susceptible to hydrolytic cleavage. The onset of
polymererosion and the duration of the lag phase in release ofpaclitaxel from 85:15
PLGA matrices can be reduced by blending a 1:1 ratio of 50:50 PLGA with 85:15
PLGA.Butthe elution profile of the drug and rate of mass loss was no different to
that for a 65:35 PLGA coating which has a similar ratio of GA:LA units. But the
onset of polymererosion was further advanced andthe lag phase of paclitaxel release
wasshortened by using a low molecular weight 50:50 PLGAblended 1:1 with 85:15
PLGA.Blending low molecular weight 50:50 PLGA with 85:15 PLGA resulted in
faster paclitaxel elution and polymer erosion than in 65:35 PLGA devices and
produceda similar early release profile to that of 50:50 PLGAalone.
In conclusion, TyRx P22-10 and PLGA (50:50, 75:25 and 87:15) are polymers that
have good biocompatibility and coating properties but their paclitaxel elution profile
would limit their usefulness as coatings for DES. Blending low molecular weight
50:50 PLGA with 85:15 PLGA can be used to effectively modify the release of
paclitaxel from PLGA devices but further work would be required to fine tune the
ratio of polymerblendsutilized in order to optimise the paclitaxel release profile for
coronarystent applications.
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GPC Chromatograms.
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Figure A.l1 GPC chromatograms for Control (not implanted) TyRx P22-10 coated
stents with and without paclitaxel. Retention time is the time taken for the peak to be
eluted from the columns. The response on the ELS detector is measured in millivolts. The
TyRx + paclitaxel chromatogram showsthe paclitaxel peak which is smallrelative to the
polymerpeak, but distinct from the baseline allowing measurement of the peak area and is
distinct from the TyRx chromatogram
     76 < —TyRx + paclitaxel5 ulS Polymer TyRx£4 + peak Paclitaxelo k23.Sao2 4 YOA a1 40 T0 10 20 30 40retention time (mins)Figure A.2_ GPC chromatograms from 14 day implanted TyRx P22-10 coated stentswith and without paclitaxel. Axes as in Figure 18. The ‘TyRx + paclitaxel’ chromatogramshowsthat the paclitaxel peakis still visible at this time point and distinct to the TyRx alonechromatogram.
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Figure A.3_ GPC chromatograms from 60 day implanted TyRx P22-10 coated stents
with paclitaxel. Axes as in Figure 18. The chamberseal from one stent remainedintact (red
line) gave a good plot for both the polymer and paclitaxel with no overlapping peaks and
allowed for paclitaxel measurement. The black line shows the chromatogram from a stent
wherethere was loss of chamberseal integrity allowing ingress of cellular elements and tissue
onto the stents resulting in extra peaks on the chromatogram which overlapped and obscured
the paclitaxel peak and paclitaxel could not be measuredin this stent.  
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Figure A.4 GPC chromatograms from 90 day implanted TyRx P22-10 coated stents
with paclitaxel. Axes as in Figure 18. Loss of integrity of the chamber seal allowed
excessive ingress of cellular elements andtissue onto the stents resulting in extra peaks on the
chromatogram which obscured the paclitaxel peak and overlapped with the tail of the polymer
peak. In such a chromatogram neither paclitaxel nor polymer peak area could be measured.
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Figure A.5 Chromatogram from 85:15/LMWt_ 50:50 PLGA film after 14 days
incubation in PBS. Data from the ELSdetector. The distribution of molecular weights is Bi-
modal with respect to the polymerand a smaller lower molecular weight peak for paclitaxel.
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Figure A.6 Chromatogram from 85:15/ 50:50 PLGA film after 22 days incubation in
PBS. Data from the ELS detector. The distribution of molecular weights is Uni-modal with
respect to the polymer and a smaller lower molecular weight peak for paclitaxel.
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PLGAstent coatin
implant 50:50 50:50 75:25 85:15
time (days) (400ng) (200ng) (400ng) (400n¢)
7 0 0 3 3
15 3 4 3 3
30 3 4 3 3
45 4 5 4 4
60 4 5 4 4
75 4 5 6 0
90 4 5 6 6
105 6 6
120 6 6   
Table A.1. The number of animals used for each time point in the degradation and
drug elution study of PLGA coated coronary stents. Two chambers, each containing one
stent were recovered from each animal at the designated time points.
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